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Résumé : Dans ce travail, les s´séquences Imagerie par Résonance Magnétique (IRM) 
radiales à temps d’écho ultra-court (UTE) sont analysées pour évaluer leur potentiel dans 
l’étude non-invasive de différents modèles expérimentaux de maladies pulmonaires chez la 
souris. Chez le petit animal, les séquences radiales UTE peuvent efficacement limiter 
l’impact négatif sur la qualité de l’image dû au déphasage rapide des spins causé par les 
nombreuses interfaces air/tissu. En plus, les séquences radiales UTE sont moins sensibles 
aux artefacts de mouvement par rapport aux séquences Cartésiennes classiques. En 
conséquence, chez le petit animal, les séquences radiales UTE peuvent permettre d’obtenir 
des images du poumon avec une résolution bien inférieure au millimètre avec des rapports 
signal/bruit importants dans le parenchyme pulmonaire, tout en travaillant en conditions 
physiologiques (animaux en respiration spontanée). 
Dans cette thèse, il sera démontré que les séquences d’IRM protonique UTE sont outils 
efficaces dans l’étude quantitative et non-invasive de différents marqueurs distinctifs de 
certaines pathologies pulmonaires d’intérêt général. Les protocoles développés seront 
simples, rapides et non-invasifs, faciles à implémenter, avec une interférence minimale sur la 
pathologie pulmonaire étudiée et, en définitive, potentiellement applicables chez l’homme. Il 
sera ainsi démontré que l’emploi des agents de contraste, administrés via les voies 
aériennes, permet d’augmenter la sensibilité des protocoles développés. Parallèlement, dans 
cette thèse des protocoles suffisamment flexibles seront implémentés afin de permettre 
l’étude d’un agent de contraste paramagnétique générique pour des applications aux 
poumons. 
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sequences are investigated as flexible tools for the noninvasive study of experimental 
models of lung diseases in mice. In small animals radial UTE sequences can indeed 
efficiently limit the negative impact on lung image quality due to the fast spin dephasing 
caused by the multiple air/tissue interfaces. In addition, radial UTE sequences are less 
sensitive to motion artifacts compared to standard Cartesian acquisitions. As a result, radial 
UTE acquisitions can provide lung images in small animals at sub-millimetric resolution with 
significant signal to noise ratio in the lung parenchyma, while working with physiological 
conditions (freely-breathing animals). 
In this thesis, UTE proton MRI sequences were shown to be efficient instruments to 
quantitatively investigate a number of hallmarks in longitudinal models of relevant lung 
diseases with minimal interference with the lung pathophysiology, employing easily-
implementable fast protocols. The synergic use of positive contrast agents, along with an 
advantageous administration modality, was shown to be a valuable help in the increase of 
sensitivity of UTE MRI. At the same time, UTE MRI was shown to be an extremely useful and 
efficacious sequence for studying positive contrast agents in lungs. 
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Abstract
Magnetic Resonance Imaging for pre-clinical lung
imaging
In this work, ultra-short echo time (UTE) Magnetic Resonance Imaging (MRI)
sequences are investigated as flexible tools for the noninvasive study of ex-
perimental models of lung diseases in mice. In small animals radial UTE
sequences can indeed efficiently limit the negative impact on lung image qual-
ity due to the fast spin dephasing caused by the multiple air/tissue interfaces.
In addition, radial UTE sequences are less sensitive to motion artifacts com-
pared to standard Cartesian acquisitions. As a result, radial UTE acquisitions
can provide lung images in small animals at submillimetric resolution with
significant signal to noise ratio in the lung parenchyma, while working with
physiological conditions (freely-breathing animals).
In this thesis, UTE proton MRI sequences were shown to be efficient in-
struments to quantitatively investigate a number of hallmarks in longitudinal
models of relevant lung diseases with minimal interference with the lung
pathophysiology, employing easily-implementable fast protocols. The syner-
gic use of positive contrast agents, along with an advantageous administration
modality, was shown to be a valuable help in the increase of sensitivity of
UTE MRI. At the same time, UTE MRI was shown to be an extremely useful
and efficacious sequence for studying positive contrast agents in lungs.
Keywords: Lung, Magnetic Resonance Imaging, Ultra-short echo time, UTE
MRI, Asthma, Lung cancer, Contrast agents, Gadolinium nanoparticles, Opti-
cal imaging, Mice models
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Techniques d’IRM pour l’imagerie pre´clinique du
poumon
Dans ce travail, les se´quences Imagerie par Re´sonance Magne´tique (IRM)
radiales a` temps d’e´cho ultra-court (UTE) sont analyse´es pour e´valuer leur
potentiel dans l’e´tude non-invasive de diffe´rents mode`les expe´rimentaux de
maladies pulmonaires chez la souris. Chez le petit animal, les se´quences ra-
diales UTE peuvent efficacement limiter l’impact ne´gatif sur la qualite´ de
l’image duˆ au de´phasage rapide des spins cause´ par les nombreuses interfaces
air/tissu. En plus, les se´quences radiales UTE sont moins sensibles aux arte-
facts de mouvement par rapport aux se´quences Carte´siennes classiques. En
conse´quence, chez le petit animal, les se´quences radiales UTE peuvent per-
mettre d’obtenir des images du poumon avec une re´solution bien infe´rieure
au millime`tre avec des rapports signal/bruit importants dans le parenchyme
pulmonaire, tout en travaillant en conditions physiologiques (animaux en
respiration spontane´e).
Dans cette the`se, il sera de´montre´ que les se´quences d’IRM protonique
UTE sont outils efficaces dans l’e´tude quantitative et non-invasive de diffe´rents
marqueurs distinctifs de certaines pathologies pulmonaires d’inte´reˆt ge´ne´ral.
Les protocoles de´veloppe´s seront simples, rapides et non-invasifs, faciles a`
imple´menter, avec une interfe´rence minimale sur la pathologie pulmonaire
e´tudie´e et, en de´finitive, potentiellement applicables chez l’homme. Il sera
ainsi de´montre´ que l’emploi des agents de contraste, administre´s via les voies
ae´riennes, permet d’augmenter la sensibilite´ des protocoles de´veloppe´s. Par-
alle`lement, dans cette the`se des protocoles suffisamment flexibles seront im-
plemente´s afin de permettre l’e´tude d’un agent de contraste paramagne´tique
ge´ne´rique pour des applications aux poumons.
Mots cle´s: Poumon, Imagerie par Re´sonance Magne´tique, Temps d’e´cho ultra-
court, IRM UTE, Asthme, Cancer du poumon, Agents de contraste, Nanopar-
ticules a` base de gadolinium, Imagerie optique, Mode`les animaux
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Motivation The spectrum of pulmonary pathologies is extremely broad and
includes, among others, lower respiratory tract infections, chronic obstructive
pulmonary diseases, asthma, and respiratory apparatus tumors. According to
the World Health Organization surveys these diseases, altogether, represent
the first cause of death worldwide [1]. The burden of lung pathologies could
be greatly reduced with an effective policy of prevention and early diagnostics,
which often results in a positive prognosis.
In the race to improve global health through an early detection of diseases,
imaging techniques play a major role since they can provide early diagnostics
of pathologies, noninvasive longitudinal follow-ups of the patients, and can
help preparing and guiding surgery.
Chest radiography and computed tomography currently represent the gold
standard for lung diseases diagnostics. Nuclear medicine imaging techniques
(e.g., gamma scintigraphy, positron-emission tomography, single photon-
emission computer tomography) have shown to be of significant aid in the
validation of X-ray or computed tomography observations, and can provide
further information about several lung pathologies (e.g., stage of lung can-
cer) [2]. Nonetheless, all these in vivo imaging techniques imply the exposure
of the patient to ionizing radiation. As a consequence, repeated acquisitions
are discouraged to reduce the cumulative radiation to which patients are
exposed, which has been shown to be associated with an increased risk of
developing cancer [3].
In this context, magnetic resonance imaging (MRI) has shown to be espe-
cially promising because of its high soft tissue contrast, good spatial resolution,
and absence of ionizing radiation [2, 4–6]. MRI was proven to be the most
adequate imaging technique for the screening and diagnostics of a number of
pathologies in brain, heart or liver. Nevertheless, this consideration cannot
yet be applied to the lung, which remains one of the most difficult organs to
vii
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image with MRI because of its intrinsic properties [5, 7–9].
In this work, ultra-short echo time (UTE) MRI sequences are investigated
as flexible tools for the noninvasive study of experimental models of lung
diseases in mice. In small animals, radial UTE sequences can indeed efficiently
limit the negative impact on image quality due to the fast spin dephasing
caused by the multiple air/tissue interfaces [10, 11]. In addition, radial UTE
sequences are less sensitive to motion artifacts compared to standard Cartesian
acquisitions [12]. As a result, radial UTE acquisitions can provide lung images
in small animals at submillimetric resolution with significant signal to noise
ratio in the lung parenchyma, while working with physiological conditions
(freely-breathing animals) [13, 14].
Aim The aim of this thesis is to implement, apply and validate MRI tech-
niques dedicated to the investigation and diagnostic of lung diseases, and
to the monitoring of drug effects in animal models of pulmonary patholo-
gies. UTE proton MRI sequences are investigated to evaluate their potential
in the quantitative and noninvasive study of a number of hallmarks in lon-
gitudinal models of relevant lung diseases with minimal interference with
the lung pathophysiology. The objective of this work is to develop easily-
implementable noninvasive protocols that are fast, simple and potentially
translatable to human studies. The possibility of using positive contrast agents
to increase the sensitivity of the developed protocols is a main objective of this
work. On the other hand, this thesis aims also at the development of imaging
protocols flexible enough to guarantee their applicability to the study of a
generic paramagnetic contrast agent applied to lungs. Multimodal imaging
techniques and conventional ex vivo procedures are used to validate MRI
results.
The main contributions of this thesis are the following:
• Implementation of a robust method to longitudinally characterize with
MRI a murine model of chronic asthma in a completely noninvasive way.
The characterization includes both the standard detection of inflamma-
tory fluids and the quantification of the subtle changes that take place
in the bronchial walls after bronchial remodeling.
• Implementation of a protocol able to detect lung cancer in a repro-
ducible and precise way. The protocol, validated with complementary
techniques (bioluminescence imaging and histology), shows the advan-
viii
tages and limitations of radial UTE sequences in small animal studies
compared to standard gradient-echo sequences.
• Implementation of an MRI protocol to study the Nuclear Magnetic Res-
onance (NMR) properties of T1-shortening contrast agents. The protocol
enables to study the gross biodistribution and elimination pathways of
the contrast agent and to test its potential interest in lungs. The imaging
protocol can be applied to study any positive contrast agent with special
interest for the MRI of the lung.
• Implementation of an MRI pharmacokinetic modelization of the biodis-
tribution of a positive contrast agent in lungs. The MRI protocol is based
on the negligibility of the T ∗2 effect generated by the contrast medium
when an ultra-short echo time is used and it allows to compute the
concentration of the contrast agent in the organ of interest. In addi-
tion, the protocol permits to obtain quantitative information about the
pharmacokinetics of the contrast agent.
• Application of the previously implemented protocols to improve the
detection of lung cancer in a mouse model. A detailed comparison be-
tween two different administration routes (orotracheal and intravenous)
is carried out and the advantages and limitations of both are critically
discussed.
Organization The research work of this thesis is organized as a collection of
articles, either published or submitted for revision in peer-reviewed journals.
Each of them will be introduced in the context of the aforementioned aims
and an overall discussion of the results will be provided in the last chapter.
Supplementary material related to the thesis research outputs is provided in
the appendices to complement the data presented and analyzed in the body
of this work.
In chapter 1, the basic concepts and terminology about the functions and
anatomy of lungs are introduced. A special attention is given to the descrip-
tion of the main pulmonary pathologies, with a major focus on asthma and
lung cancer, the diseases which will be object of investigation throughout the
entire work. An overview of the main challenges to image lung with MRI is
provided along with a short summary of the main techniques used to encom-
pass these limiting factors. A synopsis of the contrast agents principles and of
the state-of-the-art of contrast media applied to lungs is presented as well.
ix
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In chapter 2, two tools used throughout the whole thesis are described in
detail: the UTE reconstruction program and the ultra-small multimodal rigid
gadolinium-based platforms (USRPs). The former was optimized in order to
obtain the most accurate reconstruction for the subsequent analysis of UTE
MR images with standard medical imaging softwares in chapters 3, 4 and 5.
The USRPs have been used to improve the sensitivity of UTE MRI and are
largely employed in the work described in chapters 4 and 5.
In chapter 3, the UTE MR imaging technique was applied to longitudi-
nally investigate a chronic murine model of asthma. This study showed for
the first time that high-resolution UTE proton MRI of the lungs may allow
non-invasive quantification of the main hallmarks of asthma, namely the peri-
bronchial inflammation with airway occlusion by mucus and the bronchial
remodeling. The data obtained with MRI successfully correlated with the
functional information obtained from plethysmography, used to assess the
bronchial hyperresponsiveness.
The same imaging technique was then applied to an orthotopic model of
lung tumor in immunodeficient mice. The study showed that UTE MRI is an
effective sequence to detect carcinogenic formations in the lung parenchyma.
Nevertheless, the need to visualize small metastatic lesions suggested the
potential interest in using positive contrast agents to improve UTE MRI sensi-
tivity.
In chapter 4, ultra-small multimodal rigid gadolinium-based platforms
were therefore chosen for their interesting characteristics, including their mul-
timodal capacity and their high longitudinal relaxivity. In order to test their
MR properties in the lung in conjunction with an optimized T1-weighted UTE
sequence, an intra-tracheal instillation was selected as route of administration.
The study of the signal enhancements evolution in time after the administra-
tion of the contrast agent allowed detecting the elimination pathway of the
administered nanoparticles. The MRI measurements confirmed that the size
of the nanoparticle is small enough to ensure a negligible hepatic clearance,
making the contrast agent and the instillation protocol good candidates for
applications in imaging and treatment of selected lung diseases.
To further exploit the wealth of information which MRI can provide, a pro-
tocol for the quantification of the contrast agent concentration in the lung was
proposed. Quantitative pharmacokinetics models of tracheally-administered
ultra-small rigid platforms were implemented and validated against optical
imaging of fluorescent USRPs.
x
In chapter 5, the nanoparticles and the developed protocol were eventually
tested on the lung tumor model in mice mentioned above. The results showed
that a significant increase in the contrast-to-noise and signal-to-noise ratios
can be observed in the tumor after administration of the nanoparticles. The
orotracheal administration was proven to be more effective in the detection of
lung tumors, compared to the standard intravenous injection. The localization
of the tumor observed with UTE proton MRI was confirmed with complemen-
tary imaging modalities such as bioluminescence, fluorescence imaging, and
histology.
In chapter 6, the results obtained in this thesis are discussed in the light
of the data previously published in scientific literature. The perspectives and
limitations of the present work are critically analyzed and some close- and
long-term possible applications of the innovative protocols proposed in this
thesis are discussed. Finally, in chapter 7, the conclusions of this thesis are
presented considering the aforementioned aims.
In appendix A, the patent publication relative to the variety of applica-
tions which may potentially arise from the use of the USRPs administered in
animals or humans through the airways is introduced and referenced. The
patent discusses the interest of these nanoassemblies administered via the
oral route for the diagnostics and therapeutics of lung diseases. The patent
request was submitted in April 2012, before the submission of the articles
presented in chapter 4. The work presented in this thesis was the basis for
and the natural development of the ideas presented in the patent.
In appendix B, the theranostic potential of the USRPs applied to lung
cancer was investigated in mice which underwent xenotransplantation of
lung tumor. The pre-clinical study showed that the direct administration
of the nanoparticles into the airways before conventional X-ray radiation
significantly increased the life-span of mice compared to control mice that
did not receive any administration before the radiotherapy. The encouraging
result, most probably due to the radiosensitizing properties of the USRPs, can
be seen as a first step towards theranostic and image-guided therapy. The
work presented in chapter 5 was an important contribution to this work for
the investigation about the diagnostic potential of USRPs. In addition, the
fluorescence imaging technique presented in this section further validates the
results presented in chapter 5.
In appendix C, an invited review about the diagnostic and therapeutic
xi
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properties of the USRPs is presented. The work includes part of the results
obtained in this thesis along with additional applications to other heterotopic
and orthotopic tumor models. The review represents a summary of the results
obtained with such a contrast agent up to now and a starting point for future
developments.
In appendix D, the synthesis and characterization of the USRPs used in
chapters 4 and 5 is presented for sake of completeness.
xii
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Motivation Le spectre des pathologies pulmonaires est extreˆmement vaste
et inclut, entre autres, les infections des voies respiratoires infe´rieures, broncho-
pneumopathies chroniques obstructives, asthme et tumeurs du syste`me respi-
ratoire. Selon les rapports de l’Organisation Mondiale de la Sante´, l’ensemble
de ces maladies repre´sente la premie`re cause de mortalite´ dans le monde [1].
Par ailleurs, la mise en place d’une politique de pre´vention avec l’aide d’un
diagnostic pre´ventif plus efficace pourrait sensiblement ame´liorer la prise en
charge des pathologies lie´es au poumon.
Dans la course pour ame´liorer la sante´ globale a` travers la de´tection
pre´coce des maladies, les techniques d’imagerie jouent un roˆle fondamental.
En effet ces techniques permettent un diagnostic rapide et pre´cis des patholo-
gies ainsi qu’un suivi non-invasif des patients. Enfin, elles peuvent aider a` la
pre´paration et au guidage des interventions.
La radiographie et la tomodensitome´trie du thorax sont actuellement les
techniques de re´fe´rence pour le diagnostic des maladies pulmonaires. Les
techniques d’imagerie en me´decine nucle´aire (scintigraphie, tomoscintigra-
phie par e´mission de positons, tomographie d’e´mission monophotonique)
se sont re´ve´le´es eˆtre des instruments pre´cieux pour valider les observations
faites en radiographie ou tomodensitome´trie. En outre, elles peuvent fournir
des informations importantes sur plusieurs pathologies (par exemple, le stade
d’une tumeur) [2]. Cependant, toutes ces techniques d’imagerie in vivo im-
pliquent l’exposition du patient aux radiations ionisantes. Par conse´quent,
les acquisitions re´pe´te´es sont de´conseille´es afin de re´duire la dose totale de
radiations a` laquelle les patients sont expose´s. Il a, en effet, e´te´ de´montre´ que
cela augmente le risque de de´veloppement d’un cancer [3].
Dans ce contexte, l’imagerie par re´sonance magne´tique (IRM) est parti-
culie`rement prometteuse puisque elle permet d’obtenir un contraste e´leve´
dans les tissus mous et une bonne re´solution spatiale sans utiliser des ra-
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diations ionisantes [2, 4–6]. Plusieurs e´tudes ont de´ja` de´montre´ que l’IRM
est la technique d’imagerie la plus approprie´e pour le de´pistage et le diag-
nostic de plusieurs pathologies du cerveau, du cœur et du foie. Cependant,
cette conside´ration n’est pas encore valable pour le poumon, qui reste un
des organes les plus difficiles a` imager avec l’IRM a` cause de ses proprie´te´s
intrinse`ques [5, 7–9].
Dans ce travail, les se´quences IRM radiales a` temps d’e´cho ultra-court
(UTE) sont analyse´es pour e´valuer leur potentiel dans l’e´tude non-invasive
de diffe´rents mode`les expe´rimentaux de maladies pulmonaires chez la souris.
Chez le petit animal, les se´quences radiales UTE peuvent efficacement limiter
l’impact ne´gatif sur la qualite´ de l’image duˆ au de´phasage rapide des spins
cause´ par les nombreuses interfaces air/tissu [10, 11]. En plus, les se´quences
radiales UTE sont moins sensibles aux artefacts de mouvement par rapport
aux se´quences Carte´siennes classiques [12]. En conse´quence, chez le petit
animal, les se´quences radiales UTE peuvent permettre d’obtenir des images du
poumon avec une re´solution bien infe´rieure au millime`tre avec des rapports
signal/bruit importants dans le parenchyme pulmonaire, tout en travaillant
en conditions physiologiques (animaux en respiration spontane´e) [13, 14].
Aim L’objectif de ce travail de the`se est d’imple´menter, d’appliquer et de
valider des techniques IRM de´die´es a` l’investigation et au diagnostic de mal-
adies pulmonaires ainsi qu’au suivi des effets de mole´cules pharmaceutiques
dans des mode`les de pathologies du poumon. Les se´quences d’IRM protonique
a` temps d’e´cho ultra-court seront analyse´es pour e´valuer leur potentiel dans
l’e´tude quantitative et non-invasive de diffe´rents marqueurs distinctifs de cer-
taines pathologies pulmonaires d’inte´reˆt ge´ne´ral. Ces e´tudes seront effectue´es
sur des mode`les animaux avec un suivi dans le temps. L’objectif de cette the`se
est ainsi de de´velopper des protocoles simples, rapides et non-invasifs, faciles
a` imple´menter, avec une interfe´rence minimale sur la pathologie pulmonaire
e´tudie´e et, en de´finitive, potentiellement applicables chez l’homme. En outre,
la possibilite´ d’utiliser des agents de contraste pour augmenter la sensibilite´
des protocoles de´veloppe´s est un des objectifs principaux de ce travail. Par-
alle`lement, cette the`se a pour objectif supple´mentaire l’imple´mentation de
protocoles suffisamment flexibles pour permettre l’e´tude d’un agent de con-
traste paramagne´tique ge´ne´rique pour des applications aux poumons. Les
techniques d’imagerie multimodales et les proce´dures conventionnelles ex
vivoseront utilise´es dans ce travail de the`se pour valider les re´sultats obtenus
par IRM.
xiv
Les principales contributions de cette the`se sont les suivantes :
• Imple´mentation d’une me´thode robuste et comple`tement non-invasive
pour la caracte´risation longitudinale par IRM d’un mode`le murin d’asthme
chronique. La caracte´risation inclut la de´tection standard des zones
d’inflammation ainsi que la quantification de subtiles modifications qui
ont lieu dans la paroi bronchique suite au remodelage bronchique.
• Imple´mentation d’un protocole capable de de´tecter la tumeur du poumon
de fac¸on pre´cise et reproductible. Ce protocole, valide´ au moyen de tech-
niques comple´mentaires (bioluminescence et histologie), montre les
avantages et les limites des se´quences radiales UTE chez le petit animal
par rapport aux se´quences classiques a` e´cho de gradient.
• Imple´mentation d’un protocole IRM pour e´tudier les proprie´te´s de
la re´sonance magne´tique nucle´aire des agents de contraste qui sont
responsables du raccourcissement du temps de relaxation longitudinal
T1. Le protocole permet d’e´tudier la biodistribution ge´ne´rale et les voies
d’e´limination de l’agent de contraste ainsi que de tester son inte´reˆt
potentiel dans les poumons.
• Imple´mentation d’un protocole d’IRM pour la mode´lisation pharma-
cocine´tique de la biodistribution d’un agent de contraste positif dans
les poumons. Le protocole IRM se base sur le fait que l’effet T ∗2 ge´ne´re´
par l’agent de contraste est ne´gligeable quand un temps d’e´cho tre`s
court est utilise´. Ce protocole permet de calculer la concentration de
l’agent de contraste dans l’organe d’inte´reˆt et d’obtenir des informations
quantitatives sur la pharmacocine´tique de l’agent.
• Application des protocoles pre´ce´demment de´veloppe´s afin d’ame´liorer
la de´tection de la tumeur du poumon dans un mode`le murin. Une
comparaison entre deux diffe´rentes modalite´s d’administration (intra-
trache´ale et intraveineuse) a e´te´ effectue´e et les limites de chacune sont
discute´es en portant un regard critique.
Organization Dans cette the`se, le travail de recherche est organise´ a` la
manie`re d’une collection d’articles scientifiques. Certains sont de´ja` publie´s
tandis que d’autres ont e´te´ soumis dans des journaux de peer-review et sont
maintenant sous re´vision. Chacun de ces articles sera introduit dans le con-
texte des objectifs mentionne´s pre´ce´demment et une discussion ge´ne´rale des
re´sultats sera propose´e dans le dernier chapitre. Afin de comple´ter les donne´es
pre´sente´es et analyse´es, des documents supple´mentaires relatifs aux re´sultats
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scientifiques de cette the`se seront propose´s en annexe.
Dans le chapitre 1, les concepts principaux et la terminologie sur les
fonctions et l’anatomie des poumons seront introduits. Les pathologies pul-
monaires principales y seront de´crites avec une attention toute particulie`re
pour l’asthme et le cancer du poumon. Ces deux maladies feront l’objet du
travail d’investigation pre´sente´ dans cette the`se. Enfin, une vue d’ensemble
des principaux de´fis a` surmonter pour obtenir une image de poumon de bonne
qualite´ par IRM sera aussi expose´e, ainsi qu’un bref re´sume´ des techniques
couramment utilise´es pour surmonter les facteurs limitant les applications de
l’IRM pulmonaire.
Dans le chapitre 2, deux outils utilise´s dans tout le travail de the`se seront
pre´sente´s en de´tail : le programme de reconstruction UTE et des nanopar-
ticules multimodales ultrafines a` base de gadolinium (USRPs, ultra-small
rigid platforms). Le premier outil a e´te´ optimise´ dans le but d’obtenir une
reconstruction pre´cise des images IRM UTE et pour l’analyse par des logi-
ciels standards d’analyse d’imagerie me´dicale dans les chapitres 3, 4 et 5. Le
deuxie`me outil sera utilise´ pour ame´liorer la sensibilite´ de l’IRM UTE et sera
largement employe´ dans les travaux de´crits dans les chapitres 4 et 5.
Dans le chapitre 3, les techniques d’IRM radiales a` temps d’e´cho ultra-
court seront applique´es a` l’e´tude longitudinale d’un mode`le d’asthme chronique
chez la souris. Cette e´tude montrera, pour la premie`re fois, que l’IRM pro-
tonique UTE a` haute re´solution du poumon permet la quantification des fac-
teurs distinctifs de l’asthme de manie`res non-invasive, c’est-a`-dire l’inflammation
peribronchique avec occlusion lie´e a` la pre´sence de mucus ainsi que le remod-
elage bronchique. Les donne´es obtenues par IRM seront corre´le´es avec succe`s
aux informations fonctionnelles obtenues par la ple´thysmographie, utilise´e
pour e´valuer l’hyperre´activite´ bronchique.
Une technique semblable sera ensuite applique´e dans un mode`le ortho-
topique de tumeur pulmonaire chez la souris immunode´ficiente. L’e´tude
montrera que l’IRM UTE est une se´quence efficace pour la de´tection des forma-
tions carcinoge`nes dans le parenchyme pulmonaire. Cependant, la ne´cessite´
de visualiser les petites le´sions me´tastatiques sugge´rera l’inte´reˆt potentiel des
agents de contraste positifs pour ame´liorer la sensibilite´ de de´tection de l’IRM
UTE.
Dans le chapitre 4, des nanoparticules ultrafines a` base de gadolinium
seront alors utilise´es pour leurs caracte´ristiques particulie`res telles que leur re-
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laxivite´ longitudinale tre`s e´leve´ et leur capacite´ multimodale. Afin de mesurer
leurs proprie´te´s RM dans le poumon conjointement avec une se´quence UTE
optimise´e et fortement ponde´re´e en T1, une instillation intratrache´ale sera
employe´e comme voie d’administration. L’e´tude de l’e´volution du rehausse-
ment du signal en fonction du temps apre`s administration de l’agent de
contraste montrera la possibilite´ de de´tecter les voies d’e´limination des
nanoparticules. Les observations IRM confirmeront, en outre, que la taille des
nanoparticules est suffisamment re´duite pour assurer une clairance he´patique
ne´gligeable. Ces re´sultats de´montreront donc que cet agent de contraste
administre´ selon le protocole d’instillation est un bon candidat pour le
de´veloppement d’applications d’imagerie et le traitement the´rapeutique de
certaines maladies pulmonaires.
Pour davantage exploiter la richesse des informations fournies par l’IRM,
un protocole de quantification de la concentration de l’agent de contraste
sera propose´. De plus, des mode`les pharmacocine´tiques quantitatifs des
nanoparticules administre´es intratrache´alement seront imple´mente´s et valide´s
a` travers l’utilisation de l’imagerie par fluorescenceeffectue´e graˆce aux pro-
prie´te´s multimodales des USRPs.
Dans le chapitre 5, les nanoparticules et le protocole de´veloppe´ seront
enfin applique´s au mode`le de tumeur pulmonaire de´crit ci-avant. Les re´sultats
montreront qu’une augmentation significative des rapports signal/bruit et
contraste/bruit peut eˆtre atteinte suite a` l’administration des nanoparticules.
Il sera par ailleurs montre´ que l’administration intratrache´ale est plus ef-
ficace qu’une administration intraveineuse classique pour la de´tection des
tumeurs. La localisation de la tumeur par IRM UTE sera confirme´e avec l’aide
de diffe´rentes techniques d’imagerie (bioluminescence, fluorescence) et de
l’histologie.
Dans le chapitre 6, les re´sultats obtenus pendant ce travail de the`se seront
discute´s a` la lumie`re des connaissances disponibles dans la litte´rature scien-
tifique. Les perspectives tout comme les limites de ce travail seront analyse´es
avec un regard critique. De plus, ces protocoles innovants ainsi pre´sente´s
feront alors l’objet d’une discussion dans le cadre de plusieurs applications a`
court et long terme. Enfin, dans le chapitre 7, les conclusions de cette the`se
seront propose´es en conside´rant les objectifs susmentionne´s.
Dans l’annexe A, un brevet relatif aux nombreuses applications poten-
tielles pouvant eˆtre de´veloppe´es sur l’administration par voie respiratoire
des USRPs chez la souris ou l’homme est introduit et re´fe´rence´. Le brevet
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expose l’inte´reˆt de ces nanoparticules administre´es par voie intratrache´ale
pour le diagnostic et la the´rapie des maladies pulmonaires. La demande de
brevet a e´te´ soumise au mois d’avril 2012, avant la soumission des articles
pre´sente´s dans le chapitre 4. Les travaux de cette the`se sont base´s sur les ide´es
pre´sente´es dans ce brevet et en sont le de´veloppement naturel.
Dans l’annexe B, le potentiel the´ranostique des USRPs applique´es a` la
tumeur du poumon sera investigue´ sur le mode`le de cancer pulmonaire dis-
cute´ dans les chapitres 4 et 5. L’e´tude pre´clinique montrera que l’administration
directe des nanoparticules dans les voies ariennes avant radiothe´rapie con-
ventionnelle augmente significativement la survie des souris par rapport a`
celles qui rec¸oivent la radiothe´rapie sans administration pre´liminaire des
nanoparticules. Le re´sultat encourageant, probablement lie´ aux proprie´te´s
radiosensibilisantes des USRPs, peut eˆtre vu comme un premier pas vers la
the´ranostic et la the´rapie guide´e par imagerie. Le travail pre´sente´ dans le
chapitre 5 constitue une contribution importante au manuscrit pre´sente´ dans
cette annexe en ce qui concerne l’investigation du potentiel diagnostique des
USRPs. En outre, l’imagerie par fluorescence pre´sente´e dans cette annexe
valide d’autant plus les re´sultats pre´sente´s dans le chapitre 5.
Dans l’annexe C, une revue invite´e sur les proprie´te´s diagnostiques et
the´rapeutiques des USRPs sera pre´sente´e. Le manuscrit contient une partie des
re´sultats pre´sente´s dans cette the`se ainsi que des applications supple´mentaires
des USRPs dans d’autres mode`les he´te´rotopiques et orthotopiques de tumeur.
Cette revue repre´sente une synthe`se des re´sultats obtenus avec cet agent de
contraste jusqu’a` pre´sent et un point de de´part pour de futurs de´veloppements.
Dans l’annexe D, la synthe`se et la caracte´risation des USRPs utilise´es dans
les chapitres 4 et 5 sont pre´sente´es par souci d’exhaustivite´.
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Introduction
This chapter will provide the readers with the basic concepts and terminology
about the functions and anatomy of lungs. In view of the in vivo pre-clinical
studies presented in this work, a special attention will be given to the dif-
ferences between rodents and human’s respiratory systems. In addition, the
main pulmonary pathologies will be reviewed, with special focus on asthma
and lung cancer, the diseases which will be object of investigation in the next
chapters.
An overview of the main challenges to image lung with MRI will be pro-
vided along with a short summary of the main techniques used to encompass
these limiting factors.
Finally, a synopsis of the contrast agents principles and of the state-of-the-
art of contrast media applied to lungs will be presented.
1.1 Anatomopathology of lung
1.1.1 Lung anatomophysiology and morphology
The lung is the essential respiration organ in air-breathing animals. Its prin-
cipal function is to fulfill gas exchanges, transporting oxygen from the at-
mosphere to the bloodstream and removing carbon dioxide from the blood
circulation. In addition, the lungs carry out other functions like the metabo-
lization of some compounds and the filtration of undesired materials from
the circulation; moreover, it acts as a reservoir for blood and as a blood pH
balance [15].
1.1.1.1 Lung structure and physiology
In order to perform these physiologic functions, a specific architecture of
the lung is needed. Even though this differs between species, many struc-
tural components remain consistent among animals [16–18]. In reptiles, birds
and mammals, respiration takes place through a sequence of steps where air
is brought into the lungs through the airways. Since the diffusion of a gas
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through a sheet of tissue is proportional to the area of the sheet and inversely
proportional to its thickness (Fick’s law of diffusion), commonly the blood-gas
barrier is exceedingly thin and has an internal total area which is much larger
than the outer surface of the lung (between 50 and 100 m2 in humans) [15].
Such enormous surface is achieved through a complex branching pattern of
the tracheobronchial tree.
The airways consist in a series of branching conducting tubes, which be-
come narrower, shorter and more numerous as they penetrate deeper into the
lung. As shown in Figure 1.1 they can be divided into two zones: the conduct-
ing airways and the respiratory ones. The conducting zone, whose function
Figure 1.1: Schematic representation of the tracheobronchial tree. The major bronchi, bronchi-
oles, and terminal bronchioles make up the conducting zone, while the respiratory bronchioles,
alveolar ducts, and alveolar sacs make up the transitional and respiratory zones. Z denotes the
airway generation. Reprinted from [15].
is to transport the inspired air to the gas-exchanging regions of the lungs,
is formed by the trachea which divides into the bronchi, bronchioles and
terminal bronchioles. The respiratory zone, where the gas-exchange occurs,
begins when the terminal bronchioles divide into the respiratory bronchioles
and eventually to the alveolar ducts, which are lined with alveolar sacs (alve-
oli). Alveoli associated with the respiratory airways and with the more distal
alveolar sacs constitute the lung parenchyma [19].
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The portion of the cardiovascular system which carries deoxygenated
blood away from the heart, to the lungs (via the pulmonary artery), and
returns oxygenated blood back to the heart (via the pulmonary veins) consti-
tutes the pulmonary circulation. The pulmonary blood vessels branch from
Figure 1.2: Terminal alveoli connected to the network of the capillary system. Alveoli are in
contact with capillaries. The thin barrier between the alveolar and the capillary walls allows a
rapid exchange of oxygen and carbon dioxide. Adapted from [20].
the pulmonary artery accompanying the tracheobronchial tree deep into the
respiratory zone. The smallest branches of the cardiovascular system, the cap-
illaries, form a dense network of short interconnecting segments which cover
and embed the alveoli, providing an efficient arrangement for gas exchange,
as shown in Figure 1.2 [15].
From a mechanical point of view, the respiration in mammals is made pos-
sible thanks to several muscles: the diaphragm, the intercostal and accessory
muscles, and the abdominal muscles. During inhalation, the diaphragm is
the most important muscle. Briefly, when it contracts, it moves in the inferior
direction, thus enlarging the volume of the thoracic cavity. The decrease of the
internal pressure generates a gradient of pressure which allows air to enter
the lungs. During the inspiration phase, alveoli expand in volume, resulting
in an overall lower parenchyma density (Figure 1.3a).
During the expiration phase, the diaphragm relaxes, lung and chest wall
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(a) Inspiration phase (b) Expiration phase
Figure 1.3: Scanning electron microscope view of lung alveoli, magnified × 750, showing the
way in which their shape is retained as their size alters with changes in lung volume. The blue
arrows underline the changes in capillaries shape, which varies proportionally to the degree of
stretching undergone by the alveolar walls. Adapted from [21]
return to their equilibrium position because of elastic recoil. The decrease in
lung volume and the increase in the alveoli pressure generate the flow of air
from the lungs to the atmosphere, increasing the parenchyma density (Figure
1.3b) [15, 19].
1.1.1.2 Lung morphology
The airway wall can be considered as being composed of inner and outer
layers, the former extending from the lumen to the outermost layer of smooth
muscle and the latter from the smooth muscle to the airway parenchymal
boundary, as shown in Figure 1.4.
The basic morphology of lung varies while moving from the conducting
to the respiratory zone, as schematically shown in Figure 1.5. The conducting
airways are characterized by a surface epithelium largely composed of cili-
ated and secretory cells (e.g., goblet cells), overlying subepithelial tissue that
consists predominantly of connective tissues and glands. The proportion and
type of these elements vary at different levels of the conducting system [19].
The tracheal and proximal bronchial epithelia are composed predomi-
nantly of columnar ciliated and goblet cells, attached to the underlying basal
lamina. These cells are attached to one another by tight junctions, forming a
barrier physically impermeable to most substances [9, 19].
The subepithelial tissue can be subdivided into a lamina propria and a
submucosa, consisting of all the remaining airway tissue.
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Figure 1.4: Schematic diagram and real image of a medium-sized bronchus. The cartilage
reinforcement is clearly visible in dark blue. In the wall of the bronchus it is possible to
recognize the smooth muscle. The lining of all bronchi is the typical respiratory epithelium
(TRE). In the image on the right it is possible to observe one of the large arteries that run
alongside the bronchi. Numerous smaller blood vessels are present among the profiles of the
gas exchange areas. Bronchioles have a similar structure but do not present cartilage plates
since, when the airways diameter is smaller, smooth muscle in the wall has sufficient tone to
resist collapse [22].
Figure 1.5: Tissue layers of the tracheobronchial tree. Reprinted from [23].
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The lamina propria consists principally of a network of capillaries, of
reticular fibers, and bundles of elastic and nerve fibers. These fibers are
believed to help transmit to the more rigid and stronger cartilaginous fibrous
tissue the tension that arises in the airway epithelium and lung parenchyma
during breathing [9, 19].
The submucosa contains cartilage, muscle, and other supportive connec-
tive tissue elements, including the loose connective tissue known as adventi-
tia (whom mainly serves as a support for trachea and bronchi). The majority
of the tracheobronchial glands are located in the submucosa and they are
almost absent in the smallest bronchi and bronchioles. These glands are
mainly responsible to secrete mucus. A variety of substances that are poten-
tially important in local airway defense are also secreted by serous cells [9,19].
Moving towards the respiratory zone, the surface of respiratory bronchi-
oles is lined by cuboidal epithelium that gradually decreases in extent as the
number of alveoli increases. Bronchiolar-type epithelium and lamina propria
are absent in alveolar ducts [9, 19].
Alveoli are demarcated by septa composed of a continuous layer of epithe-
lial cells overlying a thin interstitium. The interstitium contains capillaries
involved in gas exchange (Figure 1.3), as well as connective tissue and a
variety of cells responsible for maintaining alveolar shape and defense. Of
particular interest is their secretion of surfactant, a phospholipid which forms
an extremely thin (4 nm) layer of material that covers the alveolar epithelial
surface and is responsible to reduce the alveoli surface tension, preventing
them from collapsing [15, 19].
1.1.1.3 Defense system
Letting aside the first-pass metabolism constituted by the nasopharyngeal
anatomy (able to stop particles with size ≥ 2-3 µm), lungs have several defense
mechanisms to clean and protect themselves from external potentially harm-
ful pathogens. Some of the most relevant of such mechanisms include the
mucociliary clearance , the epithelial barrier , and the phagocytic system [24].
The mucociliary clearance is the removal of impacted particles from the
terminal bronchioles to the trachea by the ciliary beats of epithelial cells in
the mucus of bronchi. The mucus acts as a barrier for bacteria as well.
Epithelial cells provide a mucosal barrier (with antimicrobial properties)
and contribute to the mucociliary clearance function just mentioned. At the
same time, lining the luminal surface of the airways and being tightly attached
one to the other, they form a physical barrier between the luminal space and
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the pulmonary parenchyma. Similarly, the alveolar epithelial cells strongly
contribute to pulmonary host defense through the surfactant.
Many cells concerned with airways defense are found in the lungs, in-
cluding lymphocytes, dendritic cells, and mast cells [19, 24]. Nevertheless,
macrophages are the resident mononuclear phagocytes of the lung which pro-
vide the first line of defense against organisms or particles reaching the lower
airways. In a normal lung, they account for about the 95% of all the nonep-
ithelial cells in lung parenchyma [19]. Even though still matter of debate, it
is acknowledged the possibility that pulmonary macrophages have different
functional capabilities. For this reason they are often divided in several groups
on the basis of their anatomic location [19, 24, 25]. Commonly the following
groups are distinguished: (a) the airway macrophages, situated on the epithe-
lial lining of conducting airways; (b) the alveolar interstitial macrophages; (c)
the alveolar surface macrophages; (d) the intravascular macrophages, located
adjacent to the capillary endothelial cells; and (e) the pleural macrophages.
Finally, depending on the load of pathogens, various non-resident effector
cells can be recruited. For example, eosinophils are abundant in the infiltrates
of late phase reactions and contribute to many of the pathological processes in
allergic diseases whereas the recruitment of neutrophils is a major component
of the protective host response to bacterial infections [24].
1.1.1.4 Rodents and human’s lungs comparative anatomy
In both rodents and humans, the right and the left lungs are enveloped by a
thin layer of connective tissue (the visceral pleura), which extends into the
parenchyma, dividing it into several lobes. Nevertheless, at this level, substan-
tial structural differences can be found between the two orders (Rodentia and
Primates). In mice (Figure 1.6a) and rats the left lung consists of one single
lobe whereas the right one consists of four lobes (superior, middle, inferior
and post-caval lobes) [26]. Conversely, as shown in Figure 1.6b, human’s left
lung is composed of two lobes (upper and lower) while the right side is di-
vided into three lobes (upper, middle, and lower) [15].
The total capacity of mouse lungs has been reported to be about 1 ml, com-
pared to 10 ml of the rat and 6,000 ml of a human. Mouse lungs have fewer
respiratory bronchioles and airways generations (13-17 generations) than
human lungs (17-21 generations) [27, 28]. It has also been found that, while
the branching pattern in humans is dichotomous (that is, the parent branch
divides into two parts), in rodents monopody (a small segment branching off
from the main stem) is commonly observed [16,27,29]. The parenchyma in
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(a) Mouse lung (b) Human lung
Figure 1.6: Schematic representation of mouse and human’s lung structure.
mice occupies roughly the 18% of the total lung (24% in rats), with an average
alveolus mean linear intercept of 80 µm (100 µm for rats) and a blood-gas
barrier thickness of 0.32 µm (0.38 µm for rats) [27, 29, 30]. The parenchyma
of the human occupies a smaller fraction of the total lung (12%), with larger
alveoli mean linear intercept (210 µm) and gas-blood barrier (0.62 µm) [15,27].
An important functional difference observed between rodents and humans
is the paucity of submucosal glands and the presence of a high number of
nonciliated cells (Clara cells) in rodents [27].
Even though the significance of all these anatomical features of the mouse
lung for lung function is matter of debate, it is generally believed that they
might explain the different inflammatory effects of specific allergens on ro-
dents and humans [27].
1.1.2 Lung pathologies
Respiratory diseases comprise a vast number of pathological conditions affect-
ing the pulmonary tract, including conditions of the upper respiratory tract,
trachea, bronchi, bronchioles, alveoli, pleura, pleural cavity, and the nerves
and muscles of breathing. They range from mild (e.g., common cold) or self-
limiting to life-threatening (e.g., bacterial pneumonia, lung cancer, etc.) [1,31].
While a comprehensive classification of these pathologies can be found in
specific reports of the World Health Organization (WHO) [32], for practical
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reasons the major part of the most common lung diseases can be categorized
as follows [31]:
• Obstructive diseases : All these diseases are characterized by airways
obstruction, which can originate for different reasons. Firstly, the lumen
can be partially or totally obstructed by excessive secretions (e.g. in
chronic bronchitis); secondly, the obstruction can take place in the wall
of the airway because of an excessive contraction of the bronchial smooth
muscle (e.g. in asthma), hypertrophy of mucous glands (e.g. chronic
bronchitis) or inflammation and edema of the wall (like both in asthma
and chronic bronchitis). Finally, the obstruction can be due to changes
that take place in the peribronchial region. This is for example the
case of the lung parenchyma destruction typical of emphysema (with
its loss of radial traction and consequent narrowing of the airway) or
peribronchial edema [31].
The most frequent pathologies which belong to this category are asthma
[33] (see Section 1.1.2.1) and the so-called Chronic Obstructive Pul-
monary Diseases (COPDs) [31], which include emphysema (enlarge-
ment of the air spaces distal to the terminal bronchioles, with destruc-
tion of their walls [9]), chronic bronchitis (excessive mucus production
in the bronchial tree, sufficient to cause excessive expectoration of spu-
tum) or a mixture of the two [31].
• Restrictive diseases : All these diseases are characterized by a restric-
tion of lung expansion, resulting in a decreased lung volume due to
alterations of the lung parenchyma or to pathological conditions of the
pleura (e.g., pneumothorax), chest wall (e.g., scoliosis) or neuromus-
cular apparatus (e.g., muscular dystrophies) [31]. The most frequent
pathology which belong to this category is the diffuse interstitial pul-
monary fibrosis, whose main feature is the excessive thickening of the
interstitium of the alveolar wall [9].
• Vascular diseases : All these diseases are characterized by pathological
conditions of the pulmonary vasculature. The most frequent pathologies
which belong to this category are the pulmonary embolism (blockage of
the main artery of the lung or one of its branches by a substance that has
travelled from elsewhere in the body through the bloodstream) and the
pulmonary hypertension (increase of pulmonary blood pressure which
may lead to heart failure). The abnormal accumulation of fluids in the
extravascular spaces and tissues, known as pulmonary edema, belongs
9
1. Introduction
to this category as well, even though it’s a complication of a variety of
heart and lung diseases rather than a disease on its own [31].
• Environmental, infectious, suppurative, and diseases : This category
comprises a large range of diseases which do not fit in the previous
three classes of pathologies, including many occupational lung diseases
caused by inhaled dusts, abnormal functioning of exocrine glands (e.g.,
cystic fibrosis) or viruses and bacteria (e.g., pneumonia and tubercolo-
sis). In addition, neoplastic diseases of the lung are included in this
category (see Section 1.1.2.2).
1.1.2.1 Asthma
Asthma is a complex chronic inflammatory disorder of the airways which
involves several inflammatory cells and mediators and which results in patho-
physiological changes of the lungs. As the pathogenesis of asthma is not clear,
its description is generally based on the functional consequences of airway in-
flammation, including the airways excessive responsiveness to various stimuli
that leads to recurrent episodes of wheezing, breathlessness, chest tightness,
and coughing. These episodes are often associated with diffuse airflow ob-
struction within the lungs. For these reasons, for didactic purposes, asthma is
generally categorized as an ‘obstructive disease’ [31].
The burden of asthma is consistent worldwide, with an estimate of about
300 million individuals affected by this airways disorder and 250 000 annual
deaths [34]. The economic impact of asthma is substantial all over the world,
both for direct medical costs (cost of medications and hospitalizations) and
indirect non-medical costs (asthma is a major cause of absence from work in
many countries) [34].
Pathophysiology The three main hallmarks of asthma are airway inflam-
mation , bronchial remodeling and airway hyperresponsiveness [33–37], as
schematically shown in Figure 1.7. The relation intercurring among them is
not clear; it is supposed that the inflammatory process results in the charac-
teristic pathological changes of the airways in ways that are not well under-
stood. Even though it is still matter of debate, it seems that inflammation and
bronchial remodeling may be strongly associated to airways hyperresponsive-
ness and the other asthma symptoms [34, 38].
• Airways inflammation : the presence of inflammation is a constant
feature in all asthmatic patients [34]. Typically mucosal mast cells and
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macrophages are activated by allergens and release bronchoconstrictor
and inflammatory mediators. Increased number of mast cells in airway
smooth muscle may be linked to airway hyperresponsiveness while
macrophages mediators amplify the inflammatory response [34, 36]. A
significant increase in the number of airways eosinophils, neutrophils,
and T-lymphocytes is commonly observed. While the pathophysiological
role of neutrophils and T-lymphocytes is still unclear, eosinophils are
suspected to be at the basis of the damaging process of epithelial cells
and airway remodeling [34, 36].
Figure 1.7: Schematic representation of asthma pathophysiology. Several inflammatory cells
and mediators are recruited or activated, producing acute effects on the airway (bronchocon-
striction, plasma leakage, mucus secretion, sensory nerve activation, . . . ), together with remod-
eling structural changes (subepithelial fibrosis, angiogenesis, increased thickness of airway
smooth muscle, hyperplasia of mucus-secreting cells, . . . ). Reprinted from [36].
• Bronchial remodeling : with this term it is generally indicated all the
characteristic structural changes in the airways of asthma patients,
which often result in an irreversible thickening of bronchial walls and,
consequently, narrowing of the airways [33, 34, 36, 38]. These changes
include subepithelial fibrosis with deposition of collagen fibers (base-
ment membrane thickening), airway smooth muscle hypertrophy (in-
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creased size of individual cells) and hyperplasia (increased cell divi-
sion), blood vessels proliferation (angiogenesis) and increased mucous
secretory cells (hypertrophy of mucosal glands, hyperplasia of goblet
cells,. . . ) [33–35, 39–42].
• Airway Hyperresponsiveness : with this term it is generally indicated
the excessive airways narrowing in response to an external stimulus
which would be innocuous in a person not affected by asthma. This
airway narrowing, as a consequence, leads to airflow limitation. Its
mechanism is probably connected to the excessive contraction of airway
smooth muscle, thickening of the airway wall, and sensitized sensory
nerves [34–36, 43]. It is therefore hypothesized that both inflammation
and bronchial remodeling play an important role in the hyperesponsive-
ness development [34].
Treatments Medications to treat asthma are classified as controllers or
relievers [34]. The formers are medications which are based on a long-
term approach and are taken daily to keep asthma under clinical control
mainly thanks to their anti-inflammatory effects; they include inhaled and
systemic glucocorticosteroids (e.g., budesonide) and long-acting inhaled β2-
agonists [36]. The latters are medications used on a as-needed basis in order
to quickly reverse acute asthma symptoms [34], mainly acting on the bron-
choconstriction; short-acting β2-agonists belong to this category [36].
While it has been shown that controller medications can strongly improve
patients’ quality of life (controlling airways inflammation, decreasing airways
hyperresonsiveness and severity of exacerbations), it is widely known that
they do not cure asthma and they have to be taken continuously [34]. All
these therapies are intended to treat inflammation and bronchoconstriction
whereas bronchial remodeling still remains insensitive to current asthma
treatments [44]. Whether and when to begin treating patients with asthma
to prevent or reverse the negative effects of remodeling, which components
of remodeling to target, and how to monitor remodeling are still matters of
debate.
1.1.2.2 Lung Cancer
Lung cancer is a disease characterized by uncontrolled cell growth in the lung
tissues. Its development is the result of multiple alterations which include
the classical genetic abnormalities that cause the overactivity of growth pro-
moting oncogenes and the inactivation of the tumor suppressor gene [45].
The most common cause of lung cancer is long-term exposure to tobacco
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smoke, which accounts for 80-90% of all lung cancers [46,47]. The other cases
are generally attributed to a combination of genetic factors and exposure to
a number of carcinogenic substances like radon gas, asbestos, some metals
compounds (cadmium, chromium, beryllium, nickel, arsenic, . . . ), ionizing
radiations and air pollution (including second-hand smoke) [31, 46, 47].
Lung cancer is the leading cause of cancer deaths worldwide and the third
cancer for occurrence in both sexes (after breast and prostate cancers) [48].
The burden of this disease is impressive since it is estimated that lung cancer
is responsible for more than 1.3 million deaths per year [46, 48].
Pathophysiology Lung cancers are mainly classified as either Small-Cell
Lung Cancers (SCLCs) or Non-Small-Cell Lung Cancers (NSCLCs) [47]. SCLCs
account for approximately 15% of all lung cancers, they develop mainly in
the main bronchi (bronchial submucosa), and are highly malignant, spreading
early in the course of the disease. The name comes from the fact that the oval-
shaped cells which compose this type of tumor are smaller than normal cells
with scant cytoplasm. Virtually all patients with SCLC have a smoking his-
tory [45–47]. On the other hand, NSCLCs account for approximately 85% of
all lung cancers and are commonly further divided into three sub-categories:
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [49].
• Adenocarcinoma : it is a malignant epithelial tumor with glandular
differentiation and mucus production which generally develops periph-
erally in the lungs. Adenocarcinomas account for approximately 40-45%
of lung cancers. The majority of adenocarcinoma cases are associated
with smoking; nonetheless, this type of lung cancer is the most common
in non-smokers [47, 49].
• Squamous cell carcinoma : it is a malignant epithelial tumor showing
keratinization and/or intercellular bridges that arises from bronchial
epithelium. It generally arises centrally in the main bronchi and it
accounts for approximately 30% of lung cancers. Like for SCLCs, over
90% of squamous cell lung carcinomas occur in cigarette smokers [49].
• Large cell carcinoma : it is, by definition, a poorly differentiated tumor.
It is a diagnosis of exclusion made after ruling out the presence of a
component of squamous cell carcinoma, adenocarcinoma or small-cell
carcinoma. Large cell carcinoma typically appears as a large, peripheral
mass, but may also involve large bronchi. It accounts for approximately
10% of lung cancers [49].
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Diagnosis and treatments Prognosis of lung cancer is generally very poor,
with an overall five-year survival rate of 15% [46, 47, 50]. The main reason of
this is that the disease is often diagnosed at its latest stages [45, 47]. Surgery,
when applicable, is the treatment of preference. Radiotherapy and chemother-
apy are generally used as adjuvant therapies or as primary/palliative therapies
when the tumors are inoperable [46, 47].
The diagnosis mainly relies on chest radiograph whereas Computed To-
mography (CT) imaging is generally employed to better understand the type
and extent of the disease [47, 50]. The final diagnosis of lung cancer is based
on histological examination of the suspected tissues after bronchoscopy in
order to avoid the typical false positives of CT imaging [51]. Even though it
has been shown that the benefit in monitoring subjects at risk (e.g., smok-
ers) with conventional imaging techniques (e.g., CT) brings great advantages
in terms of early diagnosis and hence prognosis [50, 52–54], concerns have
been raised about the radiation risk [3, 47]. Preliminary modeling studies
suggest that potential risks may largely outweigh benefits in nonsmokers or
in young patients [51, 55]. No current guidelines recommend mass screening
to diagnose this pathology, not even for at-risk individuals [56, 57].
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1.2 MRI of the lung
1.2.1 Main challenges in MR lung imaging
MRI is a versatile imaging tool which has shown to have a huge potential
in imaging lung diseases [2, 5]. Inter alia, its capability of providing good
spatial resolution and high contrast in soft tissues without the employment
of ionizing radiation (typical of Positron Emission Tomography (PET) or CT)
has proven to be extremely valuable in non-invasive longitudinal studies,
especially in young patients [2, 4, 5]. Furthermore, the wealth of information
which MRI can provide thanks to the different image contrast mechanisms
(e.g., proton density, T1 or T2 relaxation times, diffusion,. . . ) has contributed
to the interest in this technique. All these properties have allowed to prove
that MRI is the most adequate technique for the screening and diagnostics of
numerous pathologies in brain, heart or liver. Nevertheless, this consideration
cannot yet be applied to the lung, which remains one of the most difficult
organs to image with MRI because of its intrinsic properties [5,7–9]. In partic-
ular, the low proton density of the lung, the enormous amount of air-tissue
interfaces and the cardio-respiratory motions hamper the quality of standard
proton MRI lung images. Motion artifacts typical of standard non-optimized
gradient-echo sequences are shown in Figure 1.8a. When optimized conven-
tional sequences are used, the amount of motion artifacts can be strongly
reduced [7, 58, 59]. Nonetheless, the low proton density and short T ∗2 of lungs
generate images where the parenchyma appears extremely dark (Fig. 1.8b).
Even though a number of studies is enabled by this optimized lung images
(see section 1.2.2.4), especially when edematous or inflammatory signals are
present [60–63], the investigation of subtle changes in lung parenchyma are
often difficult with this kind of standard sequences.
1.2.1.1 Lung proton density
Human lungs weigh approximately 900-1000 g after death, including blood [9].
Considering that gas volume in lungs at end-expiration (functional residual
capacity) is about 2.5 liters and at maximal inspiration (total lung capacity)
is about 6 liters, it means that overall lung density varies from 0.3 g/ml to
0.15 g/ml [9]. This overall density actually does not reflect the complex lung
structural organization since the density of the lung is not uniform. In the
more peripheral (outer and lower) areas the conduit structures decrease in size
and undergo a progressive transition from dense nonparenchymal structures
(blood vessels, airways, lymph nodes, and thick accumulation of connective
tissue) to parenchyma (composed of about 80% air). Therefore, lung densities
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(a) Non-optimized gradient-
echo sequence
(b) Optimized gradient-echo sequence
Figure 1.8: Typical gradient-echo images of the lung. (a) When standard non-optimized
gradient-echo sequences are used, blurring and ghost motion artifacts can make the image
impossible to be exploited. (b) When these sequences are optimized, the amount of motion
artifacts can be significantly reduced and images can be used to study a few specific pathologies.
Nonetheless, lung images still appear dark and carry very little information about the lung
parenchyma signal. Image (a) is adapted from reference [64] (TR/TE=7.8/2.1 ms, FA=15 deg,
40 averages); image (b) is adapted from reference [65] (TR/TE=5.6/3.5 ms, FA=10 deg, 60
averages).
as low as 0.1 g/ml can be observed at the lung periphery [6, 9].
Since the proton MRI signal is directly proportional to the tissue proton
density, even under ideal imaging conditions, the NMR signal of the lung is
up to ten-times weaker than the one of the surrounding tissues. Furthermore,
the change in lung proton density between different phases is an important
source of amplitude modulation of the NMR signal during respiration.
The low Signal-to-Noise Ratio (SNR) in lung parenchyma makes the mor-
phological proton MRI of the lung challenging. The SNR can be increased
using larger voxel sizes (SNR ∝ voxel size) or the number of averages (SNR
∝ √averages). Nonetheless, the former choice implies a loss in spatial res-
olution with the possible consequent impossibility to detect small lesions
whereas the latter causes a significant increase in the image acquisition times
beyond 10 minutes, which would make the protocol unsuitable for clinical
applications [6].
1.2.1.2 Lung air-tissue interfaces
The extensive presence of air-tissue boundaries, due to the huge amount of
airways and alveoli, has profound effects on the NMR properties of the lung.
Since oxygen in air is paramagnetic and tissue is diamagnetic, a substan-
tial magnetic susceptibility difference (∆χ ≈ 8 ppm) is present at air-tissue
interfaces, leading to significant static local field gradients. The strongly in-
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homogenous local magnetic field gradients at the microscopic scale lead to a
rapid dephasing of the proton spins, resulting in typical magnetic resonance
(MR) images of the lung which are dark and give poor information about the
parenchymal tissue [6, 9].
The dephasing process that takes place because of magnetic field inhomo-
geneities is typically described by an apparent relaxation time T ∗2 according
to the monoexponential law [9]:
S(t) = S(t = 0) · exp
(
−T E
T ∗2
)
,
where TE indicates the Echo Time of the MRI pulse sequence and:
1/T ∗2 = 1/T2 + 1/T
′
2.
Here T2 is the transversal (spin-spin) relaxation time and T
′
2 is a contribution
to the signal relaxation time from the local field inhomogeneities.
At 4.7 T, a magnetic field commonly used in small animal scanners, T ∗2 in
the lung parenchyma of mice has been reported to be between 0.46 ms [66]
and 1.27 ms [67] whereas in humans values ranging from 0.89 to 2.18 ms have
been measured at 1.5 T [68]. In the light of these considerations, it is clear that
proton MRI of the lung becomes even more challenging and requires pulse
sequences with very short echo times (T E < 1− 2 ms).
A theoretical model of the static dephasing due to inhomogeneities was
proposed by Yablonskiy et al. [69], which assumed that magnetized spherical
objects (alveoli) are embedded in a given medium and obtained the following
analytical formula for the apparent relaxation time of the lung:
1
T
′
2
=
2pi
3
√
3
ηγ
∆χ
3
B0,
where η is the alveoli volume fraction, γ is the gyromagnetic ratio for proton,
and B0 is the magnetic flux density. This model, which provides theoretical
values of lung T ∗2 close to the experimental ones, clearly shows the dependence
of the apparent transversal relaxation time from B0. Such inverse proportion-
ality explains why, for proton lung MRI, at high fields the expected SNR gain
can often not be realized.
Under this point of view, low field proton MRI (B0 = 0.5 T ) has shown
a certain potential in lung imaging. Nonetheless, the long acquisition times
required by the low signal-to-noise due to the low field strength make this
tool less attractive from a clinical perspective [6].
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1.2.1.3 Lung cardiorespiratory motion
Two asynchronous physiological processes contribute to the signal change in
MR images of lung parenchyma: heart beats and respiration. The intensity of
lung parenchyma NMR signal i(t) can be modeled as [70]:
i(t) = i0 −Arcos(2n)
(
pit
τr
−ϕr
)
+Acsin
(2m)
(
pit
τc
−ϕc
)
, (1.1)
where i0 is a constant value, τr and ϕr the period and phase of the respira-
tory cycle, τc and ϕc the period and phase of the cardiac cycle, Ar and Ac the
amplitude of both cycles, and n and m parameters influencing the shape of
the curve.
Heart and breathing cycles can be a major source of artifacts in lung MRI
when these asynchronous movements occur on a time scale which is shorter
than the time required to obtain the image [6]. In standard gradient echo
sequences, the cardiorespiratory motion can result in a blurring of pulmonary
and vascular structures within the lungs as well as ghostlike artifacts along
the direction of the phase-encoding gradients (Fig. 1.8a) [9, 71].
The cardiac and respiratory rates for humans are 60-80 beats per minute
and 12-20 breaths per minute, respectively; for mice the corresponding values
are 480-600 beats per minute and 150-160 breaths per minute [9, 15, 27, 70].
Looking at equation 1.1, it is therefore clear that motion artifacts are even
more relevant in small animals, where spatial resolution and image quality
can be rapidly degraded.
To reduce cardiac motion artifacts, the electrocardiogram (ECG) synchro-
nization method is the most used and precise technique [71]. ECG is a transtho-
racic interpretation of the electrical activity of the heart over a period of time,
as detected by electrodes attached to the surface of the skin and recorded by a
device external to the body. ECG gating allows the signal to be acquired in the
same phase of cardiac cycle, resulting on average in reduced cardiac motion
artifacts. Nonetheless, the efficacy of this technique is partially limited due to
the normal beat-to-beat variability, premature heart contractions, and changes
due to respiration or possible patients’ arrhythmias [71]. In addition, the
limitations of respiratory synchronization methods apply as well to cardiac
gating techniques (see next paragraphs).
With respect to respiratory motion, a number of techniques have been
proposed to reduce the influence of breathing cycle on lung MR images [71].
For example, in humans breath can be voluntarily held back (breath-hold
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technique) and a fast pulse sequence acquisition can be performed whilst the
breath is held in the acquisition window of approximately 20-30 seconds. The
operation can be repeated a certain number of times (4-6) if needed. While the
breath-holding can notably reduce the respiratory motion artifacts, a series of
drawbacks can be identified. First of all, it is difficult to achieve consistently
the same lung volume in a series of images or between subjects. Secondly, this
technique requires the full cooperation of the patient, which often becomes
complicate in presence of advanced pathologies which impair lung functions
(e.g., COPD) [71]. In addition, the breath-hold technique cannot be applied to
animal studies.
When working with animals, three main categories of motion-reduction
or compensation techniques can be identified: forced-breathing gating meth-
ods, non-forced-breathing gating methods and free-breathing methods.
Forced-breathing gating methods This category is based on the use of me-
chanical ventilators. A breathing valve is generally attached directly to the
endotracheal tube and allows for independent control of inspiratory and
expiratory phases of ventilation. With the use of a ventilator, the imaging
sequence is triggered at a well defined moment of the respiratory cycle, with
a consequent improvement in the image spatial resolution. Nonetheless, this
technique has several disadvantages since it can interfere with the pathophysi-
ology of the lung and it implies complicate and invasive protocols. In addition,
it has been reported that the use of the ventilator can cause lung injuries, pul-
monary edema, hypoxemia, and increase the number of neutrophils in the
lungs [71–73].
Non-forced-breathing gating methods This category is based on monitor-
ing the displacement of the diaphragm during scanning, with or without the
use of an external sensor. In the former case a bellow device is employed
whereas in the latter navigator-echo or self-gating techniques are used. In this
case, the acquisition of a partial set of k-space data is processed to track the
motion and is usually collected when passing through the origin of k-space.
The information about the diaphragm displacement, either obtained using an
external bellow device or a navigator-echo, is used to synchronize image data
acquisition through prospective or retrospective respiratory gating [71].
During prospective gating, the respiratory motion is monitored and im-
ages are acquired only when the respiratory signal is within a predetermined
gating window. In retrospective gating, the signal is collected regardless of
the respiration phase; after the signal has been collected, the specified pa-
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rameters are used to decide whether a certain signal is accepted or rejected
for inclusion in the k-space. While the post-acquisition analysis process may
require more sophisticated algorithms, retrospective gating allows to recon-
struct images relative to different phases of respiration and does not increase
the total acquisition times as in the case of prospective gating. In addition,
it has to be noted that the use of all prospective synchronization methods
introduces magnetization instabilities due to variable repetition time of the
imaging sequence, which may alter the image contrast and influence image
quantification [9, 13, 71].
Free-breathing methods This category is based on signal averaging. Signal
averaging consists in increasing the number of acquisitions to reduce the
overall ghost artifacts and improve the SNR of the image, exploiting the
inconsistency of the motion artifacts amplitude [9, 71]. A proper trade-off has
to be found between the total acquisition time and the number of averages.
This technique has proven to be very efficient in several studies of lung
diseases, where working in physiological conditions is often required [7,58,
59].
1.2.2 MR techniques for lung parenchyma imaging
1.2.2.1 The k-space concept
Few time after the development of MRI it was understood that the description
of the time-varying signal coming from the precessing magnetization could be
easily analyzed by studying two- or three-dimension trajectories in a properly
defined space. This space, known as k-space, has become the dominating
formalism in NMR and will be shortly revised here1.
In the time domain, the signal created by the transverse magnetization
can be written as:
S(t) = c
∫
ρ (~r)e−iΦ(~r,t)d~r, (1.2)
where, ~r is the spatial variable, ρ (~r) is the spin density of the excited
protons, c is a proportionality constant and the phase Φ is:
Φ (~r, t) = γ
∫ t
0
~r · ~G (t′)dt′ .
1For comprehensive description of the MRI theory the reader is referred to references [71,
74].
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In this expression, ~G (t′) indicates the imaging gradients (~G (t′) = ~∇B0) and γ
the gyromagnetic ratio (γ/2pi ≈ 42.576 MHz/T for protons). Defining:
~k (t) =
γ
2pi
∫ t
0
~G (t′)dt′ ,
equation 1.2 can be written as:
S(t) = c′
∫
ρ (~r)e−i2pi~k(t)·~rd3r. (1.3)
The space were ~k (t) resides in is known as k-space and corresponds to the
spatial frequency domain. The time origin t = 0 corresponds to the time at
which the transverse magnetization is created by means of a radiofrequency
(RF) pulse.
Equation 1.3 shows that the MRI signal S(t) is the Fourier Transform (FT)
of the proton density ρ (~r). In other words, the spatial information of the object
is encoded as FT and can be selectively sampled by varying the gradients field.
The function ~k(t) is the Fourier conjugate variable to the spatial variable ~r.
As time evolves, S(t) describes a path ~k(t) in the k-space, known as k-space
trajectory.
1.2.2.2 Cartesian versus non-Cartesian k-space trajectories
The k-space trajectory illustrates the acquisition strategy and influences the
type of image artifacts that may occur. Several trajectory schemes have been
proposed in order to answer the different problems specific of each organ or
to obtain specific contrast mechanisms. An extensive description of common
acquisition trajectories is proposed for instance in references [71, 74].
The trajectories acquired in the k-space can be divided essentially in two
categories [71]: Cartesian and non-Cartesian. In the Cartesian encoding
scheme, the sampling points are acquired along parallel and equidistant lines,
resulting in a uniformly filled k-space, as shown in Figure 1.9a; in the non-
Cartesian scheme, the sampling can take place on non-regular or non-uniform
paths, as shown in Figure 1.9b.
From equation 1.3, it is clear that the time domain signal corresponds to
the FT of the transverse magnetization. Consequently, the MR image recon-
struction simply requires a two- or three-dimension inverse-FT of the entirety
of k-space. Since the received signal belongs to the complex domain, the image
is characterized by complex entries, and usually the magnitude values are
presented to the observer.
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(a) Cartesian trajectory (b) Radial trajectory
Figure 1.9: Schematic representation of typical (a) Cartesian and (b) radial acquisition schemes.
Adapted from [75].
When the acquired sample points lie on an equidistant grid, like for
Cartesian trajectories, the reconstruction can be performed using an inverse
Fast Fourier Transform (FFT). If the k-space is sampled with non-rectilinear
or non-uniform trajectories (e.g., spiral or radial acquisitions) the FFT cannot
be directly applied and a resampling to a uniform grid is necessary prior to
its use [71].
Cartesian k-space trajectories Since the spatial information is encoded
through the FT using a discrete sampling rate, specific requirements on the
trajectory acquisition follow from the mathematical properties of the Fourier
transform. In particular, the discrete sampling operation in the k-space in-
evitably leads to occurrence of periodic object copies in the image domain,
with the distance between the copies equal to the reciprocal of the sampling
step ∆k in the spatial frequency domain [71, 74, 75]. If ∆k is chosen too large,
neighboring copies of the object overlap or wrap around in the image space
(aliasing artifacts), making impossible the proper recovery of the object.
Defining the Field Of View (FOV) as the extent of the object to be imaged,
the Nyquist criterion imposes the following condition to be respected in all
the encoding directions in order to avoid aliasing artifacts:
∆k = 1/FOV . (1.4)
A way to reduce the sampling step is to change the sampling rate of the
receiver. It is therefore useful to define the receiver bandwidth (BW) as:
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BW = 1/∆t,
where ∆t is the sampling time of the receiver. Increasing the BW will therefore
result in a decrease in ∆k but also in a lower SNR. This is due to the fact that a
larger spectrum of Larmor frequencies is used for the spatial encoding, while
the noise floor can be assumed to be equally distributed in the frequency
space.
The field of view in the generic direction r can be written as FOV = n∆r,
where ∆r is the spatial resolution (pixel size) in the selected direction and
n the number of samples. From equation 1.4, it follows that the maximum
k-space sampling extent is related to image pixel size by:
kmax = n∆k = 1/∆r.
In Cartesian acquisitions, if the phase-encoding step size is chosen so that it is
smaller than in equation 1.4, no aliasing will occurr. In other words, in order
to obtain a given resolution ∆r without aliasing, n encoding are required, with
n equal to:
n = 2kmaxFOV . (1.5)
Examples of Cartesian k-space samplings applied to lung imaging are
presented in section 1.2.2.4.
Non-Cartesian k-space trajectories Non-Cartesian trajectories can assume
various shapes (e.g., spiral, concentric rings, etc.). In the next sections and
chapters, only the radial k-space trajectory will be discussed among the ’non-
Cartesian acquisitions’. For a more general discussion about non-Cartesian
trajectories, the reader is referred to [71, 74].
Projection Reconstruction (PR) (or radial sampling, projection acquisition)
was the first MRI k-space trajectory, introduced by Lauterbur in 1973 [76]. It
consists in filling the spatial frequency domain space with radial spokes rather
than a Cartesian rectilinear raster acquisition. These projections are generally
acquired with a constant increment ∆Φ in the polar angle (azimuthal angle)
Φ . For two dimensional radial acquisitions, the Nyquist criterion ensures
aliasing-free images if:
kmax∆Φ ≤ 1/FOV ,
where the maximum k-space radius kmax is related to the desired spatial
resolution, as described above. In other words, Nyquist criterion requires the
distance between samples on neighboring spokes (∆q in Figure 1.9b) to be
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less or equal to the distance ∆k between two samples along a spoke in order to
ensure an isotropic spatial resolution of ∆r = FOV /n. The number of required
radial spokes Ns for a 2pi sampling can be therefore written as:
Ns = 2pi/∆Φ = 2pikmaxFOV . (1.6)
Comparison of equations 1.5 and 1.6 leads to the relation:
Ns = pin, (1.7)
which suggests the minimum number of spokes required for a radial acquisi-
tion over 360◦ when n samples are acquired. Data collection can be performed
with 0 ≤ φ < pi (full echo acquisition) or 0 ≤ φ < 2pi (half-echo or Free In-
duction Decay (FID) acquisition) [71]. In the first case only one-half number
of views are required whereas in the second case radial spokes are always
acquired starting from the center of the k-space. Both the type of acquisitions
result in an identical spoke distance but differ in the orientation of the spokes,
leading to different responses to experimental inaccuracies [71, 74, 75].
1.2.2.3 UTE radial sequences
Even though radial acquisitions present a certain number of cons (e.g., sensi-
tivity to off-resonance effects, longer acquisition times, etc.), their inherent
shorter TE and reduced motion sensitivity compared to Cartesian samplings
make them especially suitable for lung parenchyma imaging. Their pros and
cons will be shortly discussed hereafter along with their main applications in
lung imaging. The description of the pulse sequence scheme and the recon-
struction algorithm used in this thesis are presented in section 2.1.
Short TE Because no phase-encoding gradient is used in PR (see section
2.1.1), the minimum TE achievable with radial acquisitions can be very short.
This property is particularly interesting when imaging very short T ∗2 tissues
such as lung parenchyma [10–12]. Various expedients have been developed
in order to further reduce the echo time achievable with PR, nurturing the
interest in the UTE radial sequences for lung imaging [71, 77, 78]. Among
these expedients, the acquisition of the FID instead of the full echo collection
is rather common. The FID is thus recorded right after the slice-selective
RF excitation and the slice-refocusing gradient. In this case, the echo time
is defined as the interval between the center of the RF excitation pulse and
the first point of the recorded FID. In order to minimize the TE, data acqui-
sition is often started from the beginning of gradient ramp using non-linear
sampling [71, 77]. Echo times shorter than 300 µs can be achieved in two-
dimension UTE radial acquisitions (see chapter 3).
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Reduced motion sensitivity One of the strong advantages of radial acquisi-
tions is less sensitive to motion artifacts (e.g., respiration, flow, etc.) compared
to Cartesian sampling [9,13,71,75,77]. As shown by Glover and Pauly [12],
the radial acquisition motion artifacts consist of streaks propagating from
the moving structure. These motion artifacts have low amplitude near the
moving object and often reside outside the anatomic boundaries of the sub-
ject. Conversely, in Cartesian imaging, the motion artifacts are manifested as
blurring and ghosting throughout the entire image, in the phase-encoding
direction. In addition, inherent oversampling of the k-space center in radial
acquisitions results in signal averaging of low spatial frequencies, which fur-
ther reduces the motion artifacts (at the expenses of a slightly increased image
blurring) [12, 71].
A side advantage of the repeated acquisition of the central point of the
k-space is the self-navigating (or auto-navigating) potential of PR. Indeed, the
NMR signal amplitude measured at the center of the spatial frequency domain
corresponds to the total transverse magnetization from the whole imaged
volume (see equation 1.3, with ~k(t) = 0). When the FOV contains moving
structures, consecutively acquired echoes will thus exhibit peak changes
proportional to the changes in the overall transverse magnetization caused by
motion. Radial acquisitions allow the detection of these signal changes at each
radial projection. As a consequence, the signal amplitude changes measured
at the center of k-space can be used to monitor or correct for motion. Such
property was shown to be useful in implementing retrospective gating without
respiratory monitoring or cardiac ECG, as shown in Figure 1.10 [13, 71].
Drawbacks Radial acquisitions present some drawbacks compared to stan-
dard Cartesian sampling schemes. A detailed analysis of some of them can be
found in [71, 75, 77, 78].
First of all, PRs are characterized by an increase in scan time compared to
Cartesian trajectories if the Nyquist criterion is satisfied. Looking at equation
1.7, Nyquist sampled two-dimension radial acquisitions require at least pi/2
(∼ 57%) more views than a comparable Cartesian sampling scheme, when
acquisition is performed over 180◦ (two times more when performed over
360◦). This is due to the fact that radial acquisitions inherently oversample
the k-space close to the center, while leaving the periphery undersampled.
Likewise, the non-uniform sampling requires the use of regridding algorithms
and weighting functions before the application of the inverse FFT (for more
details see 2.1.2).
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Figure 1.10: Schematic diagram of the retrospective self-navigating reconstruction technique.
Only the projections that are acquired during the desired respiratory window (in grey) are
used to reconstruct the image from the composite k-space. Adapted from [13].
Secondly, radial sequences are especially sensitive to off-resonance ef-
fects and eddy currents, which can result in image blurring [71, 75]. Several
non-trivial solutions have been proposed to minimize these problems. Ex-
perimentally, the former can be minimized using shorter TEs and wider
acquisition bandwidths BWs (taking into account the trade-off between BW
and average SNR) whereas the latter can be reduced optimizing the hard-
ware (e.g., working with self-shielded coils) or measuring the real k-space
trajectory [71, 75].
Applications to lung imaging The advantages described above clearly make
the UTE radial acquisitions especially interesting in lung imaging. In partic-
ular, the very short TEs achievable with UTE radial MRI allow the visual-
ization of lung tissue with high SNR (see chapter 3). This advantage over
standard Cartesian sequences has been exploited in animal studies in or-
der to detect emphysema and fibrosis microstructural changes of the lung
parenchyma [66,79,80]. In addition, alterations in ventilation/perfusion ratio
in lung injury models have been measured with UTE radial sequences in
several studies [14, 81]. Furthermore, the reduced sensitivity of UTE radial
sequences to motion artifacts was shown to allow for the accurate detection
and quantification of edematous signals and mucus plugging in acute models
of inflammation [14, 82]. Finally, UTE radial sequences have been applied on
humans to study lung morphology, physiology and pathologies [5, 83, 84].
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The advantages, the limitations, some possible new applications, and the
potential of this class of sequences will be discussed throughout the whole
thesis, as anticipated in the Preface.
1.2.2.4 Other techniques for lung parenchyma imaging
Many techniques have been proposed to study specific questions related to
lung morphology, function or pathologies. Exhaustive review articles can be
found in literature about the commonly used tools in pre-clinical and clinical
lung studies [5–7, 9, 50, 85]. In this section only some of the most common
MRI pulse sequences currently used in lung studies will be presented as a
possible alternative to UTE MRI.
Spoiled gradient-echo sequences They are a class of sequences that enable
the acquisition of a gradient echo after the RF excitation with a flip angle (FA)
lower than 90◦. The remaining transverse magnetization is destroyed after the
data acquisition (spoiling). The distance between two different RF excitations
is called repetition time (TR) while the interval between the RF excitation
pulse and the refocusing of the spins (echo) is defined as TE [71]. The Fast
Low-Angle Shot (FLASH) sequence (see Figure 1.11a) is a commonly used
acquisition scheme belonging to this category of Cartesian acquisitions2.
In FLASH sequence, a single row of k-space is acquired after one RF ex-
citation, whereas for each TR a different row is acquired (see Figure 1.11b).
Echo times in the order of the millisecond can be achieved even though, when
imaging lung parenchyma, TE ≤ 1 ms have to be used [6]. The sequence can
have a strong T ∗2 weighting component (for long TEs) even though an addi-
tional T1 or spin density contrast can be achieved, according to the chosen
parameters (TE, TR and FA) [6, 71].
This kind of sequence has several applications in lung MRI for anatom-
ical imaging, magnetic resonance angiography or contrast-enhanced stud-
ies [5–7, 85]. Beckmann et al. [59] have indeed shown that spoiled gradient
echo sequences can lead to images with reduced motion artifacts by using
averaging approaches. Since then, gradient echo imaging has been applied to
detect and quantify mucus secretions, inflammation, vascular remodeling and
parenchymal destruction in a number of animal models of lung diseases like
COPDs [62, 63, 86, 87], pneumonia [88], or lung fibrosis [89, 90]. In clinical
2Other acronyms are used by different vendors to indicate the same pulse sequence scheme.
In this work only the acronym FLASH will be used.
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(a) FLASH pulse sequence (b) FLASH k-space
Figure 1.11: Schematic representation of (a) a generic FLASH sequence and (b) its respective
sampling k-space trajectory. In the pulse sequence chronogram no gradient spoiler is repre-
sented at the end of sequence. Spoiling can indeed be achieved in different ways, including
very long TRs, end-of-sequence RF gradient spoiling or (like in this case) RF spoiling by phase
cycling the RF excitation pulse. Adapted from [64] and [75].
practice, two and three dimensional gradient echo sequences have shown to be
useful in the detection of pulmonary nodules or perfusion disorders [5,50,85].
Some applications of this class of sequences, its advantages and its limita-
tions will be sparsely presented in the next chapters, in relation to the lung
disease models which will be discussed after on (i.e., asthma and lung cancer).
Balanced steady-state free precession sequences This class of sequences
is similar to the previous one, except for the fact that the transverse magneti-
zation is not spoiled at the end of each TR. Indeed, in this type of sequences a
steady-state free precession is reached, refocusing the transverse magnetiza-
tion at the end of each repetition time interval. To do so, within each TR all
gradients are balanced (i.e., the gradient dephasing is refocused). For short
TR, this kind of sequences are characterized by a contrast T2/T1 [6]. Balanced
steady-state free precession sequences are extremely sensitive to off-resonance
and field inhomogeneities, which causes banding artifacts. A possible solution
to this common problem consists in the acquisition of several images in which
these bands are spatially shifted by RF phase-cycling, and the subsequent
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combination of them into an image with reduced banding artifacts [71].
Their similarity with spoiled gradient-echo sequences allows to reach short
TEs and TRs, which makes them interesting tool for rapid lung imaging. Their
inherent contrast makes them effective for imaging blood and mucus (long
T2 compared to lung tissue). In clinical practice, balanced steady-state free
precession sequences have shown to be effective in the detection of pulmonary
embolism and in the study of respiration mechanics [5, 6, 70, 85].
Single-shot fast spin echo sequences It is a subclass of sequences that uses
spin echoes instead of gradient echoes (i.e., the echo is collected after an
RF excitation pulse with FA = 90◦ and a refocusing pulse with FA = 180◦).
In single-shot fast spin echo sequences a train of spin echoes is obtained
by repeated refocusing of the first spin-echo. These sequences allow the
acquisition of all the lines of the k-space in a single echo train, making them
suitable for rapid imaging [5, 6, 85]. This kind of sequences is characterized
by a T2 contrast and is starting to be employed in lung imaging studies [6].
In clinical practice, single-shot fast spin echo sequences have shown to be
effective in the detection of lung infiltrates and nodules [5]. These sequences,
with or without motion compensation techniques, have shown to be extremely
useful when imaging pediatric patients because of the rapid imaging they
allow [5].
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1.3 MRI contrast agents for lung imaging
As described in section 1.2.1, a number of challenges have to be faced when
imaging lung with MRI. Several solutions have been described for minimizing
motion artifacts (see 1.2.1.3 and 1.2.2.3). Similarly, the fast dephasing caused
by susceptibility gradients can be minimized using short TEs or low magnetic
fields, as described in sections 1.2.1.2 and 1.2.2.3. Nonetheless, the weak NMR
lung signal, due to the low proton density of this organ, remains a strong
limitation [91].
Among the solutions which have been proposed in the last decades, the
use of exogenous contrast agents is a very promising one and it is in continu-
ous development. A number of techniques have been advanced to improve
lung imaging. The application and advantages of these contrast media go
beyond the simple increase in the SNR per unit time. Indeed, it has been
shown that these exogenous agents can have multiple diagnostic or thera-
peutic applications [91]. Hereafter a short overview of the main categories
of exogenous contrast agents for lung imaging and their working principles
will be presented, with special attention to the class of paramagnetic contrast
media which will be extensively used in the next chapters.
1.3.1 MR contrast agents applied to lung imaging
Paramagnetic contrast agents Elements or compounds are called param-
agnetic if they possess a permanent magnetic moment due to the presence
of one or more unpaired electrons. These substances have a small, positive
susceptibility to magnetic fields (χ > 0) and in presence of an external mag-
netic field they show a magnetization which is proportional to the applied
magnetic field and inversely proportional to the temperature [92].
Metal ions like gadolinium (Gd3+) or manganese (Mn2+) cations are para-
magnetic. In aqueous solutions, their electronic magnetic moment can have
a dipolar magnetic interaction with the small magnetic moments of water
protons. The fluctuations in the dipolar magnetic interaction, resulting from
random molecular motion, reduce both the longitudinal and transverse re-
laxation times of water proton. These changes in the relaxation properties
of water protons can be efficiently used in MRI to alter specific tissues con-
trast [92,93]. Due to their toxicity and unfavorable biodistribution, metal ions
cannot generally be used in their ionic form. Binding to specific ligands is
therefore generally used in order to obtain more desirable biodistributions
and safety profiles. The resulting metal-ion complex is called chelate [92].The
final size of these contrast media, which strongly influence their pharma-
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cokinetics and excretion, varies from 1-2 nanometers to several hundreds of
nanometers.
This class of contrast agents has been used in lung imaging to study
ventilation and perfusion [5, 6, 93–98]. The theory behind the mechanisms
responsible for the contrast produced by this type of exogenous contrast
media is presented in section 1.3.3.
Superparamagnetic contrast agents Superparamagnetic substances are most
typically iron oxide particles which, in presence of an external magnetic field,
tend to align with the field, resulting in a large net positive magnetization.
This behaviour is similar to paramagnetism but the permanent magnetic mo-
ment and susceptibility of superparamagnetic particles are larger compared
to the ones of paramagnetic substances. Such a behaviour is produced by the
union of several paramagnetic ions along with an effect of cooperativity, i.e.
the capability of the single spins to align to build up a superspin [92].
Superparamagnetic particles are generally made of a core of one or more
iron crystals embedded in a coating which prevents agglomeration and tai-
lors their targeting properties. They are conventionally divided in two cate-
gories [92]: the ultra-small superparamagnetic iron oxide (USPIO) particles
and the superparamagnetic iron oxide (SPIO) particles. The former are char-
acterized by a diameter inferior of 50 nm while the latter include all the
superparamagnetic nanoparticles with a diameter larger than 50 nm.
This kind of nanoparticles has shown several applications in multiple
organs (especially in the reticuloendothelial system (RES) organs [93, 99])
for MRI diagnostic applications as negative contrasts (see section 1.3.3) [93].
These nanoparticles have also shown a strong capacity to label specific cell,
opening the possibility of studying for instance stem cell migration and im-
mune cell trafficking [100]. Furthermore, superparamagnetic nanoparticles
have been used as therapeutic agent exploiting the possibility of inducing
localized hyperthermia in tumor cells through the use of high-frequency
electromagnetic waves [101]. However, only few applications of superpara-
magnetic particles have concerned MRI lung imaging because of the already
weak NMR signal of this organ and its strong susceptibility effects that make
their T ∗2 effect negligible. Nonetheless, Strobel et al. [102] have recently shown
that the use of T1-weighted UTE sequences can minimize the T ∗2 relaxation,
making the SPIO T1-effects of detectable and exploitable to identify iron
loaded immune cells in inflamed lungs.
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Hyperpolarized gases Compared to conventional proton imaging, gas MRI
is limited because of the intrinsic low spin density (typically three orders
of magnitude lower spin density compared to water). To encompass this
limitation, polarization techniques have been developed [103]. These tech-
niques permit to obtain polarization levels above the thermal equilibrium,
with values typically superior to the Boltzmann polarization level by 5 orders
of magnitude [104]. They have been principally applied in order to obtain
hyperpolarized (HP) 3He or 129Xe. Once polarized, HP gases return to their
thermal equilibrium following a decay time constant equal to the longitudinal
relaxation time T1 of the polarized nuclei. Being chemically inert atoms, 3He
and 129Xe present a T1 long enough to allow biomedical MR applications [91].
HP gases MRI has been successfully applied in animals and humans
to study ventilation defects, diffusion and perfusion changes in a number
of pathologies like COPDs [105–107] and asthma [108–113]. Nonetheless,
the complexity of the protocols, their considerable costs, and the increasing
paucity of 3He are somehow limiting the diffusion of this imaging technique
in clinical practice.
Fluorinated gases 19F is an inexpensive natural element with 100% abun-
dance. This nucleus presents a resonance frequency equal to 94% of the proton
and spin 1/2. These similarities of 19F with 1H are of advantage when dealing
with MRI since the same or similar RF coils and pulse sequences can be used
to perform measurements, without expensive updates of the scanner. Mobile
fluorine is present in human and rodents body tissues at very low concen-
trations (under MRI detectable threshold) whereas higher concentrations of
this element are immobilized in solid matrices in teeth or bones, presenting
extremely short spin-spin relaxation times. As a result, the endogenous NMR
fluorine signal is negligible with standard MRI sequences. On the other hand,
the absence of a relevant background is a favorable condition for obtaining
high-specificity and contrast-to-noise ratios, if fluorinated compounds can be
introduced in living being [91].
The first MRI application of fluorinated gases was proposed in early
80’s [114]. However, only with the development of HP gases MRI applications
the interest in this technique was rediscovered. Fluorinated gases such as sul-
fur hexafluoride (SF6), hexafluoroethane (C2F6) or tetrafluoromethane (CF4)
have been administered to the lungs in humans and animals to study several
functional pulmonary parameters (e.g., airways ventilation distribution, ven-
tilation/perfusion ratios, airspace size, . . . ) [115–119]. No significant adverse
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effects has been recorded in humans for the fluorinated gases, even at high
concentrations (e.g., 80% for SF6) [91].
These kind of contrast agents present two main advantages compared to
HP gases: their low cost (up to two order of magnitude lower for fluorinated
gases) and the simpler protocols (no need of polarization apparatus or prepa-
ration times). On the other hand, the SNR of fluorinated gases is significantly
lower than the HP one and time-consuming signal averaging techniques are
often required. In addition, the short relaxation times of these fluorinated
gaseous molecules can result in significant signal loss, even at short echo
times [91].
Oxygen-enhanced proton MRI The underlying principle of oxygen-enhanced
(OE) MRI is related to the fact that molecular oxygen is weakly paramagnetic
because of its two unpaired electrons in the outer shell. When the subject in-
hale room air (21% oxygen) and subsequently 100% oxygen, a change in signal
intensity can be observed due to the reduction of T1 in oxygenated tissues (in a
similar way to gadolinium compounds but with a smaller magnitude). Oxygen
enhancement is the result of the transfer of oxygen to blood and tissues by
direct diffusion of molecular oxygen from the alveoli. This mechanism was
firstly exploited by Edelman et al. [120] for ventilation imaging in the lungs
and it was shown to permit the detection of altered lung oxygen uptake.
Since then, OE proton MRI has been successfully applied to study oxygen
defects in a number of pathologies, including asthma [121], COPDs [122]
and fibrosis [123]. The good correlation between signal intensity changes and
standard pulmonary function tests has increased the interest in this contrast
agent technique [91]. However two main limitations have to be pointed out.
First of all, the measurements obtained with OE MRI are indirect (the gas
in the alveoli is not directly observed as in other ventilation techniques like
HP gases MRI [91]). As a consequence, further studies are needed to under-
stand the mechanisms responsible for the observed changes in signal intensity
and to which extent possible pathological changes are related to ventilation,
to diffusion or to perfusion. Similarly, lung relaxation times measurements
are especially delicate and influenced by the pulse sequence choice, which
introduces a further element of variability in this technique. Secondly, pro-
longed hyperoxia has shown to produce adverse effects [124] or discomfort in
patients [125], especially in COPD patients [91, 124].
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1.3.2 Contrast agent requirements
The approval of contrast agents by regulatory agencies and the subsequent
commercialization follow strict rules similar to the ones that are applied to
any medical drug. As a consequence, contrast media must comply with a
number of requirements that have to be assessed starting from pre-clinical
studies [93].
First of all, contrast agents have to show the capability of altering the
parameters responsible for the image contrast in order to provide a useful
information which could not be obtained otherwise. As mentioned above, in
MRI the parameters that can be altered are multiple and include (but are not
limited to) the relaxation times of the tissues. In this sense, the contrast agent
should be able to be enough specific to reach the desired tissue/organ (i.e., tu-
mor tissues) and remain localized for a reasonable period of time that permits
to perform imaging (or treatment, in cause of therapeutic applications). In the
light of these considerations, it is clear that the administration route strongly
affects the capability of a given contrast medium to reach the desired organ as
well as its pharmacokinetics, biodistribution and excretion.
Secondly, the contrast agent must have a favorable pharmacokinetics and
elimination. In particular, it has to be cleared from the targeted tissue or organ
in a reasonable amount of time after imaging. The contrast medium must also
be excreted from the body, through the kidneys or the RES.
Thirdly, the contrast agent must have low toxicity and be stable in vivo. The
contrast mechanism should be effective at concentrations as low as possible,
in order to minimize any toxicological effect. Acute and subacute effects
systemic tolerance, potential mutagenicity, teratogenicity, and carcinogenicity
are only some of the toxicological aspects which has to be assessed before any
application to human can be envisaged.
Finally, the contrast agent has to be stable in vitro for a reasonable period
of time in order to allow its storage and commercialization.
Factors affecting clinical safety When chelating species are involved in the
final molecule or nanoparticle, the clinical safety of the contrast agent is
strongly dependent on the stability of the chelate in vivo [92].
In this case, important features determining the safety of a contrast
medium include thermodynamics, solubility, selectivity, and kinetics [92, 93].
The chelating species must indeed have a strong affinity for the metal ion,
which is reflected by the thermodynamic binding constant (or complexation
constant) of the complex (bigger constants imply higher stabilities). In addi-
tion, the agent has to be sufficiently soluble to avoid the precipitation of the
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metal ion, which is potentially toxic. Moreover, the chelate must have high
selectivity for the specific metal ion of interest (e.g., Gd3+) to minimize the
metal exchange with endogenous ions (transmetallation) like zinc, copper or
calcium. Finally, the compound must have a slow kinetics of dissociation, i.e.
the release of the metal ion of interest (e.g., Gd3+) should be minimal in order
to facilitate the (almost) complete excretion of the complex.
1.3.3 Paramagnetic contrast agents relaxivity theory
The mechanism that describes the modification of the nuclear relaxation
properties of a solvent in presence of a paramagnetic substance is known as
Solomon-Bloembergen-Morgan theory, and it will be shortly reviewed here.
Such a theory can be applied to all the main paramagnetic contrast agents
like Gd3+- orMn2+-based compounds. Hereafter only the case of Gd3+ will be
considered. An exhaustive general description can be found in reference [92].
When a Gd3+-complex is introduced in an environment (e.g., lung tissue),
the observed enhanced relaxation rate Robsi is given by:
Robsi = R
dia
i +R
para
i , i = 1,2 (1.8)
In equation 1.8, Rdiai indicates the relaxation rate of the hydrogen nuclei of the
specific tissue in the absence of the paramagnetic contrast whereas Rparai is
the relaxation enhancement caused by the paramagnetic substance. The latter
is linearly proportional to the concentration of the paramagnetic substance
[Gd]:
1
T obsi
=
1
T diai
+ ri · [Gd], i = 1,2 (1.9)
In equation 1.9, [Gd] is generally expressed in millimoles per liter mmol/L
(mM) whereas ri is called relaxivity and it is commonly expressed in units
of mM−1s−1. In section 4.2 the term 1/T diai (with i = 1,2) will be referred as
1/Ti(0) (with i = 1,2), assuming t = 0 to be the instant right before the contrast
agent administration. From a practical point of view, the relaxivity defines the
efficacy of a paramagnetic substance to enhance the relaxation rate of water
protons, and thus its efficacy as MRI contrast medium.
Unpaired electrons of the paramagnetic substance cause rapid fluctuation
of the local magnetic field. The increase in relaxation rate is originated by the
interactions between this field and the water proton nuclear spins, and its
origin is commonly divided in two components: the inner sphere (IS) and the
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outer sphere (OS) interactions.
R
para
i = R
IS
i +R
OS
i or ri = r
IS
i + r
OS
i , i = 1,2 (1.10)
Inner sphere relaxation The IS relaxation is the result of the direct interac-
tion between the paramagnetic center and the inner sphere water molecules.
These molecules are directly coordinated by the paramagnetic ion. By means
of chemical exchange between the coordinated water protons and the bulk
water protons, this effect is transmitted to the bulk.
The interested reader is referred to reference [92] for a detailed summary
of Solomon-Bloembergen-Morgan equations describing the IS interactions.
Basically, these equations show that the relaxation rate enhancement is directly
proportional to the number of bound water nuclei per paramagnetic ion
(generally only one) and to the water exchange rate in the inner sphere (as
long as the residence time of the water molecule is long enough to ensure the
coordination by the paramagnetic center). In addition, since the dominating
interaction is of the type dipole-dipole (proportional to r−6), the distance
between the paramagnetic center and the water molecules is a key point
and inversely proportional to the relaxation rate enhancement. Finally, the
relaxivity generated by the IS interactions can be enhanced by increasing the
rotational correlation time, which increases the electronic-nuclear dipolar
interactions. It has indeed been shown that, for small Gd3+ chelates, the fast
rotation is the limiting factor for proton relaxivity at magnetic fields relevant
to MRI [92, 93].
Outer sphere relaxation The OS relaxation is the result of two different
mechanisms: (i) the binding of water molecules to the inner sphere water or
the contrast agent protective ligand (the so-called ‘second sphere interactions’)
and (ii) the interaction between the randomly translating water protons and
the paramagnetic center (the properly said ‘outer sphere interactions’).
The second sphere term is related to the fact that strong binding of water
molecules to the functional groups of the chelating ligand (i.e., COO− group)
can take place (hydrogen bonding interactions). In this case, rotational diffu-
sion theory has to be used to describe the phenomenon, in a way similar to
the IS interactions.
The outer sphere term describes the interaction between the bulk water
molecules coming in contact with the paramagnetic chelate as a result of trans-
lational motion of the complex and the water molecules. These exchangeable
water molecules are responsible for the transfer of the effect of the paramag-
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netic ion magnetic moment to the surrounding water protons.
For a detailed summary of the equations describing these phenomena, the
interested reader is referred to reference [92].
1.3.3.1 General considerations
Contrast agent design Solomon-Bloembergen-Morgan equations well de-
scribe the relation between the observed paramagnetic relaxation rate en-
hancement and the microscopic properties of the contrast. However their
complexity and dependence on several parameters (that in addition vary with
the temperature and the applied magnetic field) are the major drawbacks of
the theory. As a consequence, complicated multi-parameter simulations are
required to infer the microscopic properties of the paramagnetic complex,
starting from the measured relaxivity.
On the other hand, this theory enables to understand the most relevant
features in the design of an effective paramagnetic contrast agent. For instance,
Solomon-Bloembergen-Morgan equations clearly show that, in order to ob-
tain a significant enhancement of the relaxation rate, the paramagnetic atom
should have a high spin quantum number S 3 and long electronic relaxation
time4.
Among the paramagnetic atoms, Gd3+ is often the preferred choice. This
atom has seven unpaired electrons (S = 7/2) and a significant magnetic mo-
ment of 7.9 Bohr magnetons [126], compared for example with the five un-
paired electrons of Mn2+ or Eu3+ (S = 5/2). In addition, the electronic relax-
ation time for Gd3+ is much longer (≈ 10−9s) than for the other lanthanides
such asDy3+, Eu3+ andHo3+ (≈ 10−13s). The combination of these two proper-
ties has made gadolinium the paramagnetic atom most used for MRI contrast
agents development. Lanthanides such as Dy3+ and Ho3+ have magnetic mo-
ments higher than gadolinium (approximately 10.6 Bohr magnetons for both
the ions [126, 127]) due to their greater orbital angular momentum contri-
bution. However, because of their relatively short electronic relaxation time,
they are rarely used as paramagnetic centres for MRI contrast agents.
3Both IS and OS relaxations are proportional to S(S + 1) [92].
4The relationship between electronic relaxation times and relaxation rate enhancements is
nontrivial both for IS and OS interactions. A detailed discussion on the subject can be found in
reference [92].
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Once the paramagnetic atom has been chosen, the choice of the chelating
species is critical since it affects the MRI properties of the contrast agent.
Indeed, the ligand influences the rotation and translation of the contrast
agent in space, governs the average distance between water molecules and
paramagnetic center, and has effects on the water exchange rate in the inner
sphere. Ligands have to fulfill the requirements stated in the previous section
but should also maximize the relaxation rate enhancement properties of the
contrast agent. Up to now, the most effective approach to increase the proton
relaxivity of a contrast agent is related to the slowdown of the ligand-metal
ion complex. The reader is referred to reference [92] for a description of the
existing chelating species and their properties.
T ∗2 effect Contrast agents are commonly defined positive if they generate
an increase of the signal in the images, as compared to the baseline acqui-
sition before the administration. Similarly, they are defined negative if a
decrease of the signal is observed. These definitions are not intrinsic and
depend on extrinsic factors like, among others, the chosen pulse sequence
and parameters.
Commonly, paramagnetic contrast agents generate positive enhancements
in T1-weighted images (for low and homogeneous concentrations) whereas
superparamagnetic nanoparticles are often responsible for susceptibility ef-
fects that lead to a loss of signal in T2-weighted images (negative contrast).
Nonetheless, it has been shown that T1 changes can be detected as an increased
signal when superparamagnetic nanoparticles accumulate in the mouse lung,
if a T1-weighted UTE sequence is used (i.e., a positive contrast obtained with
iron oxide nanoparticles) [102]. Similarly, paramagnetic contrast agents can
be responsible for a loss of signal when high-concentrations are used (see
section 4.1).
As shown in equations 1.8-1.10, a generic paramagnetic contrast agent
affects both the longitudinal and transverse relaxation rates. However, this
class of contrast media is commonly used to see positive enhancements in
T1-weighted images. This is due to the fact that the longitudinal relaxation
time T1 is always longer than T2. As a consequence, being the relaxivity values
very close (generally r1 ≈ r2), the change in the signal (and therefore in the
contrast) is more important in T1-weighted images rather than in T2-weighted
ones.
On the other hand, the shortening of T2 generated by a paramagnetic
contrast (due to the effect of r2) can limit the signal enhancement originated
by r1 in T1-weighted images. In addition, if the contrast agent concentration is
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too high5, a significant T ∗2 -shortening effect can be observed along with the T2-
shortening [92]. Such a phenomenon is due to the strong difference between
the magnetic susceptibilities of the highly concentrated paramagnetic ions and
the tissue (generally diamagnetic). The resulting strong field inhomogeneities
generate a significant loss of signal (see section 4.1).
5A similar effect may be observed if the contrast agent is distributed inhomogenously in
the tissue producing voxels that contain a high concentration of paramagnetic atoms
39

2
Material and methods
This chapter will provide a description of two tools which will be extensively
used in the next studies: the UTE pulse sequence reconstruction program
and the USRPs. These instruments will be partially described in the articles
presented in the following chapters. Nonetheless, this section will provide
the reader with a precise summary of the technical details relative to the
aforementioned tools. An exhaustive description of the ‘material and methods’
section, in the strict sense of the expression, will be provided for each study
which composes this thesis work. Likewise, the reasons why these tools have
been chosen will be discussed in the subsequent chapters.
2.1 UTE sequence and image reconstruction
As mentioned in section 1.2.2.2, UTE radial sequences acquire radial spokes in
the k-space, subsequently incrementing the polar angle of a constant amount
∆Φ . Filtered backprojection or regridding algorithms can be used to recon-
struct the image [71].
This kind of acquisition scheme was the first one employed by Lauter-
bur [76, 128] but was largely replaced by Cartesian trajectories soon after
to minimize the artifacts caused by static field inhomogeneities and gradi-
ents non-linearities. Over the last decades, improvements in the static field
homogeneity and gradients linearity, along with a renovated interest in the
advantages of PR acquisitions (see section 1.2.2.2), have led to a renewed
interest in this kind of sequence [71].
2.1.1 UTE sequence acquisition scheme
In Figure 2.1, the pulse sequence of the UTE radial acquisition used in the
subsequent studies is shown. An FID acquisition mode has been preferred to
a full echo acquisition to ensure minimal echo times 1. The radial spokes are
1The scheme for a full-echo acquisition can be found in reference [129]
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thus acquired in the k-space always starting from the centre over an angle Φ
that varies between 0 and 2pi.
Figure 2.1: Pulse sequence for a radial UTE trajectory with FID acquisition. Adapted from [129].
The pulse sequence consists of a conventional slice excitation (with a cho-
sen FA which can be varied to accentuate a specific image contrast), followed
by a fast refocusing gradient (used to refocus slice dispersion). The two gradi-
ents Gx and Gy in the physical XY plane are turned on simultaneously with
amplitudes:
GX = G0 · cosΦ and GY = G0 · sinΦ ,
where G0 is the maximum readout waveform amplitude. The signal induced
by transverse magnetization is sampled by the analog to digital converter
(ADC) at constant time intervals, resulting in a set of data points along each
projection. The sampling is started right after the refocusing gradient or after
a short delay (gradient delay). Each radial projection is acquired after each RF
excitation pulse every TR.
Even though a half-pulse RF excitation can be employed in UTE radial
acquisitions to further reduce the minimum TE achievable, the conventional
excitation scheme was chosen and has been used throughout all the exper-
iments described in the next chapters. The rationale behind this choice is
connected to the shorter total acquisition times (two-fold longer for the half-
pulse acquisitions) and to the lower sensitivity to gradient imperfections [71].
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2.1.2 UTE sequence reconstruction
Once the k-space has been acquired using the aforementioned UTE radial
sequence, specific algorithms are needed to reconstruct the image. Two tech-
niques can be employed: the filtered backprojection [128] and the regrid-
ding [130]. Both the methods have been shown to work well to reconstruct PR
data and to produce equivalent images if the convolution kernel (regridding)
and the backprojection filter are properly chosen [71]. Nonetheless, regrid-
ding is generally the technique of choice since it is faster than backprojection
(regridding can be an order of magnitude faster than backprojection), it can be
easily applied to three dimensional acquisitions, extended to reconstruct any
non-Cartesian trajectory and it fits onto irregular sampling acquisitions [71].
The reconstruction program developed in IDL (RSI, Boulder, CO) that
has been used to reconstruct the UTE radial images presented in this thesis2
employs the regridding algorithm.
2.1.2.1 Regridding algorithm
As mentioned in section 1.2.2.2, when the k-space is sampled following a
non-uniform grid, the inverse FFT cannot be directly applied to the data.
Even though a non-uniform discrete Fourier transform could be used on non-
Cartesian sampled data, such an algorithm requires a considerably longer
computation time [131]. The reconstruction procedure thus generally passes
through the regridding (or gridding) procedure, i.e. the application of an in-
terpolation procedure that allows to resample the data on a uniform grid (Fig.
2.2). As a consequence, the reconstruction procedure for radial trajectories
follows four main subsequent steps: density compensation, convolution with
a gridding kernel, inverse FFT and deapodization.
Density compensation The density of the non-Cartesian sampled data
is not constant in the k-space, leading to overrepresented spatial frequen-
cies [132]. For instance, for radial trajectories, the low frequencies close to the
center of the k-space are clearly oversampled compared to high frequencies
(Fig. 2.2). Different solutions of density compensation have been proposed to
solve this problem that can lead to artifacts if not corrected for.
One commonly used method estimates the density compensation function
(or weighting function) by computing a Voronoi diagram of the trajectory,
where the size of the individual Voronoi cells is inversely proportional to the
2Even when a standard reconstruction with the Bruker software ParaVision 5.1 was per-
formed, the regridding algorithm was preferred to the backprojection reconstruction.
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Figure 2.2: Schematic drawing showing the basic problem of regridding for two radial spokes.
The aim of regridding techniques is to determine the value of the Cartesian samples from the
adjacent samples obtained with the radial acquisition. Reprinted from [132].
local sample density [133, 134]. However, for radial trajectories an analytical
density compensation function can be derived, which leads to the ramp-like
filter known as Ram-Lak filter [135, 136]:
F(~k) =
{ |~k|/Ns if |k| , 0
1/(2 ·Ns) if |k| = 0,
with Ns indicating the number of acquired spokes.
Convolution with a gridding kernel and inverse FFT Once the weighting
function has been applied, the interpolation of sampled data is performed by
convolving the measured k-space points with a radial interpolation kernel, as
schematically shown in Figure 2.3a. To avoid distortion of the signal (apodiza-
tion), the interpolations in the frequency space should be performed using
a convolution with a sinc function (corresponding to a multiplication of the
signal by a rect function). However, this ideal kernel is infinite in extent and
in practice cannot be applied. Among the kernels that best approximate the
sinc function properties, a radial Kaiser-Bessel function was shown to be a
good choice in term of interpolation quality and computational time [137].
This kernel can be written as:
KKB(k) =
 1L I0
(
β
√
1− (2k/L)2
)
if |k| ≤ L/2
0 elsewhere,
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(a) Gridding kernel convolution (b) Oversampling correction
Figure 2.3: Schematic representation of (a) the gridding kernel convolution procedure and (b)
the use of oversampling in order to correct for aliasing artifact generated by the finite gridding
kernel. Adapted from [132].
where L is the kernel width, I0(k) indicates the zero-order modified Bessel
function, and β is a shape factor. Optimized values of β for a chosen value of L
can be computed according to the equations reported in references [134, 138].
Because the exact position of the samples is lost after the interpolation onto
the grid, the density compensation function has to be applied as an initial step,
before the gridding kernel convolution [132]. Once the density compensation
function has been applied and the convolution with the gridding kernel has
been performed, an inverse FFT can be applied to the resampled data to obtain
the image like for Cartesian acquisitions.
Deapodization and oversampling Convolving the k-space with a kernel
function has necessarily side effects on the image. First of all, the apodization
has to be corrected for in order to avoid shading in the image (deapodiza-
tion). To do so, the image has to be divided by the apodization function, i.e.
by the FT of the gridding kernel [130, 137]. This transform can be computed
numerically or, like for radial acquisitions, an analytical expression can be
derived. The Fourier transform of the Kaiser-Bessel function can be written
as [130]:
FT (KKB) (x) =
sin
√
(piLx)2 − β2√
(piLx)2 − β2 (2.1)
Thus, the image (rows and columns) has to be divided by the expression above
to obtain a deapodized image.
A second side effect is produced because of the finite kernel used for
the interpolation. This operation causes side lobes in the frequency domain
and, because of the properties of the FT (see section 1.2.2.2), the side lobes
are aliased back into the image plane as neighboring object copies [132].
As shown in Figure 2.3b, a possible solution consists in oversampling the
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gridding matrix of a factor α (1 < α ≤ 2). This permits to increase the distance
between the copies, shifting the aliased side lobes away from the object. The
extended FOV can be cropped at the end of the reconstruction procedure so
that the aliasing artifacts are cut out from the image plane [130, 132].
2.2 Ultra-small rigid platforms
Each imaging modality has advantages and limitations. For instance, MRI can
provide good spatial resolution and soft tissue contrast without using ionizing
radiation. In addition, it can provide multiple information (relaxation times,
proton density, diffusion, . . . ), according to the aim of the study. On the other
hand, compared to CT, its spatial resolution is still inferior; compared to PET
or optical imaging techniques, its sensitivity is much lower [4, 139, 140].
As a consequence, multimodality can be a strong figure of merit when de-
veloping contrast agents for any application since the advantages of different
imaging techniques can be gathered together. Furthermore, as mentioned in
section 1.3.2, the contrast agent should have a favourable pharmacokinetics
and being excreted from the body in a reasonable amount of time. In this
sense, ensuring an exclusively renal filtration and excretion is an effective way
to increase the probability of having a fast elimination and a low toxicity [141].
Combining multimodality and negligible hepatic clearance is rather dif-
ficult. The former often implies coatings that are too prohibitive in size (for
instance, this is the case of quantum dots [142] or gold clusters [143]) whereas
the latter is ensured only when the total size of the contrast agent is < 5.5
nm [144].
In this context, silica- or polymeric-based nanostructures are among the
most promising strategies. The contrast agents described in this section are
called ‘Ultra-Small Rigid Platforms’ (USRPs) or AGuIX3 and have been de-
veloped by the ‘Institut Lumie`re Matie`re’ of the University of Lyon in col-
laboration with the start-up Nano-H. These nanoparticles will be used in
the research works presented in chapters 4 and 5, and their interest for lung
proton MRI will be discussed througout the whole thesis. A further summary
of their potential applications to lung imaging and lung pathologies treatment
is provided in the patent publication described in appendix A.
The nanoparticles were freeze-dried for storage (using a lyophilizer) as
described in appendix D, and sent to the University of Bordeaux for the in
3In the body of this thesis only the term USRP will be used. The commercial name, AGuIX,
will be used only in the manuscripts presented in the appendices.
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vivo tests described in the next chapters. The freeze-dried nanoparticles, sta-
ble for months without alterations, were dissolved in a NaCl solution (0.9%)
to reach the desired concentrations before animal handlings.
The following paragraphs describe the basic synthesis process of these
nanoparticles and the properties of the USRPs that were known before the
beginning of this work. A detailed description of the synthesis and properties
of these nanoparticles can be found in references [145–147]. The description
of the chemical details of the synthesis of these nanoparticles goes beyond the
aims of this thesis. Such an information can be found in appendices A and D
or in reference [145].
2.2.1 Synthesis
The USRPs are obtained using a top-down method proposed in reference [145],
consisting in the fragmentation of small nanoparticles (size < 10 nm) that
already present the desired functions, except for the sub-5 nm hydrodynamic
diameter (HD) [148]. The synthesis process consists of four steps. First of all,
Figure 2.4: (a) Starting small nanoparticle before the top-down method, with Gd2O3 core
and SiO2 shell; (b) dissolution in water of the core and chelation of the resulting free Gd3+
by DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) ligands grafted on the
surface of the particle; (c) collapse and fragmentation of the shell into ultra-small rigid
platforms (USRPs); (d) size measurement of the particles before the fragmentation process
and transmission electron microscopy image of starting core-shell nanoparticles; (e) size
measurement of the USRP HDs. Reprinted from [145].
the core of gadolinium oxide (Gd2O3) is formed; secondly, the growth of a
polysiloxane shell is obtained around the core. Thirdly, the chelating species
are grafted on the free amino functions of the inorganic matrix. Finally, the
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nanoparticles are purified and transferred to water. During the purification
in water, the top-down process occurs, with the dissolution of the core, the
trapping of the gadolinium cations by the chelates and the formation of
a hollow polysiloxane sphere. This latter collapses and fragments forming
the so-called USRPs, made of a polysiloxane network and surrounded by
gadolinium chelates covalently grafted to the nanoparticles. During this
process, the nanoparticles pass from the original HD of 5.7 ± 1.0 nm to a
smaller one, entirely under 5.5 nm (4.1 ± 1.0 nm). The top-down process is
schematically shown in Figure 2.4.
Among the paramagnetic atoms, gadolinium was chosen by the inventors
because of its slowly relaxing electrons and highest spin quantum number, key
factors that determine the ion high relaxation rate (see section 1.3.3) [92, 93].
DOTA was chosen as chelating species because of its higher complexation
constant (e.g., compared to acyclic chelating species), its lower kinetics that
limits transmetallation with endogen cations such as Ca2+ and its reduced
toxicity for patients with severe renal dysfunction (see section 1.3.2) [145].
2.2.2 Properties
The obtained USRPs have a total mass of about 10 kDa and are described by
the average chemical formula Gd10Si40C200N50O150Hx. They are schemati-
cally represented in Figure 2.5a. The particles have rather a neutral charge
at physiological pH (zeta potential of -0.2 mV at pH = 7.4) and their com-
plexation constant was shown to be very close to the one of the commercial
agent Dotarem (24.78 and 25.58, respectively) determined in the same condi-
tions. On average each nanoparticle presents on its surface ten DOTA ligands
which chelate core gadolinium ions. Measurements showed that generally
between 30 and 40% of these DOTA ligands are free and can be used for scinti-
graphic applications (e.g., immobilizing radioactive isotopes onto the USRPs).
However, when purely MRI applications are envisaged, supplementary para-
magnetic atoms can be provided (e.g., by adding a solution containing GdCl3)
to increase the total relaxivity of the nanoassemblies. In this case, less than
5% of the DOTA ligands are left free.
The longitudinal relaxivities r1 per atom of gadolinium were measured
at 310 K for different magnetic fields after dispersing the USRPs in aqueous
solutions of NaCl (0.9%). The nuclear magnetic resonance dispersion (NMRD)
profile of the USRPs is shown in Figure 2.5b for proton Larmor frequencies
ranging between 0.1 and 60 MHz and it is compared to a NMRD profile of
a standard commercially available DOTA(Gd) contrast agent. For instance,
the r1 of the USRPs at 1.4 T was found to be 11.4 s−1mM−1 per atom of
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(a) USRP scheme (b) Relaxivity of USRPs
Figure 2.5: (a) Schematic representation of a typical USRP with a polysiloxane bone and
DOTA(Gd) species grafted through amide functions (Si grey, O red, N blue, Gd yellow, H
white). (b) Proton nuclear magnetic resonance dispersion profiles for the USRPs in aqueous
solutions of NaCl (0.9%) and for a standard commercially available DOTA(Gd) contrast agent.
The relaxivity is expressed in s−1mM−1 per atom of gadolinium. Adapted from [145] and
appendix C.
gadolinium (i.e., 114 s−1mM−1 per nanoparticle) whereas at 7 T was found
to be 6.0 s−1mM−1 per atom of gadolinium. The longitudinal relaxivity for
the commercially available DOTA(Gd) contrast medium was found to be
3.8 s−1mM−1 at 1.4 T and 3.0 s−1mM−1 at 7 T. The two- to three-fold higher
relaxivity per gadolinium atom of the USRPs compared to standard DOTA(Gd)
is related to greater inertia of the rigid structure supporting the gadolinium
ions. These structures have indeed shown to be able to slow down the rotation
rate of the relaxing species, increasing the relaxivity of the nanoparticles even
at higher frequencies (see section 1.3.3) [92,145]. Finally, the ratio between
the transverse and the longitudinal relaxivity of the USRPs was found to be
1.31 at 1.4 T.
When needed to perform Fluorescence Imaging (FRI), cyanine 5.5 (Cy 5.5)
near-infrared dye can be covalently grafted onto the nanoparticles (USRPs-
Cy 5.5). For the fluorescence nanoparticles USRPs-Cy 5.5 used in the works
described in the next chapters, on average, one Cy 5.5 molecule was grafted
for every 550 atoms of gadolinium.
Even though only MRI and FRI imaging techniques were used throughout
the investigations of this thesis, the USRPs have shown to be easily modifiable
in order to perform Single-Photon Emission Computed Tomography (SPECT)
imaging (e.g., by adding a solution containing 111InCl3 with a high radiochem-
ical purity). Further functionalizations of these nanoassemblies are possible
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in order to perform PET imaging4. Similarly, specific peptides or therapeutic
drugs can be grafted on the nanocarriers to add active targeting or therapeutic
properties to the basic USRPs (see chapter 6 for further details).
When administered intravenously in healthy mice, the USRPs showed no
undesirable accumulation in lung and liver whereas a fast renal filtration was
observed. The results were confirmed by FRI, MRI and SPECT, as shown in
Figure 2.6.
Figure 2.6: (a) SPECT, (b) MRI and (c) FRI biodistribution study after intravenous adminis-
tration in healthy mice at different times (K = kidneys, S = stomach, U = urine, B = bladder).
Adapted from [145].
In particular, SPECT imaging showed a strong accumulation of the USRPs
in the kidneys and bladder 3 hours after intravenous administration (approx-
imately 29.8% of injected dose (ID) and 57.9% of ID, respectively). For the
other analyzed tissues, the uptake was lower than 0.2% ID, with no hepatic
clearance observed, as shown in Figure 2.7. The half-life of the particles in
blood was shown to be equal to 9.1 minutes, compared to the 4.7 minutes of
Dotarem. Contrarily to Gd-chelates, USRPs were still found in the kidneys 24
hours after administration, supporting the hypothesis that they are cleared
4PET imaging using functionalized USRPs with 68Ga and 64Cu has recently been per-
formed (data not yet published).
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Figure 2.7: SPECT biodistribution of 111In-USRPs 3 and 24 hours after intravenous adminis-
tration. Reprinted from [145].
from the kidneys according to a multi-exponential law (with a slow clearing
component for larger particles and a fast one for the smaller ones) [145].
Finally, the USRPs have shown a capability to passively accumulate in
vivo in different type of tumors after intravenous administration. In particular,
a significant accumulation of these nanoparticles was observed in rats bearing
gliomas or hepatic colorectal cancer metastases. The interested reader is
referred to appendix C for more details.
The accumulation of the nanoparticles in the tumors is commonly at-
tributed to the so-called Enhanced Permeability and Retention (EPR) ef-
fect [149, 150]. This phenomenon tends to explain the superior accumulation
of certain nanocarriers in tumors rather than in healthy tissues because of
two concurrent factors: (a) the increase in the extravasation from leaky ves-
sels close to the tumor5 (enhanced permeability) and (b) the lack of effective
lymphatic drainage in tumors (enhanced retention).
No application of the USRPs to lung MR imaging and pulmonary patholo-
gies detection had been proposed before this thesis.
5This phenomenon is connected to the formation of new vessels close to the tumor (an-
giogenesis), which generally are abnormal in architecture and form. These new vessels are
responsible to supply the tumor with oxygen and nutriment.
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UTE MRI applications on lung
diseases
In this chapter, two different applications of radial UTE proton MRI will be
proposed to investigate specific lung pathologies, namely asthma and lung
cancer. In particular, it will be shown that UTE sequences can be effective
tools in the longitudinal noninvasive monitoring of lung diseases and can
encompass the limitations of standard gradient-echo sequences. The possibil-
ity of using ultrashort-TE radial acquisitions in the drug-discovery process
of asthma will be presented. One of the main limitations of MRI compared
to other imaging techniques, i.e. its low sensitivity, will be pointed out and
discussed in the contest of lung cancer detection.
3.1 A chronic model of asthma in mice
As described in section 1.1.2.1, asthma is a frequent and complex chronic
disease, characterized by bronchial inflammation, airway hyperesponsiveness
and bronchial remodeling. A number of mechanisms about asthma phys-
iopathology are still unclear and require in-depth studies. In addition, current
therapies for this disease mainly rely on inflammation and bronchoconstric-
tion treatment, without an effective action on bronchial remodeling features.
In this context, it is clear that animal studies on realistic murine asthma
models assume a central role in the investigation of pathologic mechanisms
underlying this disease and in the process of new drug discovery and test.
Pre-clinical studies are indeed fundamental in order to provide evidence of a
drug efficacy and its potential non-toxicity, key points before any translational
application.
Imaging techniques like micro-CT have already provided important in-
formation on the pathophysiology of asthma. Its noninvasiveness, compared
to terminal procedures (e.g., histology), allows the longitudinal assessment
of structural and physiological changes with high resolution, limiting the
total number of animals required in the studies and simplifying the protocols.
Nonetheless, as pointed out in section 1.2.1, MRI has several advantages over
CT, including the absence of ionizing radiation and the good soft tissue con-
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trast. While hyperpolarized gases MRI has proven to be a valuable instrument
in studying asthma regional ventilation obstructions, its increasingly high
costs and complex protocols/instrumentation have limited its application in
clinical settings.
In accordance with this thesis aims, a study finalized at demonstrating the
potential application of high-resolution proton MRI for the longitudinal and
noninvasive assessment of peribronchial inflammation and bronchial remod-
eling was proposed. In this investigation, UTE MRI was preferred to standard
gradient-echo sequences since the investigation required at the same time
either high spatial resolution for the visualization of the bronchi and good
signal to noise ratio in the lung parenchyma in order to identify the changes
induced by asthma at bronchial level.
The work reported in this section confirmed the results presented in a
number of papers according to which UTE MRI is an effective tool for monitor-
ing lung inflammation. In addition, for the first time, it was shown that UTE
MRI can be a reliable tool to monitor noninvasively the evolution of bronchial
remodeling and may be used in a therapeutic drug delivery preclinical study.
The work presented hereafter has been published on NMR in Biomedicine,
26: 1451-1459 (2013), and its copyright belongs to John Wiley & Sons, Ltd.
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Abstract: 
Asthma is a chronic disease characterized by bronchial hyperresponsiveness 
(BHR), bronchial inflammation and remodeling. The great improvements in 1H 
MRI ultrashort-TE (UTE) sequences in the last decade have allowed lung images 
with high-resolution and good signal-to-noise ratio to be obtained in parenchymal 
tissues. In this article, we present a UTE 1H MRI high-resolution study of a 
chronic model of asthma in mice with the aim to longitudinally assess the main 
features of asthma using a fully noninvasive approach. Balb/c mice (n = 6) were 
sensitized with ovalbumin over a period of 75 days. The control group (n = 3) 
received normal saline on the same days. MRI acquisitions were performed on 
days 0, 38 and 78 to study the inflammatory volumes and bronchial remodeling 
(peribronchial signal intensity index, PBSI). Plethysmographic studies were 
performed on days 0, 39 and 79 to assess BHR to methacholine using the 
enhanced pause (Penh) ratio. The average inflammatory volume measured by 
MRI in the ovalbumin group (15.6 ± 2.4 µL) was increased significantly relative 
to control mice (–0.3 ± 0.7 µL) on day 38. The inflammatory volume was larger 
(34.2 ± 3.1 µL) on day 78 in the ovalbumin group. PBSI was significantly higher 
in the ovalbumin group on day 78 (1.53 ± 0.08) relative to the control group 
(1.16 ± 0.10), but not on day 38. After sensitization, asthmatic mice presented 
BHR to methacholine on days 39 and 79. Penh ratios correlated significantly with 
the inflammatory volume on day 39 and with the PBSI on day 79. This study 
shows, for the first time, that high-resolution UTE 1H MRI of the lungs may allow 
the noninvasive quantification of peribronchial eosinophilic inflammation with 
airways occlusion by mucus and of bronchial remodeling in a murine asthma 
model that correlates with functional parameters.  
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3.2 An orthotopic model of lung cancer in mice
As described in section 1.1.2.2, lung cancer is one of the most frequent and
lethal cancers. One of the main reasons for lung cancer poor prognosis is
strongly related to the difficulty in diagnosing this pathology in its early stages.
Imaging techniques are of paramount importance since they are responsible
for the detection, localization and monitoring of the evolution of neoplastic
lesions.
X-ray of the chest and CT imaging have already shown a certain potential
in the identification of some types of lung cancer and pulmonary nodules.
Nonetheless, the ionizing radiation typical of these imaging techniques limits
their use, especially in newborns and old patients. Similarly, the continue mon-
itoring of a suspected neoplastic lesion or its follow-up after a therapy remain
critical and matter of debate, since secondary radiation-induced pathologies
may arise in the patient.
Also in this case, lung MRI presents a strong potential because of its good
resolution, absence of ionizing radiation, and good soft tissue contrast. For
instance, respiratory-gated Cartesian spin-echo acquisitions were shown to be
useful in the detection and follow-up of lung carcinomas in mice.
In the following work, optimized lung MRI techniques (gated- and non-
gated-FLASH sequences and an UTE sequence) are compared to investigate
their potential as noninvasive approaches for NSCLC MRI in vivo detection
and follow-up in a mouse model of lung adenocarcinoma. The advantages
and the limitations of free-breathing UTE MRI will be discussed in the light
of the obtained results.
The work presented hereafter has been accepted for publication on NMR
in Biomedicine, and its copyright belongs to John Wiley & Sons, Ltd.
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 In vivo Magnetic Resonance Imaging for effective non-invasive 
detection and follow-up of an orthotopic mouse model of lung cancer 
 
A. Bianchi, S. Dufort, P.-Y. Fortin, F. Lux, G. Raffard, N. Tassali,  
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Abstract: 
One of the main reasons for the dismal prognosis of lung cancer is related to the 
late diagnosis of this pathology. In this study, we evaluated the potential of 
optimized lung MRI techniques as a completely non-invasive approach for non-
small-cell lung cancer (NSCLC) MRI in vivo detection and follow-up in a mouse 
model of lung adenocarcinoma expressing the luciferase gene. 
Bioluminescent lung tumour cells were orthotopically implanted in immuno-
deficient mice. Ultra-short echo-time (UTE) MRI free-breathing acquisitions were 
compared with standard gradient-echo lung MRI (FLASH) using both respiratory-
gated and free-breathing protocols. The MRI findings were validated against 
bioluminescence imaging (BLI) and gold-standard histopathology analysis. 
Adenocarcinoma-like pathological tissue was successfully identified in all the 
mice with gated-FLASH and non-gated UTE MRI, and good tumour co-
localization was found between MRI, BLI and histological analyses. An excellent 
or good correlation was found between the measured bioluminescent signal and 
the total tumour volumes quantified with UTE MRI or gated-FLASH MRI, 
respectively. No significant correlation was found when the tumours were 
segmented on non-gated MR FLASH images. 
MRI was shown to be a powerful imaging tool able to detect, quantify and 
longitudinally monitor the development of sub-millimetric NSCLCs. To our 
knowledge, this is the first study which proves the feasibility of a completely non-
invasive MRI quantitative detection of lung adenocarcinoma in freely breathing 
mice. The absence of ionizing radiation and the high-resolution of MRI, along 
with the complete non-invasiveness and good reproducibility of the proposed non-
gated protocol, make this imaging tool ideal for direct translational applications.  
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4
UTE MRI and intratracheally
administered contrast agents
In this chapter, the feasibility of using UTE proton MRI to monitor the biodis-
tribution and study the elimination pathways of intratracheally administered
gadolinium-based nanoparticles will be shown. A protocol for the quantifi-
cation of the absolute concentration of a T1-shortening contrast agent in the
lungs using a radial UTE sequence will be proposed. As a result, quantitative
pharmacokinetic models will be implemented in lungs and validated with the
help of fluorescence imaging. A basic toxicological study to evaluate the short
term negligible toxicity of the investigated nanoparticles and of the proposed
protocol will be presented.
4.1 Proof-of-concept
The investigations presented in chapter 3 clearly showed the strong potential
of UTE MRI in the detection of pathological changes occurring in lung tissue.
In particular, the investigation on the asthma model in section 3.1 proved that
UTE MRI can allow the quantification of bronchial remodeling in a group
of allergen-sensitized mice. Likewise, the study in section 3.2 showed the
possibility of detecting submillimetric neoplastic lesions in tumor-bearing
rodents. On the other hand, the MR changes involved in the asthma study
were shown to be relatively small if considering that strong remodeling fea-
tures were implicated in the study. Similarly, the need for improving the
early detection of small lung cancerogenic formations and for establishing
an observer-independent segmentation protocol arose from the study on the
NSCLC model.
In a more general way, the studies presented in the previous chapter made
clear that UTE MRI is a valuable instrument in the noninvasive detection
and monitoring of lung diseases. At the same time they confirmed one of
well-known flaw of such an imaging technique, i.e., its limited sensitivity.
As described in section 1.3, the use of properly chosen contrast agents
can help to encompass the detection limits of MRI. Among the vast range
of contrast media available for magnetic resonance imaging, the category
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of T1-shortening agents was selected for investigation. This choice was con-
nected to a number of theoretical and practical considerations. For instance,
one of the aims of this thesis was to implement noninvasive, low-cost and
easily-implementable protocols for proton MRI, which excluded the use of hy-
perpolarized media. In addition, the need to enhance the weak signal changes
which take place in diseased lung tissue advocated the use of positive contrast
agents, ruling out the employment of iron oxide-based nanostructures. Since
the morphological changes of lung parenchyma were of concern, paramag-
netic contrast agents were preferred to fluorinated gases or OE MRI, mainly
used for ventilation and perfusion studies.
The USRPs were selected for the investigations reported in the next pages.
Such nanostructures, compared to commercially available molecular com-
pounds, present several advantages like multimodality, multivalency, and
original nanoscale properties which will be demonstrated and discussed in
detail in the next sections. At the time of the choice, these nanoassemblies had
been already proven to present a negligible hepatic clearance when injected
intravenously. This property, discussed inter alia in the following article,
made the USRPs especially attractive.
Intratracheal instillation appeared to be an attractive route to test these
nanoassemblies in healthy mice in combination with the UTE sequence. In-
deed, this administration modality allowed the delivery of a known dose
of contrast agent directly into the lungs, permitting to easily evaluate the
NMR properties of the USRPs and to find the optimal dose range for possible
subsequent applications.
The work presented hereafter has been accepted for publication on Mag-
netic Resonance in Medicine, 70:1419–1426 (2013), and its copyright belongs
to Wiley Periodicals, Inc.
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 Contrast enhanced lung MRI in mice using ultra-short echo time 
radial imaging and intratracheally administrated  Gd-DOTA-based 
nanoparticles 
 
A. Bianchi, F. Lux, O. Tillement, Y. Crémillieux 
 
 
Abstract: 
Purpose: To investigate the in vivo T1-enhancement of the lung parenchyma in 
free-breathing healthy mice following intratracheal administration of Gd-DOTA-
based nanoparticles, to assess the enhancement kinetics of the instilled contrast 
medium and to identify its elimination pathways. 
Methods: Ultrashort Echo Time (276 µs) proton MRI of the lung was performed 
(N = 14) at 4.7 T after the intratracheal instillation of 50 µL of seven different 
concentrations of contrast agent solution (from 2 to 100 mM of Gd3+). The signal 
enhancement (SE) in lungs, blood, liver, kidneys, and bladder was assessed (N = 
3) for a 50 mM concentration solution at different time points. 
Results: The largest SE in lungs (266 ± 14%) was observed for a 50 mM solution 
of Gd3+. In lungs, the SE was observed to decay exponentially with a time 
constant of 149 ± 51 min. The passage of the nanoparticles from lung tissue to 
blood and kidneys, and ultimately to the bladder, was observed. No significant 
hepatic enhancement was measured. 
Conclusion: This study demonstrates the feasibility of large SEs of lung tissue 
using intratracheally administrated solutions of Gd-based contrast agents. In 
future applications, the SE in lungs could be used to image the biodistribution of 
coadministrated drug aerosols or to selectively enhance lung diseased tissues. 
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4.2. Biodistribution and pharmacokinetics
4.2 Biodistribution and pharmacokinetics
The results presented in the previous study were undoubtedly encouraging.
The use of a T1-weighted UTE MR pulse sequence allowed the detection
of large signal changes in lung parenchyma. The good temporal resolution
enabled by the chosen sequence allowed the study of the evolution of the
signal enhancements and having thus a first insight into the biodistribution
of the nanoparticles in the lungs. Similarly, a basic study of the elimination
pathways of the nanoparticles could be carried out, underlining the favourable
pharmacokinetics of the USRPs entirely eliminated through renal filtration.
The study presented in the previous section (see Fig. 2 in the previous
article) underlined also an important key property of the employed UTE
MR sequence, i.e., the negligibility of the T ∗2 effect when working with short
TEs and moderately low concentrations of contrast agents. The presence of a
strongly dominant image contrast was immediately perceived as a clear ad-
vantage of the UTE MR pulse sequence. Nonetheless, a deeper investigation of
the NMR theory behind this fact was still missing. Such an insight, presented
in the work proposed in this section, was needed to fully exploit the wealth of
information that MRI can provide.
In addition, a number of issues and concerns arose from the investigation
presented in section 4.1. First of all, the signal changes measured for the
USRPs were extremely high but the protocol had not been applied to standard
contrast agents. As a consequence, no comparison was available neither in
terms of signal enhancements for a given concentration nor in terms of elim-
ination times. Secondly, the described protocol employed a technique (i.e.,
intratracheal instillation) rather new for contrast agent delivery (compared
for example to standard intravenous injections). Considering the potential
interest of this promising delivery route and these nanoassemblies in future
applications, concerns about the safety of the proposed protocol may be com-
mon in the reader. Similarly, the use of nanoparticles arose concerns about
the potential acute toxicity of the USRPs.
In the following study, all these concerns and issues were investigated and
discussed. When possible, results were validated with the help of a comple-
mentary imaging modality, i.e. FRI.
The work presented hereafter has been accepted for publication on Mag-
netic Resonance Materials in Physics, Biology and Medicine (doi:10.1007/s10334-
013-0412-5) and its copyright belongs to the European Society of Magnetic
Resonance in Medicine and Biology (ESMRMB). The Supplementary Mate-
rial is presented in appendix D for the interested readers.
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multimodal gadolinium-based nanoparticles for lungs using 
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J.-L. Coll, Y. Crémillieux 
 
Abstract: 
Objective: To study the biodistribution and lung pharmacokinetics of tracheally 
administered gadolinium-based contrast agents [gadoteric acid and multimodal 
ultra-small rigid platforms (USRPs)], to validate their pharmacokinetics against 
optical imaging of fluorescent USRPs, and to test their short-term toxicity. 
Materials and methods: Ultrashort echo-time (UTE) lung proton magnetic 
resonance imaging (MRI) was performed at 4.7-Tesla (T) after the intratracheal 
instillation of different concentrations of contrast agent solutions in mice. 
Pharmacokinetic models were implemented on the absolute concentration 
calculated from the MRI signal enhancement measurements. Fluorescent USRPs 
were used to obtain optical images with the same protocol. Bronchoalveolar 
lavage inflammatory cell count and serum creatinine measurement were 
performed on four groups of instilled mice (sham, saline, USRPs, 
lipopolysaccharide). 
Results: MR and optical imaging showed similar kinetics of the USRPs, passing 
from the airways to the lung tissue and to the kidneys, with negligible hepatic 
clearance. No significant increase of lung and renal inflammation markers were 
observed in USRP-instilled animals. 
Conclusion: A T 1-weighted radial UTE sequence was found to be valuable in 
quantitatively monitoring the biodistribution and pharmacokinetics of 
nanoparticles in the lungs of mice. The observed favorable pharmacokinetics, 
which was validated by fluorescence imaging, ensures the negligible toxicity of 
the nanoprobes, making the USRPs and the developed protocol good candidates 
for applications on selected lung diseases.  
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A new protocol for lung tumor
detection
In section 3.2, free-breathing proton MRI was shown to be an efficient tool in
the detection of lung cancer. UTE MRI, in particular, was shown to be very
accurate in the detection of submillimetric lung neoplastic lesions, thanks to
its negligible motion artifacts and its sensitivity to lung parenchyma signal
changes (as also demonstrated in section 3.2).
Nonetheless, MR imaging techniques present a lower sensitivity compared
to standard nuclear medicine imaging modalities. To encompass this intrinsic
limitation and to further improve the detection efficiency for lung cancer,
the use of positive contrast agents can be sought. In this sense, as shown in
chapter 4, T1-weighted UTE MRI sequences are good candidates to accurately
study the signal changes induced by the presence of paramagnetic atoms in
lungs.
In this chapter, the oral administration of gadolinium-based nanoparticles,
proposed and discussed in sections 4.1 and 4.2, will be applied to the study of
the lung cancer model previously described (see section 3.2). A quantitative
comparison between such administration modality and a more conventional
one (i.e., intravenous injection) will be proposed. The sensitivity, specificity,
contrast enhancement and pharmacokinetics of this intrapulmonary adminis-
tration route will be evaluated. Complementary imaging modalities will be
used in order to validate the results observed with proton UTE MRI.
The work presented hereafter has been published on Proceedings of Na-
tional Academy of Sciences USA, 111(25):9247-9252 (2014), and its copyright
belongs to the National Academy of Sciences USA.
101
  
 
 
Pages 102-110 have been removed from this diffusion version of the Ph.D. thesis 
since they contained an article protected by editor copyright. Only the abstract 
will be reported hereafter. 
 
The removed article is: 
Targeting and in vivo imaging of non-small-cell lung cancer using 
nebulized multimodal contrast agents 
 
A. Bianchi, S. Dufort, P.-Y. Fortin, F. Lux,  
N. Tassali, O. Tillement, J.-L. Coll, Y. Crémillieux. 
 
Proceedings of National Academy of Sciences USA,  
111(25):9247-9252 (2014) 
 
 
The full article can be downloaded at: 
http://www.pnas.org/content/early/2014/06/04/1402196111.abstract 
 
 
A copy of the reference version of this Ph.D. thesis can be accessed at the Library 
of the University of Bordeaux. For further details please contact the author of 
this work (bian.drea@libero.it). 
 
 
 
 
 
 
 Targeting and in vivo imaging of non-small-cell lung cancer using 
nebulized multimodal contrast agents 
 
A. Bianchi, S. Dufort, P.-Y. Fortin, F. Lux, N. Tassali, O. Tillement,  
J.-L. Coll, Y. Crémillieux 
 
Abstract: 
One of the main reasons for the dismal prognosis of lung cancer is related to the late 
diagnosis of this pathology. In this work, we evaluated the potential of optimized lung 
MRI techniques and nebulized ultrasmall multimodal gadolinium-based contrast agents 
[ultrasmall rigid platforms (USRPs)] as a completely noninvasive approach for non-small–
cell lung cancer (NSCLC) in vivo detection. A mouse model of NSCLC expressing the 
luciferase gene was developed. Ultrashort echo-time free-breathing MRI acquisitions 
were performed before and after i.v. or intrapulmonary administration of the 
nanoparticles to identify and segment the tumor. After orotracheal or i.v. administration 
of USRPs, an excellent colocalization of the position the tumor with MRI, 
bioluminescence and fluorescence reflectance imaging, and histology was observed in 
all mice. Significantly higher signal enhancements and contrast-to-noise ratios were 
observed with orotracheal administration using lower doses, reducing the toxicity issues 
and the interobserver variability in tumor detection. The observations suggested the 
existence of an unknown original mechanism (different from the enhanced permeability 
and retention effect) responsible for this phenomenon. MRI and USRPs were shown to 
be powerful imaging tools able to detect, quantify, and longitudinally monitor the 
development of submillimetric NSCLCs. The absence of ionizing radiation and high 
resolution MRI, along with the complete noninvasiveness and good reproducibility of 
the proposed protocol, make this technique potentially translatable to humans. To our 
knowledge this is the first time that the advantages of an orotracheal administration 
route are demonstrated for the investigation of the pathomorphological changes due to 
NSCLCs. 
Keywords: 
Lung tumor; magnetic resonance imaging; bioluminescence imaging; gadolinium-
based nanoparticles 
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Discussion and perspectives
In this chapter, a short discussion about the advantages and limitations of the
protocols developed, implemented and validated will be proposed for each
published or submitted article. The short- and long- term perspectives of each
work will be analyzed, with a special attention to the on-going experiments.
Finally, some side applications originated from the work presented in this
thesis will be briefly presented.
6.1 UTE MRI applications on lung diseases
The pathologies investigated in chapter 3, namely asthma and lung cancer, are
both frequent and responsible for several millions of deaths each year world-
wide. Even when not lethal, these diseases can severely hamper the quality
of life of patients. In addition, the cost of medications and hospitalizations
along with the indirect non-medical costs (i.e., absence from work) related to
these diseases represent a social burden under the economic point of view.
Understanding the mechanisms behind these pathologies is fundamental
in order to develop new therapeutic approaches. Similarly, noninvasive and
effective diagnostic instruments are required to detect the diseases in their
early stages, which very often results in a positive prognosis, increased life
expectancy or improved quality of life of the patient. In this context, imaging
techniques have a role of paramount importance since they allow for early
detection of pathologies, they help preparing and guiding surgery, they allow
for noninvasive longitudinal follow-ups of the patients, and they permit to
study the effects of new therapeutic drugs.
In chapter 3, UTE MRI has been chosen to study the noninvasive detection,
investigation and follow-up of these lung diseases in two animal models. The
rationale behind this choice has been widely illustrated in the introduction of
the manuscripts, in the Preface and in chapter 1.
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6.1.1 Asthma
Among the vast number of asthma models existing in scientific literature
[151–154], the OVA-sensitization protocol proposed by Henderson et al. [155]
was chosen for the study. The reasons of such a choice are mainly due to the
fact that this model well represents the slow development of allergen-induced
asthma in humans. In addition, the murine model investigated in the study
presents all the main hallmarks of such pathology, developed at different
stages and time points. A further advantage of the OVA-sensitization model
is related to the fact that it had been extensively characterized under the
biological point of view before the beginning of the study reported in section
3.1.
When the study on the OVA-sensitization model was started, Lederlin et
al. [156] had shown that an index defined similarly to the Peribronchial Signal
Index (PBSI), measured with micro-CT, correlates well with the bronchial
smooth muscle size measured on histological slices1. The group was able to
find a significant difference between the OVA-sensitized mice and the controls
at day 76, studying the same asthma model. Only the baseline time point
and the endpoint at day 76 was studied by the group, due to the terminal
procedures employed to perform histological analyses.
In a successive article, Lederlin et al. [157] extended the OVA model
characterization to three different time points, as shown in Figure 6.1. They
clearly showed an increasing cell infiltration in the peribronchial space during
the first two time points (days 35-37 and 75-77) in OVA-sensitized mice. A
strong decrease in the inflammation was observed at the third time point,
roughly one month after the last administration of ovalbumin. As for the
bronchial remodeling, strong remodeling features were observed in allergen-
sensitized mice at the second time point (days 75-77) but not at the first time
point (days 35-37). Significant remodeling features were observed also at the
third time point, but not as intense as at the second time point.
The work presented in section 3.1 has been limited to the study of the
first two time points (days 35-37 and 75-77) of the same asthma model, as
a proof-of-concept2. The obtained results go on the same direction of Leder-
lin’s ones, showing the feasibility of monitoring peribronchial changes after
allergen-sensitization in order to distinguish between mice that underwent
bronchial remodeling features and controls [156, 157]. In this sense, the work
1The index defined by Lederlin et al. was called peribronchial density index (PBDI) and
was computed in the same way as the PBSI, using the Hounsfield unit scale instead of the SNR
in the peribronchial measurements [156].
2The data presented in the second article of Lederlin et al. [157] were published when the
work in section 3.1 was already under peer-review.
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Figure 6.1: Typical optic microscopic images (100X) from bronchial sections from control (top)
and OVA-sensitized mice (bottom). Bars represent 85 µm. α-smooth muscle actin staining (in
brown) underlines bronchial remodeling features (smooth muscle mass increase) while nuclei
are stained in dark blue to study cell infiltration. Reprinted from [157]
presented in this thesis on the asthma model can be considered the nontriv-
ial transposition of micro-CT results to MRI with respect to the bronchial
remodeling studies.
Such a result could be accomplished because of the simultaneous high
resolution and significant SNR achieved in lung parenchyma, obtained thanks
to the properties of UTE MRI. The resolution obtained in MRI images was
still inferior to the one of Lederlin et al. in their micro-CT studies. As a
consequence, the identification of bronchi in MRI images was performed by
two independent users and only the bronchi identified by both of them were
used for subsequent analysis3. Nonetheless, the images obtained with MRI,
contrarily to the micro-CT ones by Lederlin et al., were acquired using a
noninvasive free-breathing protocol. The absence of ionizing radiations is a
further advantage of the proposed protocol compared to micro-CT. Further-
more, the possibility of accurately identifying and quantifying inflammatory
volumes using UTE MRI was confirmed in the work presented in section 3.1.
Perspectives Before being able to exploit this protocol in pre-clinical studies
to evaluate the potential of selected lead compounds for bronchial remod-
eling treatment, a further investigation of the PBSI index should be sought.
In particular, it would be important to understand if (and, in case, to what
extent) this index is affected by the peribronchial inflammation. As discussed
3The identification of bronchi with micro-CT was performed using multiplanar reforma-
tion by a single user [156].
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in the publication of section 3.1, data seem to suggest that inflammation has
low or no influence on PBSI. Nonetheless, extending the model to a time point
characterized by bronchial remodeling in absence of inflammation would
shed light on this matter.
Preliminary studies have been conducted on the third time point described
by Lederlin et al. [157]. As shown in Figure 6.2, no significant difference
was observed between controls and OVA-sensitized mice with respect to
inflammation. On the other hand, an increase in the PBSI index was observed
between the two groups, even though the Wilcoxon’s signed-rank test resulted
in a non-significant difference. The reasons for this finding may be related to
the fact that the remodeling features developed by the OVA-sensitized mice
at day 110-112 are less strong than the ones at days 75-77.
(a) Inflammation (b) PBSI
Figure 6.2: Bar plots showing (a) the MRI inflammatory volumes and (b) the PBSI at the
different time points, calculated using the protocol described in section 3.1. The data relative
to the first and second time point (days 38 and 78) are the one reported in the published
article. The data obtained at day 110 belong to the preliminary test performed on the third
time point of Lederlin’s asthma model. The bar plot in figure (a) shows that, at day 110, no
difference exists between the OVA-sensitized mice and the controls. The increase in the PBSI
in allergen-sensitized mice at day 110 is not significant, probably due to the small number of
animals employed in the preliminary study. Reprinted from [158]
An increase in the number of animals would therefore be required to
identify these smaller changes. Since in this animal model the bronchial re-
modeling features are spontaneously regressive (in a slow but progressive
way) after the end of the sensitization protocol, a time point with purely
bronchial remodeling features may be obtained treating mice with glucocor-
ticoid steroids close to day 75. Budesonide, for example, was shown to be
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able to significantly accelerate inflammation resolution if given 24 hours post
allergen challenge [58]. This protocol would in principle allow to have a time
point with strong remodeling features (like the second time point of Lederlin’s
model) but negligible inflammation (like the third time point of Lederlin’s
model).
Finally, it has to be noted here that, for a systematic applicability of this
protocol to generalized pre-clinical studies of drug tests, an automated process
for the data analysis should be implemented. The analysis performed in the
work is indeed effective and well reproducible but rather time-consuming.
The implementation of an automatic segmentation procedure should therefore
be sought and tested.
6.1.2 Lung cancer
In section 3.2, the advantages and limitations of UTE MRI compared to opti-
mized gradient-echo sequences have been discussed. The protocol used has
permitted to effectively detect lung cancer in a model of adenocarcinoma,
as confirmed by BLI and histology. The encouraging results could be easily
applied to other models of lung cancer in order to identify which forms of
lung neoplasm can be detected in their early stages using this advantageous
imaging techniques. The protocol could be applied to the preclinical study of
the therapeutic effects of selected lead compounds for cancer treatment.
The investigation left open two main issues: (i) the possibility of using
contrast agents to improve the sensitivity of the imaging technique employed
and (ii) the applicability of the protocols in humans. The former issue has
been answered in chapter 5 whereas the latter is still pending. Noninvasive
UTE MRI techniques have indeed been applied in volunteers at the Univer-
sity of Bordeaux with satisfactory results in terms of SNR measured in lung
parenchyma [83]. Testing these sequences in lung cancer-bearing patients
could be one of the next steps.
6.2 UTE MRI and intratracheally administered
contrast agents
The interest of contrast agents for MR imaging dates back to the early 80’s [76,
126]. Since then, several exogenous contrast agents have been developed for
different purposes. Nonetheless, only few of them are currently in use in
clinical practice and only for rather specific applications, partially because of
the strict requirements on contrast media imposed by regulatory agencies.
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In the field of MRI lung imaging, several techniques have been experi-
mentally used to study pulmonary ventilation, perfusion and diffusion in
a number of pathologies [91]. In chapter 4, a protocol for the visualization
and the quantitative study of the signal changes of lung parenchyma after
the administration of a paramagnetic contrast agent has been proposed. The
protocol has several advantages related to the use of a radial UTE MRI se-
quence. In particular, the constant TR, enabled by the free-breathing radial
acquisitions, permits to maintain a stable image contrast. As a consequence,
data acquired at different times can be accurately compared (which wouldn’t
be possible, for instance, using perspective gating techniques). Furthermore,
the T1-weighting contrast of UTE sequences allows to reduce to the minimum
the T ∗2 effects.
As a result, quantitative PK models have been implemented and applied
to the study of contrast agents biodistribution and elimination pathways. The
protocol is applicable to a generic paramagnetic contrast (e.g., Dotarem) and
not only to the specific nanoparticles used throughout the thesis (see section
6.5). Nonetheless, the protocol is based on the negligibility of the T ∗2 effect,
which depends mainly on the contrast agent properties (mainly its r∗2), on the
used concentration and on the chosen sequence parameters (mainly TE). Such
negligibility has to be assessed prior to the implementation of the PK models.
Unfortunately, the relationship intercurring between these parameters is not
easy and the quantification of the transverse relaxivity of the contrast agent
is complicated by the fact that its value depends on the spin-spin transverse
relaxation but also on the tissue, MR sequence parameters and magnetic field
inhomogeneities. This means that the r∗2 cannot be easily measured, imposing
an empirical approach to verify if the T ∗2 effect is negligible and thus if the PK
models can be effectively applied to the data. In the case of the USRPs, this
assessment was conducted in section 4.1 and served as basis for the work in
section 4.2.
Perspectives The UTE MRI protocols implemented in chapter 4 have been
extensively used in chapter 5. Furthermore, several on-going studies employ
these techniques in the study of the pathological changes that take place in
the lungs or in other organs. A description of the general perspectives and ap-
plications of these protocols is proposed in the next sections. The limitations
and perspectives of the chosen administration modality are briefly discussed
in section 6.4.4.
Strictly speaking about the PK models and the contrast agent protocol
implemented in section 4.2, a validation of the absolute concentration mea-
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surement is still pending. As discussed in the relative manuscript, the use
of SPECT imaging with USRPs-11In could be an effective way to validate the
absolute values obtained with MRI. Even though the presented results are
valid independently of this pending assessment, the accurate knowledge of
the absolute concentration of the contrast agent in the healthy and diseased
tissues would permit to best exploit the therapeutic properties of the USRPs
nanoparticles (see appendix B). It would indeed permit to tailor the radiation
therapy according to the accumulation effect measurable with MRI, optimiz-
ing the theranostic efficacy of these nanoassemblies. Obviously, the possibility
of quantifying the absolute concentration of a contrast agent in a tissue using
UTE MRI would have many applications for different organs and fields, and
it’s therefore a short-term study that has to be undertaken.
Finally, to further improve the precision of the implemented PK models
and with a view to the absolute concentration quantification, further studies
are needed to evaluate the best values for the in vivo longitudinal relaxivity
of the nanoparticles and for the longitudinal relaxation time of the lungs T1(0).
Knowing this information would enable to exploit all the information that the
PK models may offer like, for example, the clearance rate and bioavailability
of the contrast medium in the various compartments.
6.3 A new protocol for lung tumor detection
In chapter 5, the protocol developed in chapter 4 was successfully applied
to the lung cancer model studied in section 3.2. The investigation clearly
showed that improvements in terms of SNR and CNR can be obtained using
gadolinium-based nanoparticles in conjunction with T1-weighted UTE MRI
sequences, with straightforward advantages in the detection and segmentation
of small lung cancer lesions.
In addition, the work showed for the first time that the oral administration
can be an advantageous delivery route for the detection of pathomorphological
changes due to lung cancer. The breadth of this finding is not limited to the
simple administration of MRI contrast agents for NSCLCs detection. The
potential application of this result may indeed be extended to other imaging
modalities, may include the establishment of effective innovative protocols
for the detection of other lung pathologies (different from lung cancer) but
also for the study of the efficacy of specific drugs for lung diseases therapy.
Some of the perspectives of these results and of this promising protocol
will be discussed in the next section.
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6.4 General perspectives
The article presented in chapter 5 contains the last validated results which
will be shown in this thesis. The work has left open a number of possible per-
spectives that are currently under study. First of all, only the passive targeting
mechanisms have been tested even though the USRPs allow grafting com-
pounds for active targeting on their surface or coating. Secondly, the USRPs
and the intratracheal administration have been tested only on one model of
pulmonary disease but they can be exploited to study other pathologies, in
lungs or in other organs (e.g., brain).
Hereafter these aspects will be explored in more detail and preliminary
results about the on-going studies will be described. Some long-term future
potential applications of the USRPs and the developed MRI protocols will be
proposed.
6.4.1 Oral administration and active targeting USRPs
As mentioned in section 2.2.2, after the top-down process that leads to the
formation of the nanoparticles, 30 to 40% of DOTA ligands are free. For the
USRPs used in this work, supplementary paramagnetic atoms were provided
to increase the total relaxivity of the nanoassemblies. Similarly, Cy 5.5 was
covalently grafted on them when needed to perform FRI studies.
As detailed explained in the patent referenced in appendix A, the free
DOTA and the available carboxylic functional groups (COO−) can be ex-
ploited also in different ways. Among these, grafting specific targeting molecules
or peptides on the nanoassemblies is the one that will be considered here and
that is currently under study. This possibility, enabled by the flexible structure
of the USRPs, can be exploited to actively target specific diseases, instead of
relying solely on the EPR effect or generic passive targeting mechanisms.
In this context, the idea is to use as targeting compound of choice the RGD
(arginine-glycine-aspartic acid), a tripeptide which was shown to be able to
recognize and target the integrin αvβ3 [159], transmembrane receptors that
play a fundamental role in angiogenesis and cancer development [160, 161].
Integrin targeting and oral administration Integrin αvβ3 has a particular
pattern of expression in lung cancer [162,163]. In normal tissues, this integrin
is expressed on the basal face of a few types of cells, where it mediates adhe-
sion between cells and the extracellular matrix. While its level of expression
is undetectable in normal quiescent endothelial cells, it is expressed at 105 or
106 copies/cells on the endothelial cells of growing or remodeling capillaries
118
6.4. General perspectives
during angiogenesis, typical feature of asthma bronchial remodeling and
growing tumors.
Accessibility to an RGD ligand coming from the bloodstream is question-
able since most of these αvβ3 integrin receptors are located on the ’hidden’
side of the endothelial cells and are engaged in an interaction with the extra-
cellular matrix. This is also true to a certain extent for cancer cells. Actively
growing and/or migrating metastatic tumor cells on the periphery of a tumor
will present increased levels of αvβ3 integrin than those present in the center
of the tumor. In addition, the presence of a tumor induces a remodeling of
the normal surrounding stromal tissues, and a cross talk exists between the
stroma and the tumor. This is accompanied by an overexpression of the αvβ3
integrin on the surface of normally negative cells of the stroma, but also by
an abnormal presence of this integrin on the apical and lateral sides of these
cells.
It thus becomes reasonable to hypothesize that approaching these cells by
the airway may be more effective than via the bloodstream.
On-going studies: active targeting USRPs for lung cancer The USRP-RGD
nanoparticles have been already synthesized and characterized by the ‘In-
stitut Lumie`re Matie`re’ of the University of Lyon. In particular, among the
vast number of RGD motifs, the class of cyclic arginine-glycine-aspartic acid
(cRGD) paptides was selected. These cyclic compounds have indeed shown a
much higher stability compared to the linear RGD peptides, better pharma-
cokinetics (renal clearance) with negligible toxicity and an improved receptor
specificity and affinity for tumor targeting [159, 164, 165]. Proper control
nanoparticles were synthesized using cRAD (cyclic arginine-alanine-aspartic
acid) tripeptides, which differ from cRGD in only one amino acid. On average,
2.5 cRGD (or cRAD) per nanoparticle were observed. Covalent grafting of Cy
5.5 for FRI studies is still possible when cRGD is grafted on the nanoparticles.
These nanoparticles have already been tested at the University of Grenoble
in a subcutaneous xenografted tumor in immunodeficient mice. As shown
in Figure 6.3, a significant increase in tumor targeting was observed when
the USRP-cRGD nanoparticles were administered intravenously, compared to
USRPs-cRAD or USRPs-Cy.
In the light of these considerations, the USRPs-cRGD will be applied in
the next month(s) to the NSCLC model developed in section 3.2, comparing
both the intratracheal and the intravenous administration routes as described
in chapter 5.
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Figure 6.3: (a) FRI images showing the accumulation of USRPs-Cy, USRPs-cRGD or USRPs-
cRAD in a xenografted subcutaneous tumor 24 hours after intravenous administration. (b)
Biodistribution in organs after administration of the three different type of nanoparticles
24 hours after the administration. A significant increase in tumor targeting was observed
when the USRP-cRGD nanoparticles were administered intravenously, because of the active
targeting potential of cRGD. Adapted from [166].
Future studies: active targeting USRPs for asthma In section 3.1 it was
shown that bronchial remodeling features can be noninvasively detected us-
ing optimized UTE MRI protocols. Nonetheless, the study showed that the
employed imaging technique has a spatial resolution that is still inferior com-
pared to micro-CT, making the analysis of the bronchial remodeling features
less simple. Even though a good reproducibility was observed, further im-
provements in the imaging protocol are desirable.
As described in section 1.1.2.1, angiogenesis is an important feature associ-
ated to bronchial remodeling in asthma patients. Considering that cRGD has
been proven to be capable of targeting the integrin αvβ3 [159] regulating the
angiogenesis process [160,161], USRPs-cRGD appear to be good candidates to
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target and thus investigate bronchial remodeling. In this sense, the UTE MRI
protocols implemented in this work are doubly advantageous since: (i) they
allow to have high resolution along with significant SNR in lung parenchyma
(see section 3.1) and (ii) they enable the detection of small signal changes in
lungs after the administration of gadolinium-based nanoparticles (see section
4.1).
In principle, the use of USRPs-cRGD could enhance the changes that
take place in the bronchial wall and enable a noninvasive investigation of
the evolution of this disease in function of time. In particular, beside the
diagnostic advantages, this would permit to study effectively the effect of
therapeutic drugs for bronchial remodeling in pre-clinical studies. If the
accumulation of the USRPs-cRGD in the remodeled bronchial walls was
confirmed, grafting therapeutic lead compounds on these nanocarriers would
therefore permit to delivery therapeutic drugs directly on-site.
6.4.2 Application of USRPs to other lung models
The UTE MRI protocols implemented in this thesis have been successfully
applied to detect lung cancer. The sensitivity of the technique was notably
improved using paramagnetic contrast agents and a favourable administration
route. The advantages observed in the study of NSCLCs could be extended to
various models of lung disease, different from the ones described in chapter
3. For instance, the application of the USRPs on an LPS model of severe
inflammation and on a model of lung fibrosis in mice are currently on-going.
In addition, the pioneering experiments proposed in references [94, 95] to
study the ventilation and perfusion defects of murine models of pulmonary
embolism or acute unilateral airway obstructions could be easily reproduced
to study the improvements achievable with the optimized protocols described
in this thesis.
Hereafter, the interesting preliminary results (to be confirmed) relative to
the on-going study on a murine fibrosis model are briefly presented.
Lung fibrosis Pulmonary fibrosis is a restrictive disease of the lung (see
section 1.1.2) characterized, among other things, by the thickening of the
blood-air barrier. Being a progressive and lethal disease, early and sensitive
diagnostic tools and follow-up imaging techniques are essential to increase
the life expectancy of patients suffering from this lung pathology and to test
new promising drugs.
The idea behind this on-going study is to investigate whether the use of the
USRPs permits to increase the diagnostic sensitivity of this pathology, using a
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UTE MRI protocol similar4 to the one presented in chapter 5. Similarly, the
possibility of evaluating the severity of lung fibrosis studying the diffusion and
the elimination time constants of the USRPs (using PK models implemented
in section 4.2) is under consideration.
The biological model used in this preliminary study is the one widely
described by Egger et al. [79], which employs various oropharyngeal adminis-
trations of bleomycin in mice over a period of 6 days.
As already shown by Babin et al. [89, 90], the development of lung fibro-
sis in bleomycin-injured mice can be successfully monitored in vivo using
standard gradient-echo sequences. Similarly, Egger et al. [79] were able to
accurately follow the progression of lung fibrosis using UTE MRI.
As shown in Figure 6.4, the intratracheal instillation of 50 µL of a 50 mM
solution of USRPs seems to result in large Signal Enhancements (SEs) ( >
300%) in the area of bleomycin-induced lesions, which makes even easier the
detection of the fibrotic lesion and of its contours in UTE MR images.
(a) Before USRPs (b) 33 min after USRPs
Figure 6.4: UTE MRI axial image of a bleomycin-sensitized mouse (a) before and (b) after the
intratracheal instillation of the USRPs. The fibrotic lesions are enhanced after the administra-
tion of the contrast. Images were acquired 30 days after the end of the sensitization protocol to
avoid the inflammation regime that follows the bleomycin administrations during the first 3
weeks. Courtesy of Dr. N. Tassali.
Longer elimination time constants have been observed in animal with
fibrosis (≈ 245 min), compared to controls (≈ 185 min). This observation
suggests a prolonged retention of the contrast agent within the diseased lung
tissue, probably related to the hampered access of the nanoparticles to the
capillary blood vessels and their subsequent renal elimination.
4The main difference is related to the fact that this study is currently performed on a 7 T
Bruker spectrometer for technical reasons.
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No significant difference has been observed in the diffusion times between
bleomycin-sensitized mice and controls. This fact can be related to an effective
absence of difference in the diffusion constants or to the need of increasing
the number of animals to obtain more stable averages and smaller SEM (since
the values of diffusion constants are rather small and the biological variability
quite significant, a proper number of animals is needed to see possible small
variations).
Further investigations, including ex vivo imaging techniques and a higher
animal statistics, are needed to validate these observations and to further
understand the behavior of the contrast agents within bleomycin-induced
injured lung. However these preliminary results represent a first and clear
demonstration of the potential of intratracheal administration of contrast
agents and UTE lung MRI for imaging and characterizing the presence of
fibrotic tissue in bleomycin-treated animal models.
6.4.3 Application of USRPs to other tumors: brain cancer study
When the USRPs are instilled intratracheally, because of their small HD, they
have been shown to pass from the lung parenchyma to the bloodstream, with
an elimination time constant of about 3 hours (see chapter 3). Once in the
bloodstream, a fraction of the nanoparticles can then theoretically passively
accumulate in any body tumor for EPR effect, in a similar way to intravenously
administered nanoparticles. The nanoparticles will be later on filtered by the
kidneys and eventually excreted via urine.
Preliminary studies conducted by the University of Grenoble using FRI
and USRPs-Cy showed that this idea was implementable. They indeed ob-
served that intratracheally administered USRPs-Cy tend to accumulate in a
subcutaneous xenotransplanted tumor (U87-MG cells implantation). An in
vivo MRI longitudinal study of brain cancer detection in tumor-bearing im-
munodeficient mice through intratracheally- and intravenously- administered
USRPs has been started. The works exploits the protocols implemented in this
thesis and the encouraging results will be object of a scientific publication
submission in the close future.
Material and methods At day 0, an orthotopic implantation of U87-MG
tumor cells (5 · 105 cells/mouse) was performed in mice brain through an
intracranial administration in immunodeficient mice. Animals (n=14) were
repeatedly imaged with MRI between day 8 and day 15 (reproducibility and
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follow-up study) according to a protocol similar5 to the one described in
section 4.1. After the acquisition of MR baseline images, the contrast agent
solution was administered to the mice at different days and MR images were
acquired at different times (from 5 minutes up to several hours after the
administration). Between two different administrations on the same mouse, at
least 2 days without any handling was foreseen in order to allow a complete
elimination of the previously administered contrast agents. In detail, a sub-
group (n=4) received an intravenous administration of USRPs 200µL 50mM
Gd3+. A subgroup (n=6) received an intratracheal administration of USRPs
50µL 200 mM Gd3+. A subgroup (n=4) received an intratracheal adminis-
tration of USRPs 50µL 200 mM Gd3+ and an intravenous administration of
USRPs 50µL 200 mM Gd3+ 2 days after.
Results Before the administration of contrast agent, UTE MR images al-
lowed the identification of the presence of brain tumor only in a small number
of animals, generally only when the tumor was in its latest stages. Further-
more, the contours of the carcinogenic formations were not easily identifiable
(Figure 6.5a). After intratracheal or intravenous administration of USRPs, a
good localization of the position of the tumor with MRI was observed, as
shown in Figures 6.5b and 6.5c. The comparison of SE and increase of CNR
(a) Before contrast agent (b) Intracheal administration (c) Intravenous administration
Figure 6.5: UTE MR images (a) before and after the (b) intratracheal administration of 50µL
200mM USRPs or (c) intravenous injection of 200µL 50mM USRPs.
in the identified tumors (Figure 6.6) showed approximately two-fold higher
values for the intravenous (200µL 50mM) administration with respect to the
intratracheal one (50µL 200mM), using the same amount of Gd3+. The SE of
the tumor was slightly longer after intratracheal administration (elimination
constant = 75± 12 min) compared to intravenous administration (elimination
constant = 55± 16 min). The mice that received an intratracheal administra-
5The main difference is related to the fact that this study was performed on a 7 T Bruker
spectrometer for technical reasons.
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Figure 6.6: Bar plot of tumor SE (left scale) and CNR (right scale) after intravenous (i.v.) and
intratracheal (i.t.) administrations.
tion of USRPs at a 2 days distance showed no significant differences in tumor
size, position, SE and CNR, confirming the reproducibility of the protocol.
Conversely, the comparison of the tumor size after intratracheal administra-
tion at 8 days distance showed a significant increase in the tumor volume as
quantified with MRI.
Discussion In this study, the results show that the sensitivity of T1-weighted
UTE MRI for the detection of glioblastoma-like tumors can be increased using
T1-shortening contrast agents. Both the administration modalities investi-
gated allow the visualization of tumor position and borders in all the mice,
confirming the detection efficiency of UTE MR combined with contrast media.
This observation indicates that both the administration routes can be effective
for tumor visualization and follow-up.
The accumulation of the nanoparticles in the brain tumor after intravenous
injection can be attributed to the disrupted blood-brain barrier, the enhanced
permeability and retention effect, and passive targeting mechanism.
Although lower SE and CNR are observed in the tumor after intratracheal
administration of USRPs compared to intravenous injection, the intratracheal
administration presents several interesting properties. First of all, it is less
invasive than a standard parenteral systemic administration. This intratra-
cheal administration modality can be considered as a first step towards a
completely noninvasive administration procedure like nebulization or aerosol
which can be potentially repeated ad libitum in preclinical or clinical studies
(see next section).
Secondly, the slow diffusion of the Gd-based contrast agents from the lungs
to the bloodstream and then to the tumor tissue can be advantageously used
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in combination with interventional or therapeutic procedures, for instance
radiosensitization (see appendix B) or opening of the blood-brain-barrier.
In conclusion, the observed high reproducibility and efficacy of the pro-
tocol, altogether, make the intratracheal administration of these multimodal
nanoassemblies a good candidate for early brain cancer detection and non-
invasive follow-up of the diseases. In addition, the previously demonstrated
negligible acute toxicity of the USRPs and favorable pharmacokinetics, and
the possibility of lung administration with a simple aerosol, altogether, make
the proposed protocol potentially translatable to human studies (see section
6.4.4). This is the first time that a study shows that the synergic employ-
ment of a T1-weighted UTE MRI sequence and intratracheally-administered
gadolinium-based nanoparticles allow the high-precision detection of brain
tumor and of its contours.
Further studies are being performed to confirm the observed results and
to better understand the accumulation mechanisms in the tumor after intra-
tracheal administration, using fluorescent USRPs.
6.4.4 Translational considerations
To envisage translational applications, the imaging protocols must be noninva-
sive. Similarly, the contrast agent must comply with a number of requirements
that ensure its negligible toxicity (see section 1.3.2) and minimal side effects.
The MR imaging protocols implemented in this thesis are indeed non-
invasive and can be repeated several times, at different time points. In this
respect, radial UTE MRI has been shown to be a promising sequence which
can be applied in clinical studies of lung morphology, physiology and patholo-
gies [6, 83, 84].
Nonetheless, when envisioning human applications, a limitation of the
imaging protocols with contrast agents developed in this thesis can be found
in the chosen administration modality, i.e. the intratracheal administration.
Even though it was shown that this administration route is safe in mice (see
section 4.2 and appendix B), this modality is rather invasive to be considered
for translational applications.
As detailed explained in 4, such an administration route was primarily
chosen in order to reach directly the lungs and investigate the NMR properties
of the USRPs. However, as mentioned throughout the thesis, the advantages
of reaching the lungs via the airways are multiples. In this sense, the results
presented in chapter 5 strongly support this idea and underline the potential
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interest of the oral route in the diagnostics and investigation of pulmonary
pathologies.
Keeping these assets in mind, other noninvasive oral administration modal-
ities can be considered as an alternative to the intratracheal administration.
In particular, the oropharyngeal aspiration and the intranasal route are cur-
rently under consideration as intermediate steps before the investigation of
the aerosol. Detailed descriptions of the advantages and limitations of all
these administrations routes are reported in references [79, 90, 167–169]. It is
noted here that, while less invasive than the intratracheal instillation, passing
through the nose imply the addition of a first-pass filter in the pathway of
the nanoparticles. This change may affect the final result and the toxicity
outcome. More studies are needed to clarify the effective applicability of these
techniques to the implemented protocols.
Finally, as clearly stated above and in section 4.2, detailed studies are
needed (on two different animal species, one of which should be different from
rodents [170]) to ensure the long-term non-toxicity of these nanoassemblies.
This is a conditio sine qua non to envisage any possible application of the
USRPs on humans. Further studies on the in vivo stability of the nanoparticles
are also needed.
6.5 Other applications of the described protocols
As stated in the Preface, one of the objectives of this thesis was to implement
MRI protocols flexible enough to be used to study a generic contrast agent. In
this section, some of the contrast agents tested with the protocols developed
in this thesis are briefly presented to demonstrate the wide interest of the
developed protocols.
6.5.1 Application to upconverting nanoparticles
In this thesis, MRI results have often been validated by FRI observations (see
section 4.2 and appendix B). The combination of these imaging modalities
permits to put together high sensitivity and resolution and is of great interest
in molecular imaging. To achieve this multimodality the design of new nano-
materials appears as one of the most promising options. A collaboration with
the ’Centro de investigacio´n en red de enfermedades respiratorias’ of Madrid
(in the framework of the European Marie Curie Network Π-net) was started
to test some of the nanoparticles they synthesized for lung applications.
127
6. Discussion and perspectives
Among the tested nanocarriers, the in vivo multimodal study of the most
promising ones will be briefly discussed here. These nanoparticles are based
on albumin-coated upconverting nanophosphors [171] and present the unique
feature of converting low energy near infrared light into higher visible light
and/or near infrared emission. As a consequence, they allow to overcome
some of the typical problems of fluorescent probes (auto-fluorescence, low
penetration depth, high costs and toxicity).
The study, published in the Proceedings of International Society of Mag-
netic Resonance in Medicine in 2013 [172], showed that this new class of
promising nanomaterials accumulates in healthy mice lungs after intravenous
injection (SE≈35%), most probably due to the albumin-coating properties [173].
The results were confirmed by ex vivo fluorescence imaging and in vivo MRI,
as shown in Figure 6.7. This study shows the feasibility of upconverting
Figure 6.7: UTE MRI axial slice (a) before and (b) 33 min after the intravenous administration
of the upconverting nanophosphors particles. The red arrow underlines the area of maximum
SE of the lung. (c-e) Fluorescence images of the HES stained lung tissue with (c) large view of
the alveolar structure (Filter 610/50 nm) and (d) zoom on the zone of interest (Filter 610/50
nm). (e) Fluorescence images of the upconverting nanophosphors particles (Filter 460/54)
merged with (d). Reprinted from [172]
nanophosphors localization in the lung parenchyma using the UTE MRI
protocols exploited in this thesis. The interested reader is referred to ref-
erence [172] for further details about the protocol and the description of
possible applications of these nanoparticles.
6.5.2 Application to MEMRI
Among paramagnetic atoms, Mn is one of the most used (after Gd) in MRI.
Manganese-enhanced MRI (MEMRI) has found several applications, espe-
cially in neuroscience [174]. As for gadolinium atoms, chelating forms of
this element are often used to reduce toxicity issues. Mn toxicity has been
indeed observed in relation with overexposure to this metal, particularly in
brain regions where it can result in neurodegenerative pathologies and in
heart [174–176].
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(a) Before contrast agent (b) Intravenous administration
Figure 6.8: UTE MR images (a) before and after the (b) intravenous administration of 150µL
20mM MnCl2. The detection of the Mn compound is a proof-of-concept that shows the
applicability of the protocols developed in this thesis for the efficient detection of a generic
contrast agent. The intratracheal administration will be soon tested to investigate if similar
results can be achieved with much lower concentrations, reducing the toxicological effects
concerns. The experiment has been performed on a 7 T scanner for technical issues. Higher
SEs are expected when the experiments will be performed on a 4.7 T spectrometer.
Compared with gadolinium chelates,Mn2+ is characterized by a small HD
and high water solubility. As shown by Gobbo et al. [177], these properties
make this metal ion attractive for aerosolized administration to the lungs since
significant lung tissue enhancements can be obtained using low concentration
solutions of MnCl2 (1 mM). Considering that the main health concern asso-
ciated with the use of manganese is the chronic exposure to excessive levels
of this metal (>100 µM in primary astrocyte culture) [175], the possibility of
using very low concentrations of MnCl2 for various applications to the lung
is especially interesting. It has to be indeed underlined that this compound is
commonly available and extremely cheap.
The protocols described in this thesis can be easily applied to MEMRI,
either on MnCl2 molecules or on Mn-based nanoparticles. Preliminary proof-
of-concept tests have indeed shown the accumulation of MnCl2 solutions
in lung cancer after intravenous administration. As shown in Figure 6.8, a
significant accumulation has been observed right after the administration of
the compound. The next step of this study will consist in administering this
molecular solution through the oral route in the same cancer model (with a
protocol similar to the one exposed in chapter 5). The idea is to investigate
if the detection of NSCLC can be obtained using this inexpensive compound
at very low concentrations, as it is reasonable to suppose in the light of the
results presented in reference [177] and in this thesis. The PK and elimination
pathways will be investigated as well. Comparisons with intravenous admin-
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istration of MnCl2 solutions and with orally- or intravenously-administered
Mn-based nanoparticles will be finally carried out.
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Conclusion
Lung pathologies represent a social and economic burden worldwide, being
among the leading causes of death and disability. In the race to diagnose these
diseases in their early stages and to develop new effective treatments, imaging
techniques play a role of paramount importance.
Gold-standard imaging techniques like X-rays or computed tomography
are currently used in clinical practice along with nuclear medicine imaging
techniques for the diagnostics and the follow-up of lung diseases. Nonetheless,
the concerns about cumulative dose coming from ionizing radiation limit their
use. As a consequence, potentially beneficial systematic screening procedures
of the population and regular follow-ups of the patients are often critical.
In the last decades, magnetic resonance imaging has shown to be able to
reach high resolution and excellent soft tissue contrast comparable or superior
to gold-standard imaging techniques, without employing ionizing radiation.
These undeniable advantages have made MRI the imaging technique of choice
when dealing with a number of heart, liver and brain pathologies. Nonethe-
less, the intrinsic properties of lung have hindered the diffusion of MRI in the
diagnostics and follow-up of lung diseases.
Several experimental pre-clinical and clinical techniques have been pro-
posed in recent years to overcome these obstacles, with various outcomes.
However, the high costs or the complicate protocols required by some of
these techniques have retarded their diffusion in clinical practice. An effective
link between pre-clinical and clinical studies requires indeed noninvasive
techniques which can be translated from animal models to human subjects
with minimal changes and at reasonable costs.
In this thesis, special attention was given to the implementation of simple,
reproducible, fast, effective, easily-implementable and noninvasive protocols
for the diagnostics of frequent lung pathologies. For this reason, radial ultra-
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short echo time proton MRI sequences have been chosen for investigation.
Throughout this work, radial UTE proton MRI was shown to be an effec-
tive tool in the quantitative characterization of different experimental animal
models of lung diseases like asthma and lung cancer. Its capability of pro-
viding images with submillimetric resolution and significant signal-to-noise
ratio in the lung parenchyma have indeed permitted to detect small changes
in bronchial walls and submillimetric lung carcinogenic formations. The de-
veloped protocols could be used, for instance, in pre-clinical drug delivery
studies to assess the efficacy of selected lead compounds for the treatment of
these diseases or of some of their hallmarks. In addition, such results were
obtained while working with freely-breathing animals.
In general, the work presented in this thesis supports the bulk of evidence
which suggests that free-breathing acquisition techniques in mice can be used
in conjunction with radial UTE MRI sequences with limited impact on im-
age sharpness, signal-to-noise ratio and spatial resolution. The advantages
of the technique employed in the present study are multiple and straightfor-
ward. The exclusion of respiratory-gated techniques from MRI acquisitions
responds to the increasing need of testing lead compounds and new thera-
pies while keeping the animal in its physiological conditions and ensuring
the non-interference of the imaging protocol with the physiopathology of
the disease under investigation. In addition, the shorter acquisition times
enabled by the non respiratory-synchronous acquisitions allow a significant
increase in the throughput in animal studies and are expected to considerably
improve the patient management workflow in clinical practice. Finally, the
easier protocol achievable when respiration-synchronous techniques are not
used permits to translate the techniques developed on animals in clinical
studies with minimal changes.
The possibility of further increasing the sensitivity of UTE MRI with the
synergic use of contrast agents was demonstrated in this thesis. Robust pro-
tocols for the quantitative investigation of the biodistribution and of the
elimination pathways of paramagnetic contrast agents have been proposed,
implemented and validated using multimodal imaging techniques. The pos-
sibility of studying signal changes in lung parenchyma after intratracheal
administration of contrast media has been widely studied thanks to the strong
T1 weighting of the chosen sequences. The negligible T ∗2 effect of the paramag-
netic contrast medium under identified conditions has allowed to implement
quantitative pharmacokinetic models. A number of applications of this proto-
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col have been discussed and are currently under experimentation. In addition,
a protocol for the quantification of the absolute concentration of a generic
paramagnetic contrast agent with MRI has been proposed. Pending on the
validation of these results, many interesting applications of the proposed
protocol can be envisaged, in the field of lung imaging as well as in other
organs.
The use of ultra-small gadolinium-based multimodal nanoparticles has
been shown to be especially promising. Their favourable pharmacokinetics,
their biodistribution and the possibility of functionalizing these nanoassem-
blies on a as-needed basis make them an extremely flexible tool for several
applications. The direct administration of these nanoassemblies via the air-
ways has indeed shown to be very promising in the noninvasive detection
of lung cancer. Pending on the confirmation of negligible toxicity of these
nanoparticles, translational applications may be envisaged.
In conclusion, the work presented in this thesis has demonstrated that
radial ultra-short echo time proton MRI has several possible applications in
the field of pre-clinical lung imaging, pathology diagnostics and noninvasive
follow-up. The simplicity, the cost effectiveness, the robustness, the rapidity,
and the good reproducibility of these imaging protocols make them excellent
candidates for translational applications. The use of properly selected contrast
agents may compensate for the limited sensitivity that this imaging technique
may have when compared to other imaging modalities.
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A
Patent
The work relative to the USRPs has been object of a patent deposition.
The invention emphasises the originality and the wealth of applications
potentially arising from the use of the USRPs administered in animals or hu-
mans through the airways. In particular, the interest of these nanoassemblies
administered via the oral route for the diagnostics and therapeutics of lung
diseases (e.g., cancer and asthma) are presented.
Because of the innovative properties of the USRPs and the multiple poten-
tial applications of the oral administration protocol proposed in this thesis,
the French Patent request FR 12 53438 was submitted on 13 April 2012, be-
fore the submission of the work described in section 4.1 (filed to Magnetic
Resonance in Medicine on 23 April 2012). The International Patent request
PCT/EP2013/057677 was submitted one year after and eventually published
in October 2013 (International publication WO 2013/153197 (A1)).
The link where the Patent publication (in French) can be found is reported
hereafter. The work is the result of the collaboration with the University
Claude Bernard of Lyon and the University Joseph Fourier of Grenoble. In
detail, the former was in charge of the chemical synthesis and characterization
of the nanoassemblies whereas the latter was responsible for the therapeutic
studies. These subjects have been treated marginally in the body of this thesis
work. On the other hand, the MRI and multimodal imaging applications of
the intratracheally-administered USRPs described in the patent have been
widely demonstrated or discussed in the previous chapters.
The interested reader can find the entire Patent publication at the follow-
ing webpage:
http://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=
20131017&DB=EPODOC&locale=en_EP&CC=WO&NR=2013153197A1&KC=A1&ND=4
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B
Lung tumor treatment with USRPs
In this thesis (see chapter 5), it was clearly shown that USRPs can be efficiently
used to improve the sensitivity of the UTE MRI for early cancer detection. The
accumulation of the nanoparticles after intravenous or intratracheal admin-
istration was proved using MRI, BLI, 2D FRI, and conventional histological
analysis.
In the following manuscript, the same result was confirmed by means of
3D FRI, ex vivo BLI, and ex vivo FRI. Such measurements were performed by
the University of Grenoble but were partially repeated and confirmed at the
University of Bordeaux, in the framework of this thesis. These data strengthen
the observations made in chapters 5 and 6. At the same time, part of the MRI
data presented in chapter 5 has contributed to the results presented in the
following article.
In addition, the negligibility of the inflammation induced by intrapul-
monary administration of the nanoparticles is proved here by means of a trans-
genic mouse model. The results clearly confirm the conclusions expressed in
section 4.2 and chapter 6.
Finally, in the following manuscript, the radiosensitizing properties of the
USRPs are discussed, and their therapeutic potential when combined with
conventional X-rays is shown. This part of the work was carried out by the
collaborators of the University of Grenoble and is reported here for sake of
completeness.
The work presented hereafter has been submitted to Small and it is
currently under review. Its copyright belongs to the authors listed in the title
page of the manuscript.
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Abstract 
 
Lung cancer is the most common and death-related cancer worldwide. Thus, improving early 
diagnosis and therapy is necessary. Previously, we developed gadolinium-based Ultra-Small 
Rigid Platforms (USRPs) that can serve as multimodal imaging probes and as radiosensitizing 
agents. In addition, we recently demonstrated that USRPs can be detected in the lungs using 
Ultrashort echo-time Magnetic Resonance Imaging (UTE-MRI) and fluorescence imaging 
after intrapulmonary administration in healthy animals. The goal of the present study was to 
evaluate their theranostic properties in mice with bioluminescent orthotopic lung cancer, after 
intrapulmonary nebulization or conventional intravenous administration. We found that lung 
tumors can be detected non-invasively using fluorescence tomography or UTE-MRI after 
nebulization of USRPs, and this was confirmed by histological analysis of the lung sections. 
The deposition of USRPs around the tumor nodules was sufficient to generate a 
radiosensitizing effect when the mice were submitted to a single dose of 10 Gy conventional 
radiation one day after inhalation (mean survival time of 112 days versus 77 days for 
irradiated mice without USRPs treatment). No apparent systemic toxicity or induction of 
inflammation was observed. These results demonstrate the theranostic properties of USRPs 
for the multimodal detection of lung tumors and improved radiotherapy after nebulization.  
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Lung cancer (including both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung 
Cancer (SCLC)) is a major health problem and is the leading cause of cancer-related adult 
deaths worldwide.
[1]
 Despite current technological and medical advances, the majority of 
patients are diagnosed with locally advanced or metastatic disease, that is inoperable in most 
cases.
[1, 2]
 In these instances, concomitant chemo-radiation therapy remains the most effective 
therapy 
[3]
 but the 5-year survival rate is only 15%.
[4]
 
The reasons for therapeutic failure are diverse and are partially due to the inability to achieve 
adequate concentrations of drugs at the tumor site after systemic administration.
[5]
 To increase 
exposure of the tumor to therapeutic agents while minimizing systemic side-effects, regional 
chemotherapy is a promising method and has already been successfully applied for the 
treatment of ovarian 
[6]
, brain 
[7]
 and bladder tumors 
[8]
 and liver metastasis.
[9]
 
Inhalation of anti-tumor agents may be an alternative administration route to improve lung 
cancer outcomes. Indeed, the lungs present a large surface area for drug absorption and an 
extensive vasculature with a weak anatomical barrier that does not limit access to the body.
[10, 
11]
 The first trial, performed by Shevchanko and Resnik in 1968, established the feasibility 
and the efficacy of administering chemotherapy by inhalation in combination with 
radiotherapy.
[12]
 Since then, a large number of drugs have been investigated for 
intrapulmonary administration in animal models and in human trials.
 [11, 13-15]
 In recent years, 
the pulmonary administration of nanoparticles has become an attractive strategy for the local 
delivery of therapeutic or diagnostic compounds 
[16]
; however, to the best of our knowledge, 
only one work discusses the pulmonary administration of iodinated nanoparticles for 
diagnostic purposes.
 [17]
 This exemplifies the necessity of additional studies on this topic.  
On the other hand, radiotherapeutic failure can be attributed to the resistance of tumors 
located in the lung, a highly radio-sensitive organ. This intrinsic property of the lung prevents 
the use of elevated doses of radiation during radiotherapy because of the resulting major side 
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effects. The local deposition of nanoparticles containing high Z-elements, such as gold, 
platinum or gadolinium, on the tumor site could enhance the effects of X-rays.
[18-21]
 This 
should maximize the radiotherapeutic efficacy via the increase of toxicity on the tumor tissues 
and result in only minor side effects in normal tissues. 
In this context, we developed “theranostic” Ultra-Small Rigid Particles, USRPs, obtained via 
an original top-down process. These particles are composed of a polysiloxane matrix and 
chelating species, e.g., DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), 
which is covalently grafted on the inorganic surface. In previous studies, the particles were 
validated as promising multimodal contrast agents for complementary imaging techniques, 
i.e., Magnetic Resonance Imaging (MRI), Single-Photon Emission Computed Tomography 
(SPECT), Computed Tomography (CT) and fluorescence imaging.
 [22]
 Despite rapid blood 
and renal clearance due to their small size (<6 nm),
[23]
 the significant accumulation of these 
multifunctional particles in tumors occurs after intravenous injection, as a result of a passive 
targeting mechanism related to the Enhanced Permeability and Retention (EPR) effect 
[24]
 and 
of a specific active tumor-targeting mechanism after the grafting of cRGD peptides on their 
surface.
[25]
 Finally, these gadolinium-based nanoparticles exhibited high radiosensitizing 
properties in vitro and in vivo.
[21, 26]
 
In a recent study, the biodistribution and pharmacokinetics of USRPs were investigated by 
Ultrashort echo-time MRI (UTE-MRI) and fluorescence imaging after intrapulmonary 
administration in healthy mice.
[27]
 The two imaging techniques showed similar kinetics for 
USRPs, with the occurrence of renal clearance after rapid passage from the airways to the 
bloodstream (elimination time of 187 ± 40 minutes). 
We undertook the present study to evaluate deep lung tumor detection by fluorescence 
imaging and MRI in vivo and the radiosensitizing effect of USRPs administered directly in the 
airways of mice bearing orthotopic human lung tumors (H358-Luc). We also evaluated the 
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 5 
potential inflammation induced by intrapulmonary administration of the nanoparticles in a 
NF-B-RE-Luc transgenic mouse model. 
 
Results and Discussion 
In vivo lung tumor detection 
An orthotopic mouse model of human NSCLC was developed. Orthotopic models take into 
account the microenvironment of tumors. Thus, they are more relevant than the widely used 
subcutaneous xenografts to evaluate the diagnostic and/or therapeutic properties of novel 
agents.
[29]
 In this model, lung tumors develop after the intrapulmonary inoculation of 
luciferase-modified human NSCLC H358 cells (H358-Luc cells). The use of bioluminescence 
in vivo is convenient for the non-invasive monitoring of the implantation and growth of these 
orthotopic tumors over five weeks.
[30]
 At this time point, tumors are well-developed with a 
strong bioluminescent signal, but this is before the appearance of obvious symptoms (e.g., 
body weight loss and breathing difficulties). Mice bearing H358-Luc lung tumors can thus be 
used for subsequent imaging and/or therapy studies before the lung tumors induce breathing 
distress that could interfere with their health. 
The ability of USRPs labeled with Cyanine 5.5 (USRPs-Cy5.5) to improve the in vivo 
detection of lung tumors was first evaluated after intrapulmonary or intravenous 
administration of equal quantities of nanoparticles using 3D-fluorescence tomography 
imaging. This was performed at multiple time points after intrapulmonary administration of 
50 L of a solution containing ~ 40 mmol/L [Gd3+] or after intravenous injection of 200 L of 
~ 10 mmol/L [Gd
3+
]. Representative images are shown in Figure 1A. 
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Figure 1: In vivo H358-Luc orthotopic lung tumors imaging. 
(A) In vivo fluorescence tomography imaging after intrapulmonary or intravenous injection of 
USRPs-Cy5.5 (50 µL at [Gd
3+
] ~ 40 mM, n=3). (B) Bioluminescence and fluorescence 
imaging were then performed on isolated lungs, and showed a colocalization between the 
H358-Luc tumors (bioluminescence) and the fluorescent nanoparticles (fluorescence) 
(arrows). (C) Biodistribution of the fluorescent nanoparticles at different time points after 
intrapulmonary administration or 24h after intravenous injection, was evaluated by defining 
ROIs on fluorescent images of extracted organs. (D) USRPs also permitted the detection of 
lung tumors by MRI after intrapulmonary instillation (50 µL at [Gd
3+
] ~ 50 mM). 
 
At the end of the experiment, the mice were euthanized, and the extracted organs were 
subjected to ex vivo bioluminescence and fluorescence imaging (Figure 1B) for semi-
quantification (Figure 1C). In both cases, in vivo and ex vivo, bioluminescence or fluorescence 
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imaging showed similar profiles. USRPs-Cy5.5 were homogeneously distributed into the 
lungs immediately after intrapulmonary administration. Highly fluorescent spots could be 
observed on both the 3D-fluorescence images and ex vivo fluorescence images of the lungs. 
These high-intensity zones corresponded to the tumor nodules, as established by 
bioluminescence imaging (arrows on Figure 1A and 1B). This was associated with the 
augmented, but not significantly different, uptake of USRPs-Cy5.5 in lungs bearing tumors 
compared to “normal” lungs. Regarding intravenous injection, USRPs-Cy5.5 were barely 
detectable in the tumor, with an augmented signal two times that of the normal lungs 
(P=0.0209). Nonetheless, at 24 hours, the fluorescent signal was 52-times lower in the tumors 
when the particles were injected intravenously compared to intrapulmonary administration of 
the same quantity of injected nanoparticles. Interestingly, the two different administration 
routes resulted in similar levels of non-specific accumulation of the fluorescent USRPs in all 
of the other organs assessed (especially in the spleen and in the liver) with a similar mode of 
elimination via the kidneys, thus showing agreement with our previous data.
[22, 27]
 These 
results confirmed that direct administration via the airways can increase the amount of locally 
delivered molecules or nanoparticles in lung tumor models, which could be of great interest 
for the treatment of lung diseases.
[5, 16, 31]
 
Moreover, the intrapulmonary administration of USRPs permitted the detection of lung 
tumors using the specific UTE-MRI sequence (Figure 1D). This result sustained and validated 
the multimodal properties of these nanoparticles 
[21, 22, 27]
 and their potential as multimodal 
contrast agents for the detection of lung tumors. 
 
Lung distribution of USRPs-Cy5.5 after intrapulmonary administration 
Fluorescence microscopy was then performed on frozen lung sections to obtain more precise 
information about the distribution of USRPs-Cy5.5 within the lung tissues after 
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intrapulmonary administration (Figure 2). A large proportion of instilled fluorescent 
nanoparticles was found in the alveoli 1 hour after administration, together with a delineation 
of the lung tumors. Similar patterns were still observable 5 hours and 24 hours after 
administration, although a decrease of the fluorescent signal in the alveoli was noted. This 
reduction of the fluorescent signal can most likely be attributed to the passage of the 
nanoparticles from the airways to the blood, owing to the small size of the nanoparticles (<6 
nm),
[23]
 as described in a previous study.
[27]
 A very weak fluorescence signal was detected by 
fluorescence microscopy on lung sections obtained from mice intravenously injected with 
USRPs-Cy5.5. 
 
 
Figure 2: Distribution of fluorescent nanoparticles on the frozen lung sections of H358-Luc 
tumor-bearing mice at different time points after intrapulmonary administration of USRPs-
Cy5.5 (50 µL of ~ 40 mM [Gd
3+
]). Lung sections were observed by fluorescence microscopy 
(in blue: Hoechst staining of the nuclei; in red: Cy5.5 signals). The upper panel presents the 
superimposed images of the Hoechst and Cy5.5 signals. The bottom panel corresponds to 
Cy5.5-only signals. The Cy5.5 signal was primarily localized close to the tumor nodules 
(arrows). 
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Radiosensitizing therapeutic study 
The significant and specific accumulation/retention of USRPs-Cy5.5 around the tumors in the 
nebulized lungs suggested that a radiosensitizing effect could be expected. H358-Luc lung 
tumor-bearing mice were therefore exposed to conventional irradiation of 10 Gy after 
intrapulmonary administration of USRPs (50 µL of ~ 20 mM [Gd
3+
]). Prior to treatment, in 
vivo bioluminescence imaging was performed for all mice, and the bioluminescent signal in 
the lungs was quantified to randomize the mice into three homogenous groups: (i) a group of 
mice treated with irradiation after intrapulmonary administration of USRPs (n=11); (ii) a 
control group (n=6; no nanoparticle administration, no irradiation) and (iii) an irradiated-only 
group (n=11; no nanoparticle administration, irradiation) (Figure 3). The control and 
irradiated-only mice groups exhibited similar median survival times (MeST) of 83 days and 
77 days (no significant difference; P=0.926). In contrast, the MeST was extended to 112 days 
in the group irradiated in the presence of USRPs. This corresponded to a 45% increase in 
lifespan (ILS) compared to the irradiated-only group (P=0.028). The improvement was 
attributed to the radiosensitizing properties of USRPs (containing high-Z gadolinium atoms), 
which were primarily present at the tumor level during irradiation, as shown by in vivo 
fluorescence imaging, UTE-MRI, and the analysis of the lung sections. This therapeutic 
protocol represents an attractive strategy for the treatment of lung tumors in radio-sensitive 
organs such as the lung. 
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Figure 3: Survival curve comparison obtained on H358-Luc lung tumor-bearing mice without 
treatment (n=6), only treated by one irradiation (n=11), and treated by one irradiation (n=11) 
24h after the intrapulmonary administration of nanoparticles, 161 days after tumor 
implantation. The irradiation was performed at 10 Gy, 37 days after tumor implantation.  
 
 
These results have completed and continued the previous works in which it was initially 
demonstrated that despite rapid renal elimination after intravenous injection or 
intrapulmonary administration, USRPs can improve the effect of radiotherapy 
[21]
 independent 
of the location and type of tumor (subcutaneous, brain, etc.). 
 
Pulmonary inflammatory potential of USRPs 
Finally, demonstrating the safety of these nanoparticles after intrapulmonary administration 
was important. In particular, several publications have reported inflammation of the lungs and 
particle-induced activation of the redox-responsive NF-B signaling pathway after in vitro 
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exposure 
[32-34]
 and after the inhalation or pulmonary delivery 
[35, 36]
 of nanoparticles. 
Therefore, the effect of USRPs nebulization in NF-B-RE-Luc transgenic mice was 
investigated. We evaluated the potential induction of inflammation that depends on the NF-
B pathway in this strain of transgenic mice, 2, 5, 24, 48, 72 and 96 hours after the 
intrapulmonary administration of USRPs (50µL of ~ 20 mM [Gd
3+
]) (Figure 4). Evaluation of 
the induced inflammation was performed using an ex vivo luciferase enzymatic activity assay 
on the protein extracts of all representative organs including the lungs, kidneys, spleen, liver 
and muscle (as a negative control) to generate highly sensitive and quantitative measurements. 
No significant variation was observed when  the luciferase activities in the organs of the 
treated versus non-treated mice (control) were compared. Furthermore, no morphological 
changes and no edema were detected in the lungs of these mice. In contrast, animals that 
received an intrapulmonary administration of lipopolysaccharide (LPS, 2 mg/kg), which was 
used as a positive control for lung injury,
[37]
 showed a 8-fold significant increase in luciferase 
activity in the lungs 24h after administration compared to the control. This observation are in 
agreement with the results of previous studies.
[38, 39]
 These results are also consistent with the 
broncho-alveolar lavage analyses performed in a previous study 
[27]
 that showed no increase in 
the number of immune cells after intrapulmonary administration of USRPs. 
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Figure 4: Evaluation of the inflammatory potential of USRPs
 
after intrapulmonary 
administration. The luciferase enzymatic activity was quantified in organs of NF-ĸ B-RE-Luc 
mice at different times after the intrapulmonary administration of USRPs (50 µL of ~ 20 mM 
[Gd
3+
]) (n=5, means ± SD). As positive control, the mice received an intrapulmonary 
administration of lipopolysaccharide (LPS, 2 mg/kg) and were sacrificed at 24 h. 
 
These results confirmed that the intrapulmonary nebulization of USRPs is a safe and efficient 
mode of administration of these nanoparticles to the lungs without inducing an inflammatory 
reaction. These findings corroborate the interest in the intrapulmonary administration 
modality, which presents several advantages compared to inhalation or intravenous injection 
for the monitoring of lung tumors.
[40-42]
 
 
Conclusions 
This study demonstrates the advantages of using gadolinium-based theranostic nanoparticles 
(USRPs) in an orthotopic lung cancer mouse model. USRPs enabled the multimodal 
detection, by fluorescence imaging and MRI, of lung tumors after both intravenous and 
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intrapulmonary administration. Their direct administration into the airways significantly 
increased their pulmonary delivery and uptake by the tumors, allowing improved detection of 
the tumor using imaging. In addition, the proposed protocol improved the use of conventional 
X-ray radiation due to the radiosensitizing properties of USRPs. Moreover, the 
intrapulmonary administration of nanoparticles did not induce inflammation. Based on these 
preclinical results, USRPs is anticipated to have potential applications as a simultaneous 
imaging and therapy modality for clinical lung cancer in the near future. The next step toward 
personalized therapy is the use of these nanoparticles for image-guided therapy. 
 
Experimental Section 
Nanoparticles synthesis and characterization 
The Gd-DOTA-based nanoparticles (USRPs) were synthesized and characterized according to 
the previously described protocol.
[22, 27, 28]
 To perform the fluorescence imaging, Cyanine 5.5 
(Cy5.5) near infrared dye was covalently grafted on the nanoparticles (USRPs-Cy5.5), as 
described in reference 25. 
 
Lung tumor animal model 
Animal experiments were conducted in accordance with protocols approved by the Ethical 
Committee of Grenoble. H358-Luc cells (Optimal, Grenoble, France), cultured in RPMI 
medium supplemented with 10% of heat-inactivated fetal bovine serum, were harvested, 
washed and resuspended in 1X PBS at 10
7
 cells/50 µL. Female NMRI nude mice (6 weeks 
old) were anesthetized with an intraperitoneal (i.p.) injection of Medetomidin (0.2 
µg/g)/Ketamine (0.1 mg/g), and the tumor cells were inoculated in the lungs with a catheter 
after orotracheal intubation. The monitoring of tumor development was followed by in vivo 
bioluminescence imaging after the i.p. injection of 150 mg/kg of Luciferin (Promega, 
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Charbonnières, France), as previously described.
[43]
 The quantification of bioluminescent 
signals allowed for the randomization of animals before each experiment. Lung tumors 
developed over a period of five weeks. 
 
Intrapulmonary spray administration 
Intrapulmonary administration was performed using a nebulizing IA-1C Microsprayer
TM
 
(Penn-Century, Inc., PA, USA) connected to a FMJ-250-high-pressure syringe (Penn-
Century, Inc.) containing 50 µL of nanoparticles labeled with or without Cy5.5. After i.p. 
anesthesia with Medetomidin/Ketamine, the tip of the microsprayer was introduced into the  
trachea of the animals using adedicated laryngoscope.  
 
Tumor imaging study 
Bioluminescence, 2D- and 3D-fluorescence imaging, fluorescence quantifications (Optimal, 
Grenoble, France) and Ultrashort echo-time Magnetic Resonance Imaging (UTE-MRI) were 
performed as described in previous studies.
[27, 44]
 
Fluorescence microscopy of the frozen lung sections (9 µm) was carried out using an 
AxioImager microscope with the AxioVision® software (Carl Zeiss, Jena, Germany) with a 
10x objective. Nuclei were labeled by 1 µg/mL of Hoechst 33342 in 1X PBS for 5 min at 
room temperature. 
 
Therapeutic efficacy study  
Bioluminescence imaging was performed 35 days after tumor implantation, and animals were 
randomized into three groups: control (n=6), irradiation (n=11) and USRPs + irradiation 
(n=11). Irradiation consisted in a single 10 Gy dose delivered with a radiation source 
operating at 200 keV with a 2 mm Al-filter. Irradiation, restricted to the chest region, was 
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performed at day 37, 24 h after intrapulmonary administration of USRPs (50 µL of ~ 20 mM 
[Gd
3+
]). The mice were followed at the animal facility after irradiation. At a later tumor stage, 
mice were euthanized when presenting clinical signs and/or 20% weight loss. 
 
Pulmonary inflammatory potential of USRPs 
At different time points (2, 5, 24, 48, 72 and 96 h) after the intrapulmonary administration of 
USRPs (50 µL of ~ 40 mM [Gd
3+
]), NF-ĸB-RE-Luc mice (Taconic, USA) were sacrificed 
(n=5 for each time point), and the organs were collected and mashed for the in vitro luciferase 
enzymatic activity assay (Promega, Charbonnières, France), as previously described.
[45]
 
The lipopolysaccharide (LPS) (Sigma-Aldrich, USA) was used as positive control. The mice 
were sacrificed 24 h after the intrapulmonary administration of LPS (2 mg/kg). 
 
Statistical analyses 
Statistical analyses were performed using the two-tail non-parametric Mann-Whitney t-test. 
All results are expressed as the means ± standard deviation. To compare survival among 
different treatment groups, the Kaplan-Meier survival data were plotted versus time after 
tumor implantation. These data were subsequently analyzed using a log-rank test. In both 
cases, statistical significance was considered when P< 0.05. 
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C
A review about USRPs
In this thesis, the NMR properties and pharmacokinetics of intratracheally
administered USRPs have been studied in chapter 4 and a possible application
of these nanoassemblies as diagnostic tools for lung cancer has been presented
in chapter 5.
As anticipated in the patent request presented in appendix A and dis-
cussed in chapter 6, a large variety of applications may be implemented
thanks to the advantages rising from the direct application of the USRPs to
the airways. In appendix B, a possible therapeutic application coming from
the radiosensitizing properties of intratracheally administered USRPs has
been shown.
The negligible toxicity of these nanoparticles, their favourable pharma-
cokinetics, their diagnostic properties when combined with proper imaging
techniques, and their potential therapeutic application after intratracheal
administration have been partially described in this thesis. However, the
USRPs have been applied to other heterotopic or orthotopic tumor models
(i.e., gliosarcoma of the brain) as well.
In the work presented hereafter, a review of the theranostic properties of
the USRPs investigated up to now is proposed. The work described in this
thesis has contributed to the results presented in the following article.
The manuscript has been accepted for publication on British Journal
of Radiology as an invited review paper (doi:10.1259/bjr.20140134). Its
copyright belongs to the British Institute of Radiology.
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Abstract: 
A new efficient type of gadolinium-based theranostic agent (AGuIX) has recently been 
developed for magnetic resonance imaging (MRI)-guided radiotherapy. These new 
particles consist of a polysiloxane network surrounded by a number of gadolinium 
chelates, usually 10. Due to their small size (<5 nm), AGuIX typically exhibit 
biodistributions that are almost ideal for diagnostic and therapeutic purposes. For 
example, while a significant proportion of these particles accumulate in tumours, the 
remainder is rapidly eliminated by the renal route. In addition, these particles present no 
evidence of toxicity, in the absence of irradiation with up to 10 times the planned dose for 
clinical trials. AGuIX particles have been proven to act as efficient radiosensitizers in a 
large variety of experimental in vitro scenarios, including different radioresistant cell 
lines, irradiation energies, and radiation sources (sensitizing enhancement ratio ranging 
from 1.1 to 2.5). Preclinical studies have also demonstrated the impact of these particles 
on different heterotopic and orthotopic tumours, with both intra-tumoural or intravenous 
injection routes. A significant therapeutical effect has been observed in all contexts. 
Furthermore, MRI monitoring was proven to efficiently aid in determining a radiotherapy 
protocol and assessing tumour evolution following treatment. The usual theoretical 
models, based on energy attenuation and macroscopic dose enhancement, cannot account 
for all the results that have been obtained. Only theoretical models, which take into 
account the Auger electron cascades that occur between the different atoms constituting 
the particle and the related high radical concentrations in the vicinity of the particle, 
provide an explanation for the complex cell damage and death observed. 
 
 
D
USRPs synthesis and characterization:
Supplementary Material
In this appendix, the detailed description of the synthesis and characteri-
zation of the USRPs used in the works presented in sections 4.2 and 5 is
proposed. The work presented hereafter has been carried out by the collabora-
tors of the University of Lyon, co-authors in the manuscripts presented in the
aforementioned sections. This information is reported here only for sake of
completeness. The interested reader can find the description of the synthesis
and characterization of the nanoparticles used in section 4.1 in reference [145]
(slightly different from the one presented here).
The copyright of this work belongs to the European Society of Magnetic
Resonance in Medicine and Biology (ESMRMB) since it has been published
on Magnetic Resonance Materials in Physics, Biology and Medicine as Sup-
plementary Material (see section 4.2).
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Supplementary Material:  
Nanoparticles synthesis and characterization 
 
MATERIALS AND METHODS:  
Chemicals:  
Gadolinium chloride hexahydrate ([GdCl3.6H2O], 99%, Nano-H France), sodium hydroxide 
(NaOH, 99.99%, Sigma Aldrich), diethylene glycol (DEG, >99%, SDS), 
tetraethylorthosilicate (Si(OC2H5)4, TEOS, 98%, Sigma Aldrich), (3-
aminopropyl)triethoxysilane (H2N(CH2)3-Si(OC2H5)3, APTES, 99%, Sigma Aldrich), 
1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid (DOTAGA, 
CheMatech®), triethylamine (TEA, 99%, Sigma Aldrich), anhydrous dimethylsulfoxyde 
(DMSO, Sigma Aldrich), Pre-activated Cyanine 5.5(Cy5.5-NHS, GE Healthcare®). 
Size measurements and surface potential: 
Hydrodynamic diameters (HD) and ξ-potentials of our samples were determined with a 
ZetasizerNanoS PCS (Photon Correlation Spectroscopy, Laser He-Ne 633 nm) from Malvern 
Instruments®. 
Fluorescence measurements: 
Fluorescence measurements were carried out at room temperature using a Varian Carry 
Eclipse fluorescence spectrophotometer. 
High Performance Liquid Chromatography: 
Gradient HPLC analysis was carried out using the Shimadzu® Prominence series UFLC 
system equipped with a CBM-20a controller bus module, an LC-20AD liquid chromatograph, 
a CTO-20A column oven and SPD-20AUV-visible detector. Sample UV-visible absorption 
was measured at 295 nm. Sample aliquots of 20 µL were loaded in 95% solvent A – 5 % 
solvent B (A =Milli-Q water/TFA 99.9:0.1 v/v; B = CH3CN/Milli Q water/TFA 90:9.9:0.1 
v/v/v) onto a Jupiter C4 column (150 x 4.60 mm, 5 µm, 300 Å, Phenomenex®) at a flow rate 
of 1 mL/min over 5 min. In a second step, samples were eluted by a gradient developed from 
5 to 90 % of solvent B in solvent A over 30 min. The concentration of solvent B was 
maintained over 10 min. Then, the concentration of solvent B was decreased to 5 % over a 
period of 10 min to re-equilibrate the system, followed by additional 10 min at this final 
concentration. Before each sample measurement, a baseline was performed following the 
same conditions byloading Milli-Q water into the injection loop. 
Nanoparticles synthesis: 
The synthesis of the gadolinium based nanoparticles is a four step synthesis. The first step is 
the synthesis of a gadolinium oxide core by addition of soda on gadolinium chloride salts in 
DEG [a]. The second step is the growth of a polysiloxane shell by addition of adapted 
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amounts of TEOS and APTES in DEG. Then DOTAGA anhydride is covalently grafted on 
the free amino functions of APTES and during the transfer from DEG to water of the particles 
a top down process is observed with a dissolution of the gadolinium oxide core due to the 
chelation by DOTAGA. This lead to the ultrasmall gadolinium based nanoparticles made of a 
polysiloxane matrix surrounded by gadolinium chelates [b, c]. 
Preparation of gadolinium oxide cores: 
Gadolinium chloride salt (167.3g, GdCl3.6H2O) was placed in 3 L of diethylene glycol (DEG) 
at room temperature under vigorous stirring. The suspension was heated at 140°C until the 
total dissolution of gadolinium chloride salt (about 1 h). When the solution is clear, sodium 
hydroxide solution (120 mL, 3.38 M) was added drop by drop under vigorous stirring. 
Afterwards, the solution was heated and stirred at 180°C for 3h. A transparent colloid of 
gadolinium oxide (Gd2O3) nanoparticles (HD = 1.6±0.5 nm) was obtained ([Gd] = 30 
mM)and can be stored at room temperature for weeks without alteration. 
Coating of gadolinium oxide cores by a polysiloxane shell: 
The previously obtained Gd2O3colloidal solution is diluted in DEG to obtain a final volume of 
4.5 L ([Gd] = 30 mM). The silane precursors (APTES (75.8 mL)) and TEOS (48 mL)) and 
hydrolysis solution (aqueous Et3N in DEG (0.75M of TEA, 75M of water) are continuously 
added to the precedent solution over a four day period under stirring at 40°C (HD= 3.5±0.7 
nm). After the end of the addition, the final mixture was stirred for 48H at 40°C (HD = 
5.7±1.0 nm). 
Functionalization of the polysiloxane shell by DOTAGA: 
To perform the functionalization of the core-shell nanoparticles (core: Gd2O3/ shell: 
polysiloxane) DOTAGA anhydride (108.9 g diluted in 500 mL of anhydrous DEG) is added 
to 3.25 L of the precedent solution during a period of three days under strirring. 
Purification and dissolution of the gadolinium oxidecore: 
The precedent solution is precipitated in 14L of acetone before filtration and washing by 2x2L 
of acetone. A white powder is obtained that is dispersed in water and purified by tangential 
filtration to a 1000 factor over a 5 kDa membrane (HD = 4.1±1.0 nm at pH 7.4). The 
nanoparticles are then freeze-dried for storage, using a Christ Alpha 1-2 lyophilizer. The 
freeze dried nanoparticles are stable for months without alterations. 
Grafting of Cy 5.5 near infrared dye: 
To perform optical imaging, Cy 5.5 near infrared dye was grafted on the nanoparticles.Cy5.5-
NHS was diluted in anhydrous DMSO (2.5 mg/L) and added to an aqueous solution of freshly 
dispersed USPRs in water at pH 7-7.4 for 8 hours under stirring (molar ratio Cy5.5/Gd 
0.044/1). Nanoparticles were then submitted to tangential filtration to a 1000 factor over a 5 
kDa membrane before freeze-drying. 
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 RESULTS 
The USRPs are synthesized by a previously described protocol [b, c] slightly modified to 
obtain higher quantities of nanoparticles. It consists first in the synthesis of gadolinium oxide 
core by addition of soda on gadolinium trichloride previously dissolved in DEG. Then the 
growth of a polysiloxane shell is ensured by the addition of adapted amount of silane 
precursors (TEOS and APTES). Nanoparticles presenting a HD of 5.7 ±1.0 nm are obtained at 
this step. DOTAGA anhydride is then covalently grafted on the free amino functions issued 
from APTES. During the transfer to water of these nanoparticles, an original top down 
process occurs: the gadolinium issued from the core is chelated by the DOTAGA and then a 
collapse and a fragmentation of the polysiloxane shell into ultrasmall nanoparticles, made of 
polysiloxane and surrounded by about ten DOTA chelates, is observed as previously 
described. When needed for optical imaging experiments, Cy 5.5 was grafted on the USRPs 
as described in the experimental section.  
The nanoparticles present a HD of about 4.1 ± 1.0 nm. The particles have rather a neutral 
charge at physiological pH, namely a value of zeta potential of -0.2 mV at pH = 7.4. The 
number of free DOTAGA on the nanoparticles has been determined by adding increasing 
amounts of europium chloride and by evaluating the fluorescence of the chelated europium 
ions [c]. Less than 5% of free DOTAGA are present on the nanoparticles maximizing the 
relaxivity of each nanoparticle. The r1 per nanoparticle is equal to 8.22 mM-1s-1 per 
gadolinium ion at 4.7T. Finally, the purity of the nanoparticles has been evaluated more than 
95% by HPLC. 
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